Trading Analysis Report: NKE¶

Analysis date: 2026-10-08
Rating: Underweight
Generated: 2026-10-09 08:14:51
TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-opus-5-5
Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 34.74 USD Price As Of: 2026-10-08

NKE (NIKE, Inc.): Technical Report¶

1. Summary¶

NKE is in a long, well-established downtrend on every timeframe I checked. The close of 34.74 is 51.6% below the 2025-10-01 close of 71.83. All three SuperTrend timeframes point down, and the moving averages are stacked bearishly: price < 10 EMA < 20 SMA < 50 SMA < 200 SMA.

The newest change is that the decline may be running out of steam. The weekly and monthly TD-9 buy setups are both complete. The Oct 2 gap-down was bought heavily during the day. MACD has crossed just above its signal line. Taken together, these make a short-term relief bounce possible. They are not yet confirmed: RSI did not diverge from price, OBV has recovered only part of its losses, and volume has fallen on the rebound.

In short: the main trend is still down, with early signs of a possible bounce. A dense resistance zone sits between 35.0 and 36.4.

2. Indicators used and why¶

Category	Indicator	Why it fits NKE now
Trend	close_50_sma (+ 200 SMA, 10 EMA, Bollinger bands from the verified snapshot)	Measures how strong and how stretched the downtrend is, and where resistance sits
Trend, 3 timeframes	supertrend	Shows trend direction and trailing stop levels on weekly, monthly and daily charts
Momentum	macd (+ signal line and histogram from the snapshot)	Shows whether downside momentum is fading and whether a crossover is forming
Momentum	rsi	Checks oversold readings and whether RSI confirms or diverges from new price lows
Volatility	atr	Sets stop distances and position size after the gap
Volume	obv	Shows whether money is still leaving or coming back
Exhaustion	td_9	Checks for signs the selling is exhausted on higher timeframes
Stretch	z_score	Measures how far price sits below its average on each timeframe

The indicator tool's values matched the verified snapshot (50 SMA 38.10, MACD −1.05, RSI 38.26, ATR 1.12), so there were no conflicts to flag.

3. Price structure (12 months)¶

Lower highs and lower lows throughout. Rally peaks kept falling: closes of 64.59 (Jan 13), 63.92 (Feb 19), 46.46 (May 28), 44.10 (Jul 16), 39.18 (Aug 28) and 36.39 (Sep 28). Lows kept falling too: 41.87 (Apr 7), 40.32 (Jun 26), 38.04 (Aug 27), 35.51 (Sep 18) and 33.87 (Oct 2).
Three big gap-downs on heavy volume. The tools don't say what caused them; they may have been quarterly results.
Dec 19, 2025: 63.94 → 57.20 (−10.5%) on 108.7M shares. The close was in the lower quarter of the day's range. The stock then recovered fully to 64.59 by Jan 13 before the downtrend resumed.
Apr 1, 2026: 51.80 → 43.77 (−15.5%) on 114.2M shares. It closed near the day's low and kept falling to 41.87 on Apr 7. The gap never filled; the best close afterward was 46.46.
Oct 2, 2026: It opened at 32.55, a −7.4% gap, and touched a low of 31.97. It then closed at 33.87, near the top of its 31.97–33.97 range (about 95%), on 142.7M shares, the highest volume in the dataset. That is the opposite of the two earlier gaps, which closed weak. Buyers absorbed the selling, which can mark a short-term bottom.
Since the gap: closes of 33.96, 34.61, 34.36 and 34.74, with no close below 33.87. The Oct 5 low (32.76) was higher than the Oct 2 low (31.97). Price is now trading inside the unfilled gap between 33.97 and 35.02 but has not closed it.

4. Trend¶

Moving averages (snapshot): 10 EMA 34.94, 20 SMA (Bollinger middle) 35.60, 50 SMA 38.10, 200 SMA 47.31. Price is 0.20 below the 10 EMA, 8.8% below the 50 SMA and 26.6% below the 200 SMA. The 50 SMA sits 9.21 below the 200 SMA, so the death-cross condition is well established.
50 SMA slope: it fell from 41.06 (Sep 8) to 38.10 (Oct 8), about −0.13 per session. The oldest closes in its 50-day window (Jul 30 to early August) are around 41–42. As those drop out, the 50 SMA will keep falling even if price goes sideways, so it will be a lower but still falling resistance level.
SuperTrend:
Weekly (primary): DOWN, stop 42.72, price 18.7% below it.
Monthly: DOWN, stop 59.30, price 41.4% below.
Daily: DOWN, stop 36.38, price 4.5% below.
The daily stop at 36.38 lines up with the Sep 28 close of 36.39, the top of the late-September range. A daily close above about 36.4 is the first real trend-change signal. The weekly stop at 42.72 is far away, so the bigger trend is not at risk soon.

5. Momentum¶

MACD: −1.05, signal −1.06, histogram +0.01. This is a bullish crossover only in the narrowest sense; the line is essentially sitting on its signal.
The MACD line has risen from −1.125 (Oct 5) to −1.050.
There is a modest bullish divergence. On Sep 18 price closed at 35.51 with MACD at −1.205. After the gap, price closed lower (33.87 to 33.96), but MACD's worst reading was only −1.125. Selling pressure is weakening even though price set a new low.
MACD is still far below zero, so this is a bounce signal inside a downtrend, not a trend reversal.
RSI: 38.26. It hit 28.49 on Oct 2 and 29.41 on Oct 5 (oversold) and has now climbed out.
RSI did not confirm the MACD divergence. RSI's Oct 2 low (28.49) was below its Sep 18 reading (32.80), in line with the lower price.
Over the last 30 days RSI never rose above 41.64 (Sep 28), which is typical of a bear market. A move above about 42–45 would be the first change in that pattern.

6. Volatility¶

ATR: 1.12, or 3.2% of price, up from about 0.96 before the gap (Sep 30). Expect bigger daily swings than in September.
Bollinger bands (snapshot): middle 35.60, upper 37.40, lower 33.81. Price sits about 26% of the way up from the lower band to the upper band.
The lower band at 33.81 equals the Oct 7 low (33.81) and is just below the Oct 8 low (33.83), so it is a nearby support level.
The middle band at 35.60 sits just above the gap-fill level (35.02–35.15).

7. Volume and money flow¶

OBV: fell from −1,230.2M (Sep 8) to −1,681.4M (Oct 2), a drop of 451M that confirmed the decline. It has since recovered to −1,555.6M (+125.8M), only about 28% of that drop.
Volume pattern: September volume (roughly 30–52M a day) ran well above July–August (roughly 12–28M) while price fell, which looks like sustained selling.
After the Oct 2 spike, volume tapered: 69.6M, 50.1M, 37.6M and 43.7M.
A bounce on falling volume is often a weak one, so a bear-flag pattern is possible: a brief rise on light volume before the decline continues.

8. Exhaustion and stretch¶

TD-9:
Weekly +9 and monthly +9: buy setups complete. This is the strongest exhaustion signal in the set, and the two higher timeframes agree.
Daily −1: the first day of a new sell setup, meaning the close was above the close four days earlier. This supports a short-term upturn.
In DeMark practice, completed setups often lead to a bounce lasting a few bars. They lose their meaning if price breaks to new lows below the setup's low. I'd use the Oct 2 low of 31.97 as that reference, though the tool doesn't provide the setup's exact low.
Z-score: weekly −1.59, monthly −1.60, daily −0.96. Price is well below its average on the higher timeframes but not at the ±2 level that usually signals an extreme. There is still room to fall further before it becomes statistically extreme.

9. Key price levels¶

Level	What it is
31.97	Oct 2 low, the lowest price in 12 months; main invalidation level for a bounce
32.76	Oct 5 low, a higher low after the gap
33.81–33.87	Bollinger lower band, Oct 7–8 lows, Oct 2 close: nearest support
34.94	10 EMA, the first short-term hurdle
33.97–35.02 / 35.15	Unfilled gap and the Oct 1 close before the gap
35.60	Bollinger middle (20 SMA)
36.38–36.39	Daily SuperTrend stop and Sep 28 close: key resistance
37.40	Bollinger upper band
38.10	50 SMA (still falling)
42.72 / 47.31 / 59.30	Weekly SuperTrend, 200 SMA, monthly SuperTrend

10. Scenarios and trade setups¶

A. Relief bounce. This fits the weekly and monthly TD-9 signals, the strong close on the gap day and the MACD divergence. - Confirmation steps: a daily close above 34.94 (10 EMA), then above 35.15 (gap filled), then above 35.60. - Better still: MACD histogram growing past roughly +0.05 and RSI above 42. - Targets: 35.60, then 36.38, then 37.40. - Only a close above 36.4, which would flip the daily SuperTrend, would change the short-term trend. Even then, the 50 SMA (about 38) and the weekly stop (42.72) stay well above.

B. Downtrend resumes. This is the base case given the trend structure. - Signals: rejection in the 35.0–36.4 zone, or a daily close below 33.81. - That would point to a retest of 32.76 and 31.97. - A close below 31.97 would cancel the higher-timeframe exhaustion signals and leave no support visible in the data.

Risk and position sizing (ATR 1.12): - Short sellers / trend followers: the risk/reward is better when selling into 35.6–36.4 than at 34.74. - Stop around 37.4–37.5 (the upper band, or about one ATR above the daily SuperTrend). - Targets 33.81, then 31.97. - That is about 1.1–1.9 of risk for 1.8–4.4 of potential gain. - Tactical longs: keep size small and treat them as counter-trend trades. - Entering at 34.74 with a stop under 31.97 risks 2.77 (8.0%, about 2.5 ATR) to make 1.64 at 36.38. That is a poor ratio of about 0.6:1. - A stop under 32.76 risks 1.98 and gives roughly 1.3:1 to 37.40 and 1.7:1 to 38.10. - Waiting for a close above 35.15 confirms the move but costs some upside. - Sizing: shares = account risk ÷ stop distance. A 2-ATR stop is about 2.24 (6.4%). - Background facts: NKE paid a 0.41 dividend each quarter, with ex-dates on Dec 1, Mar 2, Jun 1 and Sep 1. That is 1.64 a year, about 4.7% at the current price, though the tools don't confirm future payments. The record volume around Oct 1–2 points to a major news event, but the tools don't identify it.

11. Summary table¶

Area	Reading (verified)	Signal	What it means
Price	34.74 close (2026-10-08); −51.6% over 12 months	Bearish	Lower highs and lower lows are intact
Moving averages	10 EMA 34.94 / 20 SMA 35.60 / 50 SMA 38.10 / 200 SMA 47.31	Bearish	All stacked against price; 50 SMA still falling
SuperTrend	Weekly DOWN 42.72; Monthly DOWN 59.30; Daily DOWN 36.38	Bearish	A close above 36.4 is the first trend-change trigger
MACD	−1.05 vs signal −1.06; histogram +0.01	Early bullish	Higher MACD low vs Sep 18 (−1.205); unconfirmed
RSI	38.26 (low 28.49 on Oct 2)	Neutral to bearish	Out of oversold; no divergence; stayed under 41.64 for 30 days
ATR	1.12 (3.2% of price)	Volatility up	Size for about 1.1 a day; 2-ATR stop ≈ 2.24
Bollinger	Lower 33.81 / Middle 35.60 / Upper 37.40	Lower half	33.81 support; 35.60 first resistance
OBV / Volume	−1,555.6M; recovered only 28% of drop; volume fading on bounce	Bearish lean	Sellers still dominant; bear-flag risk
TD-9	Weekly +9, Monthly +9 (complete); Daily −1	Exhaustion	Bounce watch; fails if price breaks 31.97
Z-score	Weekly −1.59, Monthly −1.60, Daily −0.96	Stretched, not extreme	Room to fall before the ±2 extreme
Gap day Oct 2	Low 31.97, closed 33.87 near day's high, 142.7M shares	Constructive	Unlike the Dec and Apr gaps, which closed weak
Resistance	34.94, 35.02–35.15, 35.60, 36.38, 37.40, 38.10	—	Dense supply zone overhead
Support	33.81–33.87, 32.76, 31.97	—	A close below 31.97 confirms the downtrend continues
Overall	Main trend DOWN; short-term bounce conditions forming	Bearish trend, possible bounce	Short sellers: sell rallies into 35.6–36.4. Longs: small, confirmed, stop under 32.76 or 31.97

Sentiment Analyst¶

Overall Sentiment: Mildly Bearish (Score: 3.8/10) Confidence: Low

NKE Sentiment Report: 2026-10-01 to 2026-10-08¶

Data coverage caveat: Only one of three sources returned usable data. - StockTwits: returned an 'unavailable' placeholder because the endpoint serves only recent items. This does NOT mean there was no $NKE chatter. - Reddit: skipped by configuration (sentiment_include_reddit disabled). - News: 14 Yahoo Finance headlines with source attribution but no article bodies.

This read therefore rests on headline framing alone. There is no retail bull/bear ratio, no message counts and no community discussion. Confidence is low.

1. Source-by-source breakdown¶

Yahoo Finance news (14 headlines) - About 9 are directly about NKE. - 3 cover peer Lululemon. - 1 covers competition in the footwear sector. - 1 covers the broad market.

1a. Dividend and yield cluster (4 headlines, the dominant theme) - Barchart, 'With a Yield Fast Approaching 5%, Nike Says Its Dividend Is the Top Priority': management is explicitly committing to the payout. This is constructive for income holders and a signalling effort by the company. - Motley Fool, 'Nike's Dividend Yield Surges to a Record 4.8%. Is the Dow Component the Ultimate Turnaround Dividend Stock or a Yield Trap?': the framing is openly two-sided. A record yield mostly reflects how far the share price has fallen, not a dividend increase. - TIKR, 'Nike Guided Earnings Below Its Dividend. Here's What Backs the CFO's Payout Pledge': this is the most important fact in the feed. Forward earnings guidance does not cover the dividend, implying a payout ratio above 100% of guided earnings. The article frames this defensively by asking what backs the pledge, but the coverage gap itself is a bearish fundamental. - Motley Fool, '1 Stat That Makes Nike Hard to Ignore This October': mildly constructive and value-oriented. The specific stat is not visible; it may be the yield or valuation, but that is inference. - Net: Mixed to mildly bearish. The yield is drawing income and value attention, but it exists because of price weakness, and guidance does not cover the payout. Mainstream outlets are openly asking whether it is a 'yield trap'.

1b. Earnings reaction and drawdown cluster (3 headlines) - Zacks, 'NIKE's Shares Fall More Than 2% Post Q1 Earnings: What's Ahead?': a negative price reaction to the fiscal Q1 print. The results and guidance evidently did not reassure. - Motley Fool, '1 Reason to Still Avoid Nike Even Though It's 80% Below Its All-Time High': explicitly bearish. It argues the drawdown alone is not a reason to buy. - Yahoo Finance, 'These 7 major S&P 500 stocks need to rally at least 200% to reclaim their peaks': its appearance in the NKE feed suggests NKE is on the list. A 200% rally to reach the peak would mean trading at roughly one-third of it or less. This reinforces the broken-chart narrative. - Net: Bearish.

1c. China cluster (2 headlines) - Barron's, 'Nike and LVMH Took China for Granted, and Both Stocks Are Paying the Price': bearish framing of a strategic misstep in a key growth market. - Simply Wall St, 'Why Is Nike (NKE) Giving Investors Less Insight Into China Sales?': NKE is disclosing less about China. Markets typically read reduced disclosure in a weak segment as a transparency concern and may assume the worst. - Net: Bearish.

1d. Peers and competition (4 headlines) - Lululemon (Quartz, Retail Dive, Trefis): three headlines on an executive reshuffle. LULU hired Athleta CEO Maggie Gauger as president and CPO, and Retail Dive says the new team has 'a great deal to prove'. Trefis asks 'What Is Lululemon No Longer Telling You?', which echoes NKE's China disclosure change. - Read-across from LULU: athletic apparel as a sector looks to be in turnaround and reduced-transparency mode. This is neutral to slightly negative for sector sentiment and neither a clear win nor loss for NKE. - Footwear News, 'This Heritage Boot Player and a Chinese Sneaker Brand Are Among the Fastest Growing U.S. TikTok Shoe Shops': challenger brands are gaining in social-commerce channels. NKE is not named, but this fits the market-share fragmentation narrative. Mildly negative.

1e. Macro (1 headline) - Motley Fool, 'Stock Market Today, Oct. 8: Tech Stocks Slide as Treasury Yields and Oil Prices Surge'. - Rising Treasury yields make a roughly 4.8% dividend yield less attractive by comparison, especially one with coverage questions. - Higher oil weighs on consumer discretionary spending and on freight and input costs. - Net: Mildly negative backdrop for a consumer cyclical.

StockTwits: unavailable. There is no bull/bear split and no message count, so it is impossible to tell whether retail is capitulating, bottom-fishing the yield, or pressing shorts.

Reddit: disabled. No read is available from r/wallstreetbets, r/stocks or r/investing.

2. Cross-source divergences and alignments¶

No cross-source comparison is possible because only news is available. The key test of whether retail is leaning against the institutional framing, for example buying the yield, cannot be performed.

Within the news flow there is a clear split: - Income and value framing: the record yield, 'dividend is the top priority', and 'hard to ignore'. - Structural bearish framing: the post-Q1 drop, China missteps and opacity, 'still avoid', and 'needs 200% rally'.

The Motley Fool alone ran three NKE pieces in one week ('avoid', 'hard to ignore', 'yield trap?'). That pattern suggests a contested name near a possible sentiment trough rather than a consensus view.

Notably, the bull case in the headlines rests almost entirely on the dividend. No headline cites revenue reacceleration, product or innovation momentum, or margin recovery as a positive.

3. Dominant narrative themes¶

Dividend sustainability vs. yield trap. The most frequent theme, in 4 of about 9 NKE headlines. The tension is management's 'top priority' pledge against guided earnings that do not cover the payout.
Deep drawdown and an unfinished turnaround. Shares are cited as about 80% below the all-time high and among the S&P 500 names furthest from their peaks, and they fell after the Q1 report.
China weakness and reduced transparency. Both a strategic-misstep narrative and a disclosure-cut narrative.
Disclosure reduction across athletic apparel. NKE on China and LULU on unspecified metrics; a sector-wide credibility theme.
Competitive fragmentation. Challenger and Chinese brands growing in US social commerce.

4. Catalysts and risks surfaced by the data¶

Potential upside catalysts - Management's explicit dividend pledge gives income investors a floor narrative. Any board affirmation or maintenance of the payout would validate it. Timing of the next dividend action is not in the provided data. - Contrarian setup: dense negative coverage, a record yield and a severe drawdown can mark sentiment exhaustion. Without StockTwits or Reddit data, capitulation or accumulation cannot be confirmed. - Any evidence of China stabilisation or better guidance would directly counter two of the main bearish themes. Nothing in the feed indicates this yet.

Downside risks - Dividend coverage: with guidance below the dividend, a stalled earnings recovery would make cut risk the dominant narrative. A cut after 'top priority' messaging would likely be a severe sentiment and credibility shock. - Q1 follow-through: the negative post-Q1 reaction suggests the market is not yet buying the turnaround timeline. - China opacity: reduced disclosure limits visibility, and the market may price in the worst case. - Macro: the 2026-10-08 surge in Treasury yields and oil pressures both yield-stock appeal and consumer discretionary demand. - Competition: challenger brands are gaining share in fast-growing digital channels.

5. Summary of key sentiment signals¶

Signal	Direction	Source	Supporting evidence
Dividend is 'top priority'	Mildly Bullish	Barchart	Management payout pledge; yield approaching 5%
Record 4.8% dividend yield	Mixed	Motley Fool	Framed as 'ultimate turnaround dividend stock or yield trap?'
Earnings guided below dividend	Bearish (defensively framed)	TIKR	Payout not covered by guidance; article examines what backs the CFO pledge
'Hard to ignore' October stat	Mildly Bullish	Motley Fool	Value/income attention; body unavailable
Shares fell >2% after Q1	Bearish	Zacks	Negative price reaction to fiscal Q1 results
'Still avoid' despite 80% drawdown	Bearish	Motley Fool	Drawdown not enough to justify buying
Needs 200%+ rally to reclaim peak	Bearish	Yahoo Finance	Deep-drawdown context (NKE inclusion inferred from feed)
China strategic misstep	Bearish	Barron's	'Took China for granted', paired with LVMH
Reduced China disclosure	Bearish	Simply Wall St	Transparency concern on a weak segment
LULU exec reshuffle and disclosure cut	Neutral to slightly negative (sector)	Quartz, Retail Dive, Trefis	Peer also in turnaround mode with less disclosure
Challenger brands on TikTok Shop	Mildly Bearish	Footwear News	Competitive fragmentation in social commerce
Treasury yields and oil surge	Mildly Bearish (macro)	Motley Fool	Hurts yield-stock appeal and consumer discretionary
Retail sentiment	N/A	StockTwits	Unavailable (recent-items-only endpoint)
Community discussion	N/A	Reddit	Disabled by config

Bottom line¶

Of the roughly 9 NKE-specific headlines: - about 5 lean bearish; - 2 are explicitly two-sided; - 2 are mildly constructive, and both rest on the dividend or valuation.

Peer and macro headlines add a mildly negative backdrop. Overall sentiment is Mildly Bearish (3.8/10) with low confidence, because two of three sources are missing and only headlines, not article bodies, were available.

The key swing factor in the narrative is dividend credibility. If the payout holds and earnings begin to close the coverage gap, the heavily negative framing could flip quickly. If not, the 'yield trap' narrative likely dominates.

This is a sentiment signal to weigh alongside fundamentals and technicals, not a price call.

News Analyst¶

NKE (NIKE, Inc.) news and macro report, as of 2026-10-08¶

Bottom line¶

Nike's own news is mixed, and the macro backdrop works against it right now.

Company: The stock is near multi-year lows. Headlines put it about 80% below its all-time high. Its dividend yield is a record ~4.8%. After Q1 FY27 earnings, guided earnings came in below the dividend. China disclosure is shrinking. Sentiment is very negative.
Macro: Over the last month, several things hit a global consumer brand at once:
The Fed raised rates.
The 10-year Treasury reached its highest level since 2002.
Oil and gas prices jumped.
The dollar rallied hard.
The household saving rate is down to 4.1%.
Lean: These sources point to a cautious-to-bearish stance in the near term. There is a contrarian deep-value case, but nothing in the next 4–8 weeks is likely to set it off. I'm not making the trade call; that is for the next agent.

1. Company news (Oct 1–8)¶

Caveat: The news tool returned headlines only, not article text, and returned nothing for Sep 24–Oct 1. Exact earnings figures (revenue, margins, EPS guidance) could not be checked and should be confirmed separately.

Theme	What the headlines say	Read-through
Q1 FY27 earnings	"NIKE's Shares Fall More Than 2% Post Q1 Earnings" (Zacks)	A modest drop for a stock already down this much. Expectations were low, so this may be partly priced in.
Dividend	"Nike Guided Earnings Below Its Dividend" (TIKR); "Yield Fast Approaching 5%, Nike Says Its Dividend Is the 'Top Priority'" (Barchart); "Record 4.8%… Turnaround Dividend Stock or Yield Trap?" (Motley Fool)	Guided EPS is below the yearly dividend, so the payout ratio is over 100%. The CFO's pledge makes a cut less likely soon, but this is now the main debate.
Price level	"80% Below Its All-Time High"; "7 major S&P 500 stocks need to rally at least 200% to reclaim their peaks"	This is my inference: with the 2021 high near $179 and a dividend around $1.60–1.64 a year, the headlines suggest NKE trades roughly in the mid-$30s. Check against live price data.
China	"Nike and LVMH Took China for Granted—and Both Stocks Are Paying the Price" (Barron's); "Why Is Nike Giving Investors Less Insight Into China Sales?" (Simply Wall St.)	Warning sign. Companies usually cut disclosure when a segment is getting worse. China has historically been one of Nike's most profitable regions.
Competition	A Chinese sneaker brand and a heritage boot maker are among the fastest-growing U.S. TikTok Shop shoe sellers (Footwear News)	More share loss to newer brands and new sales channels, on top of pressure from On, Hoka and others.
Peers	Lululemon reshuffles executives (hires Athleta's CEO as president) and also cuts disclosure ("What Is Lululemon No Longer Telling You?")	The wider athletic apparel group is under strain. A Nike-specific recovery would stand out against that.
Sentiment	"1 Reason to Still Avoid Nike"; "1 Stat That Makes Nike Hard to Ignore This October"	Retail and media opinion is split but mostly negative. That is what you'd expect near a bottom, but it doesn't prove one.

2. Macro backdrop (FRED data)¶

The Fed is raising rates again¶

The daily effective Fed funds rate rose from 3.63% to 3.88% on 2026-09-17. That is a 25bp hike at the Sep 15–16 FOMC, which puts the target range at about 3.75–4.00%. The Fed had cut from 4.09% (Oct 2025) to 3.64% (Jan 2026) and then held.
The 2-year yield is 4.77%, about 90bp above the Fed funds rate. That fits a market expecting more hikes.

Long rates: highest since 2002¶

The 10-year is 5.28% (Oct 7), up 72bp since Jul 10 and 45bp since Sep 9. It peaked at 5.31% on Oct 5. Headline: "10-year Treasury yield hits highest level since 2002."
The 10-year real yield is 2.92%, up 60bp in three months. Implied 10-year inflation expectations are about 2.36%.
The 10y–2y curve has steepened to +0.47 from +0.20 on Sep 21, with long rates rising faster than short ones. That points to a term-premium or inflation-risk sell-off, not a growth scare.
Mortgage rates are at their highest in nearly three years. A Yahoo chart of the day warns that "rapid bond yield moves have preceded nearly every major financial blowup."

Inflation and the oil shock¶

Headline CPI was +3.4% year over year in August (334.131 vs 323.291).
Core PCE was +3.0% year over year. Over the last three months it ran at about 2.0% annualized, but the oil spike hasn't reached the data yet.
WTI was $96.24 on Oct 6, up 33% since July, after a $107 peak on Sep 15. Prices are very volatile and tied to Iran headlines; Trump said the U.S. will not attack Iran before the midterms.
Gasoline is $4.35 a gallon, versus $3.78 in early July and a $4.48 peak on Sep 21.

Consumer health: still earning, but stretched¶

Indicator	Latest	Trend
Unemployment	4.2% (Sep)	Stable, roughly 4.1–4.3%
Initial jobless claims	197k (w/e Oct 3)	Low; the labor market is tight
Retail sales (nominal)	+1.1% m/m (Aug)	Firm, but helped by inflation
Personal saving rate	4.1% (Aug)	Down from 5.6% in January; consumers are spending savings
UMich consumer sentiment	51.7 (Aug)	Very weak; it was 44.8 in May 2026

Dollar and markets¶

The broad dollar index rose ~3% in three weeks (117.9 on Sep 9 to 121.4 on Oct 2). EUR/USD fell from 1.163 to 1.126.
The VIX is about 15, which looks complacent given how fast rates are moving. Gold is at $4,132. Bitcoin is below $83k. On Oct 8, tech fell as yields and oil rose. Small caps and the Dow (which includes NKE) slipped midweek.

3. How the macro hits NKE¶

Valuation: Real yields of 2.9% hurt long-duration turnaround stories. NKE's ~4.8% yield is now below the 10-year (5.28%) and about equal to the 2-year (4.77%). Income buyers can get similar yields from Treasuries with no risk of a dividend cut, so they have little reason to support the stock.
Currency: More than half of Nike's revenue comes from outside the U.S. A ~3% rise in the dollar within the quarter, and a 3% drop in the euro, will hurt reported results. Hedges soften this but delay it rather than remove it.
Costs: Oil at about $96 feeds into foam (EVA), synthetic rubber, polyester and freight. That adds gross-margin pressure while Nike is already clearing inventory.
Demand: Gas at $4.35, a 4.1% saving rate, weak sentiment and mortgage rates at a three-year high squeeze the lower- and middle-income shoppers who buy Nike's mainstream products, heading into the holidays.
Policy: A Fed that hikes when inflation is 3%+ and unemployment is 4.2% offers no "Fed put" for consumer stocks.
Offsets: Jobs are solid (claims under 200k), so people still have income. Valuation and sentiment are near extremes. The quiet earnings reaction suggests most of the bad news is known.

4. Bull vs. bear¶

Bear case (stronger right now) - Guided earnings are below the dividend. If the turnaround stalls, the dividend is at risk. - Cutting China disclosure suggests weakness there. - Share is shifting to newer brands, TikTok Shop sellers and Chinese brands. - Rates, the dollar, oil and consumer stress are all working against Nike at once.

Bull case (contrarian) - The stock is about 80% off its high, with a record yield and very negative sentiment. - The CFO publicly committed to the dividend, which cuts near-term cut risk. - The muted post-earnings move hints at capitulation. - Any easing in oil or yields (for example, from the Iran comment) could spark a sharp short-covering rally in a heavily shorted Dow name.

5. Upcoming catalysts¶

Date (approx.)	Event	Why it matters for NKE
Mid-Oct	September CPI	The first CPI with the oil shock in it. A hot print means more hikes and higher yields.
Mid-Oct	September retail sales	Shows whether spending holds up as savings fall.
Oct (prelim and final)	UMich sentiment, October	Read on the consumer heading into the holidays.
Oct 27–28	FOMC	Whether the Fed hikes again. The 2-year suggests the market expects more tightening.
Nov 3	U.S. midterms	Iran-strike risk is pushed past this date. Tariff policy may shift after.
~Mid-Nov	Nike's usual dividend declaration	Key test of the "top priority" pledge.
Late Nov–Dec	Black Friday and holiday sales	Demand check for discretionary spending.
~Late Dec	Q2 FY27 earnings	Next fundamental catalyst: China, margins, guidance.

6. Takeaways for the decision-maker¶

Watch the 10-year as the trigger. The 5.30–5.31% area (Oct 5 high) is the line. A sustained break above it likely means more multiple compression for NKE. A drop back below about 5.0% would be the first good macro sign for the stock.
Don't use the yield as a floor. At 4.8% it sits below the 10-year, and payout cover is over 100%. Treat it as a risk to manage.
Mind the timing. The next real company catalyst (dividend declaration, then Q2 earnings) is 5–11 weeks away, while CPI and the FOMC land within three weeks. Macro is likely to drive NKE until then.
Expect currency to hurt the next report. The dollar's September move points to reported-revenue pressure at Q2 FY27.
Look at relative value. The dollar, China and oil hurt NKE more than domestically focused discretionary names. Any pair trade is for the next agent to size.
Remember the contrarian case. Sentiment is extreme and the reaction to bad guidance was muted. If oil, the dollar and yields all reverse together, NKE could rally sharply. Shorts face that squeeze risk.

What I couldn't get: - Prediction-market odds were withheld for this date, so there are no market-implied odds for Fed moves or recession. - Company news for Sep 24–Oct 1 was unavailable. - Earnings details weren't verified. - The price level is inferred from headlines.

Summary table¶

Category	Key point	Evidence	NKE impact
Earnings	Q1 FY27 reaction was mild	Shares fell >2% after earnings (Zacks)	Neutral / slightly positive (bad news largely priced in)
Dividend	Guided EPS below dividend; CFO calls it "top priority"	TIKR, Barchart; record ~4.8% yield	Negative (payout ratio >100%; cut risk)
China	Less disclosure; Barron's says Nike "took China for granted"	Simply Wall St., Barron's	Negative
Competition	Chinese and heritage brands growing fast on TikTok Shop; Lululemon turmoil	Footwear News, Retail Dive	Negative (share loss; sector stress)
Price and sentiment	~80% below ATH; needs 200%+ to recover; "avoid" headlines	Motley Fool, Yahoo Finance	Contrarian positive, but no catalyst soon
Fed policy	25bp hike Sep 16; EFFR 3.63% → 3.88%	FRED DFF	Negative
Rates	10y 5.28% (highest since 2002); real 10y 2.92%; 2y 4.77%	FRED DGS10, DFII10, DGS2	Negative (valuation; yield no longer stands out)
Inflation	CPI +3.4% y/y; core PCE +3.0% y/y	FRED CPIAUCSL, PCEPILFE	Negative (more hikes possible)
Oil and gas	WTI ~$96 (+33% since Jul); gas $4.35/gal	FRED DCOILWTICO, GASREGW	Negative (input costs; squeezed consumer)
Dollar	Broad USD +3% since Sep 9; EUR/USD 1.163 → 1.126	FRED DTWEXBGS, DEXUSEU	Negative (currency hit to reported results)
Consumer	Saving rate 4.1%; UMich 51.7; unemployment 4.2%; claims 197k	FRED	Mixed (jobs firm, spending power stretched)
Risk mood	VIX ~15; gold $4,132; BTC <$83k; "rapid yield moves precede blowups"	FRED VIXCLS, news	Tail risk underpriced
Geopolitics	Trump: no Iran strike before midterms	Yahoo Finance	Lowers near-term oil spike risk; pushes it out
Next catalysts	Sep CPI (mid-Oct), FOMC (Oct 27–28), dividend declaration (~mid-Nov), Q2 FY27 (~late Dec)	Calendar	Macro drives the stock until company events
Overall lean	Cautious to bearish near term; contrarian value longer term	All of the above	Final trade call left to the decision agent

Fundamentals Analyst¶

NKE (NIKE, Inc.): Fundamental Research Report¶

As of: 2026-10-08 | Exchange: NYQ | Sector: Consumer Cyclical / Footwear & Accessories Fiscal year: Ends May 31. The latest filed quarter is Q1 FY27, the quarter ended 2026-08-31.

1. What data was available¶

Tool	Result
`get_income_statement` (quarterly and annual)	✅ SEC EDGAR figures as originally filed, up to 2026-08-31
`get_balance_sheet` (quarterly and annual)	✅ Up to 2026-08-31
`get_cashflow` (quarterly and annual)	✅ Year-to-date figures, which I split into individual quarters
`get_fundamentals` (market cap, multiples, 52-week range)	❌ Withheld: the vendor can't give values as they stood on this date
`get_insider_transactions`	❌ Withheld: no filing dates, so it can't show what was public on this date

What this means for the next analyst: - I have no share price, valuation multiples, insider activity, or news from the past week. Section 9 gives a valuation grid you can read against the live price. - Operating income, total liabilities, debt, inventory, receivables and dividends were not tagged in the data. Some figures below are calculated from other lines, and I label those. - The fiscal Q4 figures (quarters ended May) are calculated as the annual total minus the first nine months.

2. Company profile¶

NIKE, Inc. (NKE) is the world's largest athletic footwear and apparel company. Its brands include Nike, Jordan and Converse, and it sells through wholesale partners and its own stores and apps (NIKE Direct). Footwear is most of its revenue. Its business follows consumer spending, so it is sensitive to the economy, foreign exchange and tariffs. The November quarter (Q2) is usually its biggest.

3. Latest quarter: Q1 FY27 (ended 2026-08-31) vs. the same quarter a year earlier¶

Metric	Q1 FY27	Q1 FY26	Change
Revenue	$11,213M	$11,720M	−4.3%
Cost of revenue	$6,415M	$6,777M	−5.3%
Gross profit	$4,798M	$4,943M	−2.9%
Gross margin	42.8%	42.2%	+0.6 pts (see caveat in §5)
Net income	$712M	$727M	−2.1%
Net margin	6.3%	6.2%	+0.15 pts
Diluted EPS	$0.48	$0.49	−2.0%
Operating cash flow	$135M	$222M	−39%
Capital expenditure	$199M	$207M	−4%
Free cash flow	−$64M	+$15M	Negative
Cash and equivalents	$6,903M	$7,024M	−1.7% (−8.7% vs. May 2026)
Shareholders' equity	$15,220M	$13,468M	+13.0%
Current ratio (current assets ÷ current liabilities)	2.07x	2.19x	Lower

Takeaways: - Earnings held up but sales did not. Revenue fell 4.3%, yet EPS fell only 2%. - Profit was protected in two ways. Gross margin rose about 0.6 points. Costs between gross profit and net income also fell about $130M (−3.1%, from $4,216M to $4,086M). That bucket includes overhead, marketing, interest and tax. - Revenue is down about 2.2% versus the same quarter two years ago, but EPS is down 31% ($0.70 → $0.48). Earnings have stopped falling, but they remain far below past levels.

4. Last nine quarters¶

Quarter (end date)	Revenue	Revenue vs. year earlier	Gross margin	Net income	EPS	EPS vs. year earlier	Op. cash flow	Free cash flow
Q1 FY25 (Aug-24)	11,589	−10.4%	45.4%	1,051	0.70	−26%	394	274
Q2 FY25 (Nov-24)	12,354	−7.7%	43.6%	1,163	0.78	−24%	1,049	920
Q3 FY25 (Feb-25)	11,269	−9.3%	41.5%	794	0.54	−30%	1,792	1,711
Q4 FY25 (May-25)*	11,097	−12.0%	40.3%	211	0.14	−86%	463	363
Q1 FY26 (Aug-25)	11,720	+1.1%	42.2%	727	0.49	−30%	222	15
Q2 FY26 (Nov-25)	12,427	+0.6%	40.6%	792	0.53	−32%	579	386
Q3 FY26 (Feb-26)	11,279	+0.1%	40.2%	520	0.35	−35%	430	284
Q4 FY26 (May-26)*	10,972	−1.1%	49.2%?	1,069	0.73	+421%	1,637	1,499
Q1 FY27 (Aug-26)	11,213	−4.3%	42.8%	712	0.48	−2%	135	−64

*Calculated as annual total minus the first nine months. Dollar figures are in $M.

Revenue is getting worse again. Year-over-year growth went +1.1%, +0.6%, +0.1%, −1.1%, then −4.3%: five quarters of steady slowdown. The FY26 recovery was flat sales, not real growth, and it is now reversing. This is the main fundamental concern.

5. Margins, and a data problem to check¶

Gross margin trend: about 45% in early FY25, falling to 40.2% in Q3 FY26. That reflects discounting, inventory clearance, tariffs and shifts in sales channel.
Q1 FY27's 42.8% is the first year-over-year gross margin gain since Q1 FY25.
⚠️ Q4 FY26 anomaly. The first nine months of FY26 had a 41.0% gross margin, but the full year shows 42.9%. That implies Q4 FY26 gross margin of about 49.2%, which Nike has never come close to. The likely cause is that the annual report reclassified some costs differently from the quarterly reports.
Why it matters: if costs were moved out of cost of revenue, Q1 FY27's 42.8% may be on a new basis. The +0.6-point gain over Q1 FY26 (old basis) might not be a true like-for-like improvement.
To do: check the Q1 FY27 10-Q's restated prior-year comparison before treating the margin improvement as real.
Net income is not affected by that reclassification, so EPS comparisons are more reliable.
Calculated Q4 FY26 net income was $1,069M (EPS $0.73), up from $211M the year before.
That jump came on 1.1% lower sales, so it may include one-off items such as a tax benefit or a reversal of restructuring costs. Check the 10-K.
Net margin over the years: 12.9% (FY21–22), 11.1% (FY24), 7.0% (FY25), 6.7% (FY26), 6.3% (Q1 FY27). Profitability is about half its peak.

6. Annual history¶

Fiscal year	Revenue ($M)	Change	Gross margin	Net income ($M)	Net margin	EPS	Op. cash flow ($M)	Capex ($M)	Free cash flow ($M)
FY20	37,403	−4.4%	43.4%	2,539	6.8%	1.60	2,485	1,086	1,399
FY21	44,538	+19.1%	44.8%	5,727	12.9%	3.56	6,657	695	5,962
FY22	46,710	+4.9%	46.0%	6,046	12.9%	3.75	5,188	758	4,430
FY23	51,217	+9.6%	43.5%	5,070	9.9%	3.23	5,841	969	4,872
FY24	51,362	+0.3%	44.6%	5,700	11.1%	3.73	7,429	812	6,617
FY25	46,309	−9.8%	42.7%	3,219	7.0%	2.16	3,698	430	3,268
FY26	46,398	+0.2%	42.9%⚠️	3,108	6.7%	2.10	2,868	684	2,184
Last 12 months (to Q1 FY27)	45,891	—	—	3,093	6.7%	2.09	2,781	676	2,105

Longer-term context: - Revenue is 10.7% below the FY24 peak. Net income is 49% below the FY22 peak, and EPS is 44% below it. - Revenue grew about 3.7% a year from FY16 to FY26, but under 1% a year from FY21 to FY26. - FY26 operating cash flow ($2.87B) was the lowest since the COVID year FY20. Before that, you have to go back to FY12. - EPS before FY12 is not adjusted for the 2012 and 2015 stock splits. FY18 includes a one-time charge from the 2017 US tax law (Q3 FY18 loss of −$921M).

7. Cash flow and capital returns¶

Cash generation is weakening. Free cash flow fell from $6.6B (FY24) to $3.3B (FY25), $2.2B (FY26), and $2.1B over the last 12 months.
FY26 free cash flow covered only 70% of net income, versus 116% in FY24.
Q1 is seasonally weak, but this was the first negative Q1 free cash flow since FY24 (Q1 FY24 operating cash flow was −$66M).
Share buybacks look to have stopped. Total cash paid out through financing fell from −$7.4B (FY23), −$5.9B (FY24) and −$5.8B (FY25) to −$2.3B in FY26. It was −$618M in Q1 FY27.
Quarterly payouts of about $0.5–0.6B match a dividend of roughly $0.40–0.41 per share on about 1.48B shares.
So recent payouts look like dividends only, with no meaningful buybacks. This is my inference; dividends are not broken out in the data.
Diluted share count has stopped shrinking (calculated as net income ÷ EPS): about 1,543M (Q1 FY24), 1,501M (Q1 FY25), 1,484M (Q1 FY26), 1,483M (Q1 FY27). EPS no longer gets a lift from buybacks.
⚠️ The dividend isn't fully covered. Last-12-month free cash flow of $2.1B against about $2.3B paid out gives roughly 0.9x coverage. The payout is about 75% of net income.
The dividend looks safe in the near term given about $6.9B cash and an equity base that is growing.
But there is little room for buybacks or dividend increases unless free cash flow recovers.

8. Balance sheet and liquidity¶

Item ($M)	Aug-26	May-26	Aug-25	May-25	May-24	May-22
Total assets	37,794	38,410	37,334	36,579	38,110	40,321
Current assets	23,673	24,603	23,898	23,362	25,382	28,213
Cash and equivalents	6,903	7,563	7,024	7,464	9,860	8,574
Current liabilities	11,409	12,547	10,911	10,566	10,593	10,730
Shareholders' equity	15,220	14,865	13,468	13,213	14,430	15,281
Total liabilities (assets − equity)	22,574	23,545	23,866	23,366	23,680	25,040
Current ratio	2.07x	1.96x	2.19x	2.21x	2.40x	2.63x
Liabilities ÷ equity	1.48x	1.58x	1.77x	1.77x	1.64x	1.64x

Solvency is solid. Equity of $15.2B is near its 2022 high, and liabilities relative to equity are the lowest in this period. Keeping profits instead of buying back stock is rebuilding the balance sheet.
Liquidity is lower but still healthy.
The current ratio has fallen from 2.6–2.7x (FY22–23) to about 2.0x.
Current liabilities rose from November 2025 onward. One possibility, not confirmed, is that a bond maturing within a year was moved into current liabilities.
Cash covers 0.61x of current liabilities. Short-term investments are reported separately and are not included in this cash figure.
Cash has fallen almost $3.0B from May 2024 ($9.86B → $6.90B).
⚠️ Possible inventory build. Current assets other than cash (inventory, receivables, investments and prepaid items) were $16.8B, flat year over year, while revenue fell 4.3%. Inventory can't be isolated in this data. If inventory is rising against falling sales, that would point to more discounting later. Check the 10-Q.

9. Returns and valuation¶

Returns: - Return on equity: about 22% over the last 12 months (FY26: 22.1%), down from about 40% (FY24) and 43% (FY22). - Return on assets: about 8.2%, down from about 15%.

Valuation grid: I have no share price, so read these against the live NKE quote. They use last-12-month EPS of $2.09, free cash flow of $1.42 per share, book value of about $10.26 per share, and about 1.483B diluted shares.

NKE share price	Price ÷ earnings	Free cash flow yield	Price ÷ book	Price ÷ sales
$50	23.9x	2.8%	4.9x	1.6x
$60	28.7x	2.4%	5.8x	1.9x
$70	33.5x	2.0%	6.8x	2.3x
$80	38.3x	1.8%	7.8x	2.6x

At almost any plausible price, NKE trades at a recovery multiple: earnings are about half their peak and free cash flow yield is low. The stock price is betting that margins and EPS return toward the FY22–24 range of $3.2–3.75. The latest quarter shows margins and costs stabilizing, but not the revenue growth that a full recovery would need.

10. Insider activity and news¶

Not available. The insider tool withheld data for this date, and I have no news tool. Another agent should check recent Form 4 filings and news from the past week, including the Q1 FY27 earnings call and guidance.

11. Fundamental view for the next analyst (not a trade call)¶

Positives: 1. EPS decline has narrowed to −2% from −30% to −35% through FY26. 2. Gross margin rose year over year for the first time in five quarters (pending the reclassification check). 3. Costs below gross profit are falling about 3% a year. 4. Equity is up 13% year over year, the liabilities-to-equity ratio is the lowest in this period, and the current ratio is about 2x. 5. Calculated Q4 FY26 net income of $1.07B (if it is not a one-off).

Negatives: 1. Revenue decline is speeding up again (−4.3%). 2. Q1 free cash flow was negative. Last-12-month free cash flow of $2.1B doesn't fully cover the roughly $2.3B dividend. 3. Operating cash flow is the lowest in years. 4. Cash is down $3B over two years. 5. The buyback lift to EPS is gone. 6. Return on equity has halved. 7. Inventory may be building against falling sales. 8. The data problem in reported margins.

Overall fundamental lean: neutral to cautious. Profit stability has improved, but the top line, which a full recovery depends on, is going the wrong way.

What would change that view: - More positive: revenue growth turning positive in Q2 FY27 (the November holiday quarter, typically reported in mid-to-late December), gross margin above 43% on a like-for-like basis, and buybacks resuming. - More negative: revenue falling more than 5%, another quarter of negative or very low free cash flow, or the margin gain turning out to be only an accounting change.

Summary table¶

Category	Key point	Evidence	Signal
Revenue trend	Decline is speeding up again	Growth +1.1% → +0.6% → +0.1% → −1.1% → −4.3% (Q1 FY27: $11.21B)	🔴 Negative
Earnings	Decline has largely stopped	Q1 FY27 EPS $0.48 vs $0.49 (−2%), after −30% to −35% in FY26	🟡 Stabilizing
Gross margin	First year-over-year gain in five quarters, but may not be like-for-like	42.8% vs 42.2%; calculated Q4 FY26 margin of 49.2% points to a reclassification	🟡 Verify
Cost control	Costs below gross profit down about 3%	$4,086M vs $4,216M	🟢 Positive
Net margin	About half its peak	6.3% now vs 12.9% in FY21–22	🔴 Weak
Last 12 months	Revenue $45.9B, net income $3.09B, EPS $2.09	Built from annual and quarterly filings	—
Free cash flow	Falling; Q1 negative	FY24 $6.6B → FY26 $2.2B; Q1 FY27 −$64M	🔴 Negative
Dividend coverage	Tight	Free cash flow about 0.9x of ~$2.3B payout (payout estimated)	🟠 Watch
Buybacks	Effectively stopped	Financing outflow $5.8B (FY25) → $2.3B (FY26); share count flat at ~1.48B	🟠 No EPS lift
Cash	Shrinking	$9.86B (May-24) → $6.90B (Aug-26)	🟠 Watch
Solvency	Strong and improving	Equity $15.2B (+13% YoY); liabilities ÷ equity 1.48x	🟢 Positive
Liquidity	Lower but adequate	Current ratio 2.07x (vs 2.6x in FY22)	🟡 Neutral
Returns	Return on equity halved	~22% now vs ~40% in FY24	🔴 Weak
Inventory	Possible build-up	Non-cash current assets flat while sales fell 4.3%	🟠 Verify in 10-Q
Valuation	Priced for recovery	At $60: ~29x earnings, ~2.4% free cash flow yield (no live price available)	🟡 Depends on price
Insider and news	Not available	Tools withheld data for this date	⚪ Gap
Next catalyst	Q2 FY27 results (Nov-26 quarter)	Typically reported mid-to-late December	📅 Key event
Overall lean	Neutral to cautious	Profits stabilizing, revenue falling, cash generation weak	⚖️

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # Bull Opening: NKE

The bear hasn't spoken yet, so I'll open with the case and answer the objections I expect to hear.

My thesis is simple. The stock has fallen much further than the business. NKE closed at $34.74, down 51.6% in twelve months and about 80% from its all-time high. Over the same period, trailing revenue of $45.9B sits only 10.7% below the FY24 peak. The market is valuing NKE as a broken franchise. The numbers describe a stressed one, still earning a 22% return on equity at what looks like the bottom of its cycle.

1. Valuation is already pessimistic¶

Here is what you pay at $34.74, using trailing figures from the filings:

Metric	At $34.74
Trailing P/E (LTM EPS $2.09)	~16.6x
Price/Sales (~$51.5B market cap on $45.9B revenue)	~1.1x
Free cash flow yield (LTM FCF $2.1B)	~4.1%
Dividend yield ($1.64/yr)	~4.7%
Return on equity	~22%

The fundamentals analyst built a valuation grid for "any plausible price," and the lowest row was $50. The stock trades about 30% below that floor.

You don't need a heroic recovery for this to work. Suppose net margin returns to 9.9%, Nike's FY23 level, which is well below its 12.9% peak. On today's smaller revenue base, that gives about $3.05 in EPS. At today's 16.6x multiple, that's roughly $51, about 46% upside, before dividends and with no revenue growth.

I'll concede one point up front. Management guided earnings below the $1.64 dividend, so on forward guidance the multiple is above 21x. NKE is not cheap on next year's guide. The bull case is that this guide is the trough, and franchises are bought at trough earnings, not peak earnings.

2. Earnings are stabilizing¶

Look at Q1 FY27 more closely:

EPS fell only 2% ($0.48 vs $0.49). Every quarter of FY26 fell 30–35%. That is a clear change in trend.
Revenue fell 4.3%, gross profit fell 2.9%, and net income fell 2.1%. Profits are falling at half the rate of sales.
Operating and other costs fell $130M (−3.1%). Cost discipline is showing up in the numbers.
Gross margin rose 0.6 points to 42.8%, the first year-over-year gain in five quarters.
The caveat: a possible reclassification in the FY26 annual report may flatter this comparison. That needs checking against the 10-Q.
Net income can't be moved by reclassification, though, and net margin still rose from 6.2% to 6.3%.

3. The "yield trap" worry is overstated¶

The bear's strongest point will be dividend coverage, so here are the numbers:

The coverage gap is small. LTM free cash flow is about $2.1B against roughly $2.3B in dividends, a shortfall of about $200–300M a year.
Nike has $6.9B in cash, not counting short-term investments.
The negative Q1 cash flow is seasonal. In FY26, Q1 free cash flow was $15M and Q4 was $1.5B. Q1 is always the weak quarter.
The balance sheet is getting stronger.
Equity rose 13% year over year to $15.2B.
Liabilities-to-equity is 1.48x, the lowest in the dataset.
The current ratio is 2.07x.
The paused buybacks are what rebuilt that equity base. They are also a lever management can pull later.
The CFO has publicly called the dividend the "top priority." Cutting it after that pledge would cost management a lot of credibility. The mid-November dividend declaration is a clear test, and I expect it to pass.

The bear may say a 5.28% 10-year Treasury beats a 4.7% NKE yield. A Treasury returns par at best. NKE pays 4.7% and also gives you exposure to a recovery in earnings. And if the 10-year falls back from its highest level since 2002, the yield comparison reverses quickly.

4. The Oct 2 price action was a capitulation signal¶

On Oct 2, the market absorbed the worst news package it could have gotten: falling revenue, guidance below the dividend, and less disclosure on China. Here is how the stock traded:

It opened down 7.4% at $32.55 and hit a 12-month low of $31.97.
It closed at $33.87, at about 95% of the day's range.
Volume was 142.7M shares, the highest in the dataset.
It finished down only about 3.6% from the prior close. Buyers absorbed roughly half the gap.

Compare that with the last two gap-downs. On Dec 19 and Apr 1, the stock closed weak and kept falling. Oct 2 was the first time sellers were absorbed.

Since then the evidence has built:

No close below $33.87.
A higher low of $32.76 on Oct 5.
Weekly and monthly TD-9 buy setups are both complete. Those are higher-timeframe exhaustion signals, and both timeframes agree.
MACD shows a bullish divergence. Price made a lower low, but MACD bottomed at −1.125 versus −1.205 on Sep 18. It has also crossed its signal line.
RSI recovered from 28.5 to 38.3.

I'm not claiming the trend has reversed. The stock is still below every moving average, volume is fading on the bounce, and OBV has recovered only 28% of its drop. My claim is narrower: selling exhaustion is showing up on the higher timeframes, and that is where bottoms usually appear first.

5. Sentiment and macro are already extremely negative¶

Sentiment scores 3.8 out of 10. Headlines include "Still Avoid," "Yield Trap?," and "Needs a 200% rally." The Motley Fool ran three contradictory NKE pieces in a single week. Coverage like that usually shows up near a sentiment low, not in the middle of a decline.

The macro headwinds are real and I'm not dismissing them:

The Fed hiked rates.
The 10-year is at 5.28%.
WTI oil is at $96.
The dollar is up 3%.

But several of these are at or near extremes, and the consumer is still employed:

Jobless claims are 197k.
Unemployment is 4.2%.
August retail sales rose 1.1%.
The President has said there will be no strike on Iran before the midterms, which lowers near-term oil spike risk.

That leaves an asymmetry. If oil, the dollar and yields ease together, NKE's three biggest macro headwinds turn into tailwinds at the same moment.

6. Answering the bear in advance¶

"Revenue is decelerating." This is the clearest negative, and I won't dodge it. But revenue down 4.3% alongside rising gross margin and falling costs fits a company choosing better-quality sales over volume. That's my reading, and the December quarter will test it. Even if revenue stays flat, margin recovery alone gets EPS back toward normal.

"China." The reduced disclosure is a legitimate warning sign. But when Barron's runs the headline, the concern is widely known and largely reflected in the price.

"Competition from Hoka, On and TikTok shops." Nike makes roughly $19–20B a year in gross profit, which pays for marketing, athlete deals and distribution at a scale challengers can't match. Losing some share at the edges doesn't make a $46B brand a value trap at 1.1x sales.

"The trend is down." Every bottom forms inside a downtrend. What matters is whether the risk is defined, and here it is.

7. How I'd own it¶

Time horizon. This is a position trade, not a swing trade. The technical report is right that the reward-to-risk up to the first resistance level is poor.

Entry and sizing. Start with half a position near current levels, and add on pullbacks toward $33.8.

Where I'm wrong. A daily close below $31.97, about 8% downside. A break there also cancels the TD-9 exhaustion signals.

Signals to add more: - A close above $35.15, which fills the gap. - A close above $36.38, which flips the daily SuperTrend.

Upside targets:

Target	Level	Upside
50-day SMA	$38.10	+10%
Weekly SuperTrend	$42.72	+23%
200-day SMA	$47.31	+36%
Normalized value (12–18 months)	~$46–51	—

On top of that, the stock pays about 4.7% a year. Against 8% defined downside, that's roughly 4–5:1 reward-to-risk over the full horizon.

Upcoming catalysts: - September CPI - FOMC, Oct 27–28 - Dividend declaration, mid-November - Q2 FY27 results, late December

Questions for the bear:

If NKE at 16.6x trough earnings and 1.1x sales, with a 4.7% yield backed by $6.9B in cash and a 22% ROE at the bottom, isn't a buy after a high-volume earnings reversal, at what price would it be one?
What specific risk is not already reflected in a stock that has lost half its value in twelve months? Bull Analyst: # Bull Rebuttal: NKE

The bear caught several real mistakes in my opening. I'll correct those first. Then I'll show why the corrected numbers still support owning NKE, though in a smaller position, with a slower entry, and sized for gaps.

1. What I got wrong¶

Q4 FY26 was up 421%, not down 30–35%. My "every quarter" line was wrong, and it means the $2.09 trailing EPS is flattered. From here I'll use guided earnings as the main multiple. On that basis NKE trades at about 21–22x, not 16.6x.
Dec 19 did not "keep falling." It closed weak, then fully recovered to $64.59.
The $50 row was where the grid started, not a floor. I withdraw that point.
Sentiment is 3.8/10, "mildly bearish," with low confidence. Calling it "extremely negative" overstated it.
Buybacks aren't a lever while free cash flow is below the dividend. I withdraw that too.
The 4–5:1 reward-to-risk was wrong. A stop doesn't protect against a gap. Section 7 has revised numbers.

These corrections change how I'd size and enter the trade. They don't change the direction.

2. Most of the bear's "−28%" comes from one quarter¶

The bear uses Q4 FY26 in two different ways: - It's an anomaly when it inflates my trailing P/E. - It's a real base when he calculates how far Q2–Q4 have to fall.

It can't be both. Here is the split:

EPS	FY26	FY27
Q1	$0.49	$0.48 (−2%)
Q2 + Q3	$0.88	?
Q4	$0.73 (flagged as a possible one-off)	?
Full year	$2.10	below $1.64 (guide)

Suppose Q2 and Q3 come in roughly flat, as Q1 did. That puts FY27 at about $1.34 before Q4. The guide then implies Q4 below about $0.30, which sits between the $0.14 of Q4 FY25 and the unusual $0.73 of Q4 FY26.

So the guide is consistent with three roughly flat quarters plus a Q4 that falls back from an outlier. It doesn't require the broad 28% decline the bear describes. One caveat: neither of us has the exact guide figure or knows whether it's GAAP. We're both working from a headline.

The "net margin falls at every step" sequence also mixes annual and quarterly figures. Comparing the same quarter each year: - Q1 FY25: 9.1% - Q1 FY26: 6.2% - Q1 FY27: 6.3%

On a like-for-like basis, the decline has stopped. I accept that some of that 0.15 points could come from the tax line. The data can't split it out.

This makes the thesis testable. Q2 FY26 EPS was $0.53. I've lowered my bar for the stronger dollar. - If Q2 FY27 comes in at the high $0.40s or better, stabilization holds. - If it comes in below about $0.45 (−15%), the bear's reading is right, and I'll cut.

3. The multiple has already deflated¶

I agree with the bear that most of the 80% drop came from a 48x multiple deflating. The question is how much of that deflation is left. He says "the same was said at $71, $51 and $43." Here is what those prices meant at the time:

Date	Price	Trailing EPS then	Trailing P/E
Oct 1, 2025	$71.83	$1.95–2.16	~33–37x
Dec 19, 2025	$57.20	$1.70	~34x
Apr 1, 2026	$43.77	$1.51	~29x
Oct 8, 2026	$34.74	$2.09 trailing / ≤$1.64 guided	~16.6x / ~21–22x

The earlier figures include the weak $0.14 Q4 FY25, which inflates them. Swap in a normal Q4 and they still land in the mid-20s to low-30s. On management's own guide, NKE now trades at its lowest multiple of the past year. The earlier "it's cheap" calls were made near 30x. This one isn't.

On the bear's "$31 buy price": that is the price where the earnings yield equals the nominal 10-year yield. That method has two problems. - It treats a nominal earnings stream like a fixed coupon. Earnings rise with inflation and bond coupons don't. The fairer comparison is the real 10-year yield of 2.92%. NKE's guided earnings yield of about 4.7% gives roughly 1.8 points of premium over that, at trough earnings, before any recovery. - The "fair price" moves with rates. Under this method it shifts about $1.50 for every 25bp move in the 10-year. That's a call on rates, not a valuation of Nike.

4. Dividend and cash: rechecking the bear's numbers¶

The $3B cash decline was buybacks, not dividend funding. - FY25: cash fell $2.4B. That was the last buyback year, with a $5.8B financing outflow. - FY26: buybacks stopped, and cash went from $7.46B to $7.56B while Nike paid the full dividend. - Q1 FY27: cash fell $660M, versus a $440M Q1 drop the year before. That's the same seasonal pattern, a bit worse.

So in the one full year without buybacks, Nike funded its dividend from cash flow and held cash flat.

The $700M gap assumes the worst cash conversion in six years. Free cash flow as a share of net income:

Year	FY21	FY22	FY23	FY24	FY25	FY26
Conversion	104%	73%	96%	116%	102%	70%

The bear uses FY26's 70%. The six-year average is about 93%.
At 93% on about $2.4B of guided net income, free cash flow is about $2.25B. That is close to the ~$2.3–2.4B dividend.
A realistic gap is $0.1–0.7B.
Capex is also flexible: $430M in FY25 versus $684M in FY26.
Even the bear's worst case is small next to $6.9B of cash. He also agrees the November declaration should pass.

The "0.61x cash coverage" leaves out short-term investments. Those sit inside the $16.8B of other current assets. The current ratio of 2.07x is the better measure. The bond reclassification is also flagged in the fundamentals report as "not confirmed."

Inventory is unknown in both directions. That same $16.8B bucket mixes inventory, receivables, short-term investments and prepaid items. A flat total doesn't tell us inventory is building any more than it tells me it isn't. I agree this is the most important thing to check in the 10-Q.

5. The chart: correction accepted, but the starting points differ¶

The Dec 19 reversal still rallied about 13% in 3½ weeks ($57.20 to $64.59). The failure came afterward. The stock was trading at about 34x, and the next quarter's EPS fell 35%. Today's reversal starts at about half that multiple, after a quarter where EPS fell 2%.
The reaction to bad news is getting smaller. Closing gaps went −10.5%, then −15.5%, then −3.6% on Oct 2. Oct 2 brought what both of us call the worst news package: falling revenue, a guide below the dividend, and less China disclosure.
I agree that Scenario B is the technical base case and that volume is fading. I'm not claiming a confirmed bottom, which is why I only add above $35.15 and $36.38.

6. Macro: one correction and several concessions¶

The correction. The bear compares +1.1% monthly retail sales with 3.4% annual CPI. CPI of 3.4% a year is about 0.3% a month, so real retail sales rose roughly 0.8% in August alone. That's strong spending, not weak.

Other context: - UMich sentiment at 51.7 is low, but it is up from 44.8 in May. - WTI is below its $107 peak, and gasoline is below its $4.48 peak.

What I actually need. I don't need oil, the dollar and yields all to reverse. I need employed consumers to keep spending: jobless claims are 197k and unemployment is 4.2%. A three-way macro reversal would be upside, not my base case.

What I concede: - The Fed is hiking, and the 2-year is pricing in more hikes. - The dollar's September jump will hit Q2 reported revenue. - Oil is pressuring input costs. - China is the biggest unknown, and I can't refute the disclosure warning with data.

These are why my Q2 bar is the high $0.40s rather than $0.53, and why the position is smaller.

7. Revised reward-to-risk¶

These scenarios cover 12–18 months. EPS and multiples are my assumptions. Dividends assume five quarterly payments, or a cut in the bear case.

Scenario	FY28 EPS (net margin)	Multiple	Price	Dividends	Total return
Bear: decline continues, dividend cut	$1.40 (~4.6%)	16x	$22.40	~$0.80	~−33%
Base: guide is the trough, slow repair	$1.90 (~6.1%)	20x	$38.00	~$2.05	~+15%
Bull: margins back to ~8%	$2.50 (~8.1%)	20x	$50.00	~$2.05	~+50%

Weighting 30/45/25 gives an expected return of about +9%.
For "avoid" to be the right call, the bear case needs to be roughly 45% or more likely.

That's a positive skew, not a 4–5:1 trade. It supports a modest position, which is what I'm now proposing.

The bear's "buy at $38 with confirmation" also has costs. - $38 is 9.4% above today, which is about two years of dividends. - His confirmation list includes the Q2 results. If Q2 is good, the stock is more likely to gap past $38 than to offer it. - Shorts pay the dividend. If the usual schedule holds, the ex-date is around Dec 1. That's $0.41, about 1.2%, against a target roughly 6% away ($35.9 to $33.81).

8. Answering the bear's questions¶

Which EPS do I believe? The guided figure, which puts NKE at about 21–22x. It's not cheap on trough earnings. It is at its lowest multiple of the year, and most of the guided decline comes from lapping one unusual quarter.
How does Q1's −2% mark a turn? The guide doesn't require Q2 and Q3 to collapse. Q2 against $0.53 is the test, and I've given my exit threshold above.
What if inventory rises against −4.3% sales? Then my "quality over volume" reading fails, and I exit before Q2.
What is my actual loss on a gap?
A repeat of April's −15.5% gap would open near $29.35, about a 15.5% loss.
A −20% gap would open near $27.80.
I now size for a 20% gap, not 8%.

9. Revised positioning¶

Starter position now, sized for a 20% gap. For example, with a 1% risk budget, a full position is capped at 5% of capital. Start with half of that.

Add only when all of these hold: - a close above $35.15; - then a close above $36.38; - the 10-Q shows inventory not growing faster than sales.

Before Q2 results in late December: if price hasn't confirmed above $36.38, trim back to the starter size.

Exit on any of these: - the 10-Q shows an inventory build; - Q2 EPS comes in below about $0.45; - the dividend is cut; - a daily close below $31.97.

Questions for the bear¶

If Q4 FY26 is an anomaly in my trailing P/E, why is it a valid base for your −28%? What Q2 EPS do you expect against $0.53?
Why model 70% cash conversion instead of the roughly 93% six-year average?
In FY26, the one year Nike paid its dividend without buybacks, cash rose about $100M. What makes FY27 different enough to threaten the payout within your time horizon?
Your short runs through a likely Dec 1 ex-date. Do your risk and reward figures include the $0.41?

The bear has convinced me to size smaller and to wait for confirmation before adding. He hasn't shown that NKE should be avoided entirely, given that: - it trades at its lowest multiple of the year; - it funded its dividend last year without drawing down cash; - most of the guided decline comes from one quarter's comparison. Bull Analyst: # Bull Rebuttal (Round 3): NKE

This was the bear's strongest round, and it moves my position again. I'm cutting the starter size, setting a firmer test, and I won't buy anything until the 10-Q inventory line is read.

Three of his new central claims still fail when checked against the data he cites:

His "$1.65 underlying earnings" reuses the Q4 figure I derived from the guide. That makes "the guide is flat" true by construction.
FY26 cash wasn't "rescued by one quarter." It shifted from Q3 to Q4, and second-half operating cash flow fell only 8%.
His $24–28 fair value works only if Nike never again earns its FY25 margin.

What the bear got right¶

My thresholds drifted. I called −2% "a clear change in trend," then set my exit at −15%. A quarter down 11% isn't stabilization. §6 sets a firmer line.
Q1 cash conversion has fallen three years running (37%, 31%, 19%). I can't answer that without the 10-Q.
The 93% average conversion is inflated by FY24's inventory liquidation. I've dropped it, and §2 uses a different method.
The real-yield argument doesn't hold. Nike's real revenue fell, so it hasn't shown earnings that keep pace with inflation. I withdraw it as a valuation anchor.
Oct 2. Counting the September selloff, the total move was −13.6%, in line with the earlier gaps. I withdraw "reactions are shrinking." I also accept that the Dec 19 starting multiple was about 31x normalized, not 34x.
Expected return. With his reweighting, my 12–18 month expected return sits near T-bill yields. That's why the starter gets smaller (§7). Any remaining case has to rest on where his numbers are wrong.

1. The $1.65 is my number, recycled¶

The bear calls a $0.28 Q4 "normal." That is the figure I backed out of the FY27 guide: the guide, minus Q1, minus flat Q2 and Q3. Put it into FY26 and FY27 will always look flat against FY26. That is arithmetic, not evidence.

His normalized P/E table has the same problem. With both Q4s set to $0.28, the "flat" trailing EPS from April to October just restates Q1's −2%.

An independent anchor. Q4 is not a seasonally weak quarter for Nike. FY24 is the most recent year whose Q4 isn't flagged as abnormal. Working back from the growth rates in the fundamentals table:

FY24 (implied)	Q1	Q2	Q3	Q4
EPS	~$0.95	~$1.03	~$0.77	~$1.00

Q4 FY24's net margin was about 11.9%, roughly 1.1x the first nine months' ~10.8%.

Apply that 1.1x uplift to FY26's nine-month margin of 5.76%: - Q4 net income comes to about $695M, or about $0.47 a share. - Underlying FY26 EPS becomes about $1.84, not $1.65.

This cuts both ways: - Against me. The guide implies a real decline of about 11%, not just lapping one quarter. Lapping Q4 explains roughly $0.26 of the ~$0.46 drop. My claim that the decline is "mostly the lap" was about half right. - Against him. Nike isn't trading at "21x for zero growth" on underlying earnings. It trades at about 19x what it actually earned, and about 21x a forecast decline that the one quarter we've seen (−2%) hasn't shown yet. - His base-case critique doesn't hold. He said my $1.90 FY28 base case needs 16% growth. On this anchor it is roughly a return to FY26's underlying $1.84, at a margin about 0.2 points higher.

What this means for Q2. On a $1.84 base, getting below $1.64 requires Q2–Q4 to fall about 14%, from ~$1.35 to under $1.16. Spread evenly, that puts Q2 around $0.45–0.46.

The bear's mid-$0.40s estimate is simply the guide. It doesn't contradict "the guide is the trough." My thesis is that the guide is conservative, so my test has to sit above it (§6). If Nike merely meets the guide, the bear's expected-return math wins and I'd rather hold T-bills.

2. FY26's cash shifted between quarters; it wasn't rescued¶

His nine-month cutoff falls exactly between the two quarters where the cash moved. Split by half-year instead:

($M)	H1 FY25	H1 FY26	Change	H2 FY25	H2 FY26	Change
Operating cash flow	1,443	801	−44%	2,255	2,067	−8%
Free cash flow	1,194	401	−66%	2,074	1,783	−14%

The timing moved. FY25 collected its second-half cash in Q3 ($1.71B free cash flow). FY26 collected it in Q4 ($1.50B). The real deterioration was in the first half, not a one-off rescue at year end.
The flag was about earnings, not cash. The fundamentals report flagged Q4's net income and gross margin. Q4 operating cash flow ($1,637M) exceeded Q4 net income ($1,069M), so the cash was real.
The untraced ~$200M most likely came from short-term investments maturing. Those sit outside the $6.9B cash figure, so this points to more liquidity, not less.

FY27 free cash flow on this basis: - First half: about $0.3B. Q1 is $79M behind last year, and I assume Q2 matches last year's $386M. - Second half: down another 14%, to about $1.5B. - Total: about $1.85B, against a $2.3–2.4B dividend. That leaves a gap of about $0.45–0.55B.

The bear's $0.7B is close, so we disagree about fragility, not size. The gap is about 8% of cash, before counting short-term investments, and it doesn't force a cut within my horizon. A cut at the FY27 results is my bear case, which I weight at 30%.

3. His fair value assumes a permanent trough¶

The bear's 14–17x multiple assumes zero real growth and a 3–4 point equity premium. Applied to $1.64, it values Nike at a 5.3% net margin forever.

Keep his multiple and use FY25's 7.0% net margin instead. FY25 was the inventory-clearance year, with a $0.14 Q4. I'm using it rather than FY26 so the flagged Q4 doesn't help my case. - On trailing revenue, 7.0% gives about $2.17 of EPS. - At 14–17x, that's $30–37, a range that contains today's $34.74.

So on the bear's own multiple, today's price pays for roughly FY25's depressed margin. It pays nothing for a return to the 9.9–12.9% Nike earned every year from FY21 to FY24.

His $24–28 is not a fair value. It is a forecast that Nike never regains its FY25 margin. That's a legitimate bear case, and it's close to mine ($22.40). It belongs in the scenario weights, not at the midpoint.

4. What the last 21% priced¶

From the Jul 16 rally high of $44.10, NKE fell 21% to $34.74. Nearly all of that, down to $35.15, happened before the Q1 report.

Over the same window: - Nike's only report was Q1, with EPS down 2%. Q4 is normally reported in late June, before the window starts. - Macro moved sharply: - The 10-year rose about 72bp. - Real yields rose about 60bp. - The Fed hiked. - Oil peaked at $107. - The dollar jumped 3%.

Some of the September selling was investors anticipating the guide, as the bear says. But he has agreed the valuation is "partly a call on rates," and this window lines up with a rates shock more than with any reported deterioration.

That makes his short partly a rates bet: - If the 10-year breaks above 5.31%, that works for him. - If CPI or the FOMC push yields down, the multiple can recover without Nike reporting anything.

5. Q2 headwinds: some real, some just seasonal¶

Promotions are seasonal in both years. Gross margin fell 1.8 points from Q1 to Q2 in FY25 and 1.6 points in FY26. Apply that drop to Q1 FY27's 42.8% and Q2 lands at 41.0–41.2%, still above last year's 40.6%. The caveat is one we share: like-for-like comparisons have to come from the 10-Q's restated figures.
The dollar is real, but it's translation. It hits reported revenue and says nothing about brand health. Nike usually reports currency-neutral revenue, and that's the figure that tests demand.
Oil hits later. Footwear product costs are generally set with factories months in advance. A mid-September peak is mostly a second-half FY27 cost issue, though freight costs move faster. Oil delays the hit; it doesn't remove it.
"Consumers spent, Nike shrank, so it's losing share" doesn't follow.
More than half of Nike's revenue is outside the US. One month of US retail sales can't explain a global June–August quarter.
Deflating dollar-reported global revenue by US CPI doesn't produce real revenue either.
China is the likelier drag, and I've already conceded it's the biggest unknown. That is a different claim from US share loss to On and Hoka. Neither of us can show the split without segment data.
"Both paths hurt Nike" is a framing no data could ever contradict.

6. A firmer test, set where we disagree¶

Before buying anything: read the Q1 10-Q, which the bear thinks is already filed. If inventory rose while sales fell 4.3%, take no position. Waiting for it costs nothing.

Q2 results (late December): conditions to add - EPS of $0.47 or more. That is above the guide's implied path, roughly a 6% net margin on revenue down 4–6%. - Gross margin up year over year on a like-for-like basis. - A currency-neutral revenue decline no worse than Q1's −4.3%. - Q2 free cash flow at or above last year's $386M.

Exit on any of these: - Q2 EPS below $0.47. - Currency-neutral revenue down more than 5%. - Like-for-like gross margin down year over year. - An inventory build in either 10-Q. - A daily close below $31.97. - A dividend cut.

The bear expects Q2 in the mid-$0.40s, and my exit line sits just above that. In about ten weeks one of us will be wrong, on a number neither of us controls.

7. Revised position¶

Size: one-third of the capped full position, down from one-half. With full size capped at 5% of capital, the starter is about 1.7%, and a 20% gap would cost about 0.3% of capital.
Entry: scale in on dips toward $33.8, where the lower Bollinger band and the Oct 7–8 lows sit. Don't chase into $35.6–36.4. The bear and the technical report are right that buying into that zone has a poor reward-to-risk ratio.
Add: only if Q2 passes the tests above and the stock closes above $36.38.

Why a starter rather than nothing: - The bear's bar can't be met this quarter. He'd change his mind on Q2 EPS of at least $0.53 with revenue flat or up. But he says this quarter carries a 3% dollar jump, peak oil and the heaviest promotions. By his own list of headwinds, Nike can't clear that bar on reported numbers this quarter, so "revisit after Q2" really means "not before FY28." - Waiting isn't free insurance in this stock. The Dec 19 gap filled completely, which is exactly the kind of confirmation on his list. The stock then fell about 48%. Waiting for confirmation swaps one set of errors for another.

Questions for the bear¶

Your $1.65 uses the Q4 figure I derived from the guide. What is your independent estimate of a normal Q4, and why is FY24's seasonal pattern the wrong anchor?
At your 14–17x, FY25's 7.0% margin gives $30–37. Is your $24–28 a forecast that Nike never regains its FY25 margin?
Second-half operating cash flow in FY26 was within 8% of FY25's. Which part of that was the outlier?
Suppose Q2 prints $0.48–0.50 with like-for-like margin up and inventory falling, but reported revenue down 5% on currency. Do you cover the short? Does your investor stance change, or is your real bar FY28?

Where we stand¶

What the bear has shown: - NKE isn't cheap on guided earnings. - The 12–18 month expected return is thin. - Q1 cash conversion is a real warning.

What I've shown: - His "flat at $1.65" is circular. - FY26 cash wasn't a one-quarter rescue. - His fair value assumes Nike never regains its FY25 margin.

That leaves three facts. On the bear's own multiple, the stock is priced for roughly its FY25 inventory-clearance margin. The balance sheet can carry a dividend gap of about half a billion dollars through the test. And the Q2 print, about ten weeks away, will settle it. Together these justify a small, conditional starter. They don't justify a conviction long, and I'm no longer arguing for one. Bull Analyst: # Bull Rebuttal (Round 4): NKE

The bear's last round was sharp, and several points land. I'll fix those first. His round also contains a contradiction that matters more than any single number: the checklist he says would move him to neutral doesn't fit the fair value he uses to call the stock expensive. Once that's resolved, only one question is left: should you hold a small, pre-screened position through a test we have now defined identically?

What the bear got right¶

My add trigger contradicted my own concession. I said a quarter down 11% isn't stabilization, then set my line at −11%. I'll fix it in the only way that can't be called drift: I'm adopting his neutral checklist, number for number, as my add-or-exit test (§1). And plainly, my thesis is now "the guide is conservative," not "earnings have stabilized."
FY26's dividend wasn't fully self-funded. If the ~$200M came from maturing investments, cash plus investments fell. Coverage was about 95%, not 100%. My Round 2 wording overstated it.
My FY27 free cash flow estimate implied ~76% conversion. I'll use his range instead: $1.7–1.85B, which leaves a dividend gap of $0.45–0.7B.
Dec 19 was a failure of chart confirmation, not fundamental confirmation. That's fair, and it's why every add condition below is fundamental first.
Underlying FY26 EPS is $1.80–1.84, so the guide is a 9–11% decline. Agreed.
Oil costs land in the second half. Agreed.

1. Our tests are now the same¶

Q2 FY27 condition	Bear: "moves me to neutral"	Bull: add (fail any → exit)
EPS	≥ $0.48	≥ $0.48 (was $0.47)
Currency-neutral revenue	better than −4.3%	better than −4.3% (was: exit only below −5%)
Like-for-like gross margin	up YoY, restated	up YoY, restated
Inventory	falling	falling (was: exit only on a build)
Q2 free cash flow	≥ $386M	≥ $386M

Every change makes my rules stricter. In ten weeks we'll read the same five numbers with the same pass marks.

The remaining difference is what each of us holds before the print: - He runs a short until Dec 1. - I hold a ~1.7% starter, and only if the 10-Q is clean.

2. His fair value doesn't survive his own checklist¶

Suppose Q2 prints exactly his neutral bar of $0.48, still down 9.4% from last year. With Q3 and Q4 on the guide's path, FY27 tracks about $1.65–1.70. At his 16x midpoint, that's about $27. Even at the top of his 14–17x range, it's under $29.

So on that print, he'd move to neutral on a stock his own model values at $27. It trades at $34.74 today, and probably higher after a beat. A stock 25–30% above fair value doesn't earn a neutral rating.

His checklist shows how he actually values Nike: on trajectory, not as a zero-growth perpetuity of trough earnings. One quarter that beats the guide changes the multiple he'd pay. That's how cyclicals are priced near a bottom, and it's why $24–28 isn't a real downside anchor.

Here is what that $24–28 actually capitalizes:

	FY20 (COVID)	FY21	FY22	FY23	FY24	FY25	FY26	FY27 guide
Net margin	6.8%	12.9%	12.9%	9.9%	11.1%	7.0%	6.7%	~5.3–5.5%

It assumes a margin below every year in the table, held forever. That includes the COVID year. He calls it "the value of guided earnings." It is, if those earnings never improve. That's the same assumption with a different label.
His "32% recovery" only gets EPS back to $2.17. Nike reported $2.16 in FY25, sixteen months ago, in a year with a $0.14 Q4. That's not a heroic recovery. It's the last full fiscal year before this one.
His own EPS path shows the declines shrinking.
FY24 to FY25: −42%
FY25 to FY26: −15%
FY26 to the FY27 guide: −11%

Yes, my base case needs the first up year in four. Every recovery does. The real question is whether it's priced. By his own checklist, one decent quarter would take the stock well above his fair value.

3. The reclassification estimate is the worst end of his own range¶

His reasoning runs in two steps: 1. Q4 had ~$880M of excess gross profit but only ~$374M of excess net income, so most of the margin jump was cost moved between lines. 2. He then restates as if all $880M were reclassification. That makes Q1 FY27 down 1.3 points like-for-like.

Those steps don't fit together, because the extra net income had to come from somewhere:

Source of Q4 excess net income	Implied full-year reclass	Per quarter	Q1 FY27 like-for-like gross margin
All from below gross profit (e.g., tax)	~$880M	~1.9 pts	−1.3 pts (his case)
All from a real gross profit gain (~$470–550M pre-tax at his ~20% rate)	~$330–410M	~0.7–0.9 pts	−0.1 to −0.3 pts

The truth is probably in between, and only the 10-Q will show it. Two things follow.

The cost story changes with it. At his end, costs below gross profit fell about 8% like-for-like against sales down 4.3%. At the other end they fell about 5%, roughly in line with sales. His claim that "EPS held up through spending cuts" depends on the extreme case.

My rule doesn't change. If restated like-for-like gross margin is down at all, even by 10bp, I don't buy. There's no tolerance band. If that's what the 10-Q shows, he wins the argument about the starter, and I'll say so.

I'll also add a check that addresses his own concern. Nike's 10-Q splits operating costs into demand creation and operating overhead. - If demand creation fell faster than revenue, that's the brand harvesting he warned about, and I don't buy. - If the cuts came from overhead, that's operating leverage for when revenue turns.

4. He trusts management on the guide but not on the dividend¶

His core argument for the guide is that management set it with Q1 in hand and a month of Q2 visible. On that view, betting against the guide means betting against people who can see the orders.

The same people, looking at the same orders, on the same day: - issued a guide below the dividend, and - called the dividend the "top priority."

If management's information decides the guide, it also decides the pledge. His dividend-cut scenario needs the guide to be right and the pledge to be wrong. Under-promising earnings costs management little, while breaking a pledge they just made costs a lot. That's an inference, but it's the same kind of inference he asks me to accept about the guide.

The guide was also set at a bad macro moment. EUR/USD was at 1.126, and oil had just come off its $107 peak. Oil and gasoline are now below their September peaks, though oil jumped again on Oct 8. The dollar hasn't eased, as far as our data shows. CPI and the FOMC could push the other way. As I've conceded, the starter is partly a rates bet.

5. His −33% case can't reach the starter¶

The bear places the dividend risk at the FY27 results in late June 2027. Here's everything that happens first:

When	Event	My rule
Now	Q1 10-Q	No position unless inventory, restated margin and demand creation all pass
Mid-Nov	Dividend declaration	Both of us expect it to pass
Dec 1	Ex-dividend date	Collect $0.41
Late Dec	Q2 results	Five-item test; fail any → exit
Late Mar	Q3 results	Same −9% bar vs last year's $0.35 (≈$0.32) or exit
Late Jun	FY27 results and board decision	His cut scenario

A June 2027 cut needs earnings to keep deteriorating. That would trip my Q2 or Q3 exit first. If Q2 and Q3 both pass, the payout ratio is falling and a cut becomes less likely. So the realistic downside isn't −33%. It's a 15–20% gap at Q2 on a 1.7% position, about 0.3% of capital.

Carry is a wash through the test. - The Dec 1 dividend is about 1.2% of a $34 entry. - T-bills at 4.77% earn about 1.0% over the ~11 weeks to the print. - For this window, "T-bills pay the same" slightly favors the dividend.

Gap risk is concentrated at the print. Before then, the only Nike-specific event is a dividend declaration we both expect to pass. The $31.97 stop handles macro moves through November. The gap risk I sized for sits at the print, which is the test itself.

6. Where the edge comes from¶

The bear is right that sizing alone isn't an edge. The edge comes from three things.

The 10-Q filter. I only buy if inventory, like-for-like margin and demand creation have already cleared. His mid-$0.40s Q2 estimate rests partly on margin pressure, so it's weakest in exactly that case.
How the market reacts. His neutral trigger is one cent above my old line. The news report describes NKE as heavily shorted, and sentiment is 3.8/10 with "still avoid" headlines. A print that clears his own bar forces repositioning, including his.
What the starter pays for. It pays off in one case: a beat that gaps the stock through resistance. That's also the only case where waiting is expensive.

Questions for the bear¶

Suppose Q2 prints $0.48 and FY27 tracks ~$1.70, about $27 at your 16x. Would you really go neutral with the stock at $35 or higher? If so, what multiple are you actually using?
Your restatement assumes none of the Q4 excess net income came from gross profit. Why that end of the range?
Why is management's information decisive for the guide but not for the dividend pledge made the same day?
With my Q2 and Q3 exits in place, what path takes the starter to your −33% before the June 2027 board meeting?

Positioning¶

Before entry (Q1 10-Q). Take no position if any of these hold: - inventory rose while sales fell; - restated like-for-like gross margin is down at all; - demand creation expense fell more than revenue.

If the 10-Q is clean: - Size: one-third of a full position, with full size capped at 5% of capital, so about 1.7%. - Entry: scale in toward $33.8. Don't chase into $35.6–36.4. - Stop: a daily close below $31.97. - Dividend: hold through the Dec 1 ex-date.

Q2 (late December): apply the bear's five-item checklist. - Pass all five: add on a close above $36.38. - Fail any one: exit.

Q3 (late March): exit if EPS comes in below about $0.32.

At any time: exit on a dividend cut.

Closing¶

The bear summed up: "the guide calls for decline, the price assumes recovery." The fuller picture: - The guide calls for Nike's lowest net margin in at least seven years, below the COVID year. - The price, on his own multiple, assumes Nike earns what it reported sixteen months ago. - His own checklist says one quarter that beats the guide by a few cents would make him neutral, at a price well above his fair value.

We agree on the test, the pass marks and the date. I'd rather hold a small, pre-screened position before that test, with the carry covered by the dividend and the downside around 0.3% of capital, than pay for the answer after it prints. Bull Analyst: # Bull Rebuttal (Round 5): NKE

This was the bear's strongest round, and on one point he is simply right: on my own arithmetic, the most likely result of reading the 10-Q is that I don't buy. I'll say that up front, and I won't loosen the rule.

Two of his central claims still fail on his own numbers:

"Today's price is the pass-case value." His ranges only fit $34.74 if the market is pricing an 84–100% chance of a five-for-five pass. Nobody believes that. The market is pricing the guide at about 21x, so our disagreement is about the multiple, not the forecast.
"The starter's payoff is negative." His −1.1% applies unconditional weights to a trade I only take after a clean 10-Q. His own closing commitment calls that conditional trade "a fair bet."

That commitment matters more than anything else in his round. We now agree on the conditions that make NKE a buy.

What the bear got right¶

My own table most likely rejects the starter. At my end of the range, restated Q1 gross margin is −0.1 to −0.3 points. My rule says no buy below zero. The rule stands.
FY26 is the last full fiscal year, not FY25. $2.17 is 18–21% above FY26 underlying EPS of $1.80–1.84. I misspoke.
"Heavily shorted" is unmeasured. None of our reports gives a short-interest figure, so I drop it as an edge.
Bills yield about 3.9%, not 4.77%. The dividend's carry advantage through the print is about 0.4 points. That's real but small.
A margin below the COVID year with 4.2% unemployment isn't explained by the economic cycle. Agreed. §4 covers what does explain it.
My planned full position is about three times the starter by June. Agreed. §5 adds a rule for it.

1. The 10-Q: a likely fail, but a pass doesn't need two miracles¶

The bear says a positive restated margin needs "a genuine gross-profit windfall near $880M" plus "roughly $400M of one-off charges" to offset it. That describes the zero-reclassification extreme, not what a pass actually requires.

Q1 FY27 is up 0.6 points on the old basis. Like-for-like turns positive if the reclassification is less than 0.6 points per quarter, about $280M for the full year.
The rest of the ~$880M Q4 excess would then be real: at least ~$600M of gross profit. That implies a Q4 gross margin of about 46.5%. That's high, but close to FY22's full-year 46.0% and Q1 FY25's 45.4%. It isn't the "never come close" 49.2%, which was the whole anomaly.
The offset needed below gross profit is small. $600M taxed at his ~20% gives ~$480M after tax.
Against my $695M "normal" Q4, excess net income was $374M, so the offset needed is ~$110M.
Against his own $632M anchor, excess net income was $437M, so the offset needed is ~$45M.
That's a modest restructuring charge in a year of cost cuts.

My honest read: a pass is a minority outcome, but not a long shot. If the 10-Q shows like-for-like margin down even 10bp, I don't buy, and the bear and I give the same recommendation until Q2.

2. The price is pricing the guide at 21x, not a pass¶

Take his values at face value. A pass is worth $33–36. A fail, or the guide merely met, is worth $22–28. What probability of a pass makes $34.74 fair?

His inputs	Implied probability of a five-for-five pass
Top of both ranges ($36 pass / $28 fail)	84%
Midpoints ($34.50 / $25)	over 100%

Both of us put a pass near 25%. So does the market's tone: 3.8/10 sentiment and "yield trap" headlines. The market can't be pricing an 84% pass.

Now run it the other way. At 25% pass and $36, the fail case would have to be worth about $34.3. That is about 21–22x guided EPS of $1.55–1.64, which is exactly where the stock trades.

So the market isn't "already priced for a good Q2." It is pricing a bad-but-guided year at 21x. The real dispute is 16x versus 21x on a trough year.

Trough years carry high multiples by construction. The same price is 19x FY26 underlying EPS and 16x FY25's $2.16.
The 21x was set after the guide was public, on 142.7M shares, the heaviest volume in the dataset. For his model to be right, the market has to be off by about 60 percentage points on a fully disclosed number. The model deserves at least as much suspicion as the price.
His fail range would put the yield at 5.9–7.5% on a dividend both of us expect to be paid through FY27. That's 0.6–2.2 points over the 10-year and 2–3.6 points over bills. I'm not calling it a floor. It's a reason his fail range is the deep end of the outcomes, not the middle.

His pass-case value also ends the recovery where it starts. "FY28 back to FY26 underlying" at a ~6% net margin is the trough plus one year. After a five-for-five pass, with currency-neutral revenue improving, margin up like-for-like, inventory falling and free cash flow up, the market would price FY29.

If a pass puts FY29 on track for FY25's 7.0% margin (about $2.17), his own 18–19x gives $39–41. That path needs two up years, so it's the bull case, not the base. But it means my add rule above $36.38 buys below his own pass-case recovery value, not above it.

3. His −1.1% prices a trade I'm not making¶

His §6 applies my 12–18 month scenario weights (30/45/25) to the Q2 print, as if I'd buy blind. I don't. I buy only after the 10-Q clears restated margin, inventory and demand creation.

Those are the same lines behind his mid-$0.40s Q2 estimate. A clean 10-Q removes much of the case for a miss.

He has already priced this. In his own words: if the 10-Q is clean, "I'll call his starter a fair bet." His §6 and §8 can't both describe the trade I'm proposing. §8 does.

An illustration using his own table, shifting ten points from miss to pass (the least a clean 10-Q should do):

Q2 outcome	Weight	Move	Contribution
Five-for-five pass	35%	+12%	+4.2
In line with guide (I exit)	45%	0%	0
Miss	20%	−15%	−3.0
Dividend vs bills	—	—	+0.4
Total			≈ +1.6%

On "all three earnings moves were down": those reports showed EPS −32%, EPS −35%, and a guide below the dividend. None looks like a print that beats the guide with margin and inventory improving. That sample can't tell us how NKE reacts to a pass.

So we agree on both halves. Buying unconditionally isn't worth it. Buying after a clean 10-Q is fair. That has been my recommendation since Round 3.

4. Management and the below-COVID margin¶

I accept the bear's reading of the guide. It cost management something to issue it, which makes it credible. The pledge is credible for the same reason.

Read the two statements together. The "yield trap" headlines were already written on Oct 2. A board that saw a permanent decline had its cheapest moment to cut right then. Instead it chose to bridge FY27 from the balance sheet and called the dividend its top priority. That only makes sense if management sees FY27 as a bridge year. It's the same management information he asked me to respect.

On the margin: he's right that the consumer cycle doesn't explain it. I'm not arguing it does. The fundamentals report attributes the gross margin slide to four things: - discounting; - inventory clearance; - tariffs; - channel shift.

Two of those correct themselves once inventory is clean. One is policy, and the macro report notes tariff policy may shift after the Nov 3 midterms. That's not my base case, just an option the price doesn't need. Only the share-loss part fits his structural reading.

The two readings predict different 10-Q lines:

10-Q line	His reading (structural share loss)	My reading (inventory / channel / tariff cycle)
Demand creation	Cut faster than revenue	Held
Inventory	Not falling	Falling
Q2 currency-neutral revenue	Worse than −4.3%	Better than −4.3%

This is where scale matters. Roughly $19–20B of annual gross profit lets Nike cut overhead while protecting brand spending, which a challenger can't do. Q1's cost ratio improved 0.2–0.4 points even at my end of the range, by his own arithmetic. If that came from overhead, it's operating leverage waiting for revenue. If it came from demand creation, he's right, and I don't buy.

Downturn risk is real. The Fed is hiking, the 10-year is near its high, and savings are being drawn down. That's why the stop sits at $31.97 and the position is sized for a 20% gap.

5. A rule for June¶

He's right that passing Q2 and Q3 still leaves the June board with a payout ratio of ~96–99% and a second year of free cash flow below the dividend. I'll close that gap using his own Round 2 metric.

Before the FY27 results, cut back to starter size unless both hold: - Nine-month FY27 free cash flow beats FY26's $685M. With Q1 at −$64M, that means Q2 plus Q3 has to exceed ~$750M, versus $670M last year. That's a real improvement, not a formality. - Q3 currency-neutral revenue is flat or better.

Even at full size, a 20% gap costs 1% of capital, which is the risk budget I set in Round 2. The −33% case unfolds over 12–18 months, and every exit above sits in front of it.

Questions for the bear¶

At $34.74, your values imply the market prices an 84%+ chance of a five-for-five pass. If it's really pricing the guide at ~21x, isn't "already priced for a good Q2" just "21x is too high"? What justifies 16x for a trough year?
Your −1.1% is unconditional. Your commitment calls the conditional starter fair. Which one describes the trade I'm proposing?
On your own $632M Q4 anchor, a positive restated margin needs ~$45M of after-tax charges below the line. Why is that "two unusual items of matching size"?
If management saw permanent decline, why pledge a dividend it has to fund from the balance sheet instead of cutting on Oct 2, when the damage was already done?

Final positioning¶

Today: no position. Read the Q1 10-Q first. On this, the bear and I agree.

Macro gate: if September CPI pushes the 10-year to a sustained close above its 5.31% high, wait for the Oct 27–28 FOMC before entering.

If the 10-Q is clean (restated like-for-like gross margin up, inventory falling, demand creation falling no faster than revenue): - Size: about 1.7% of capital, one-third of the 5% cap. - Entry: scale in toward $33.8, and don't chase into $35.6–36.4. - Stop: a daily close below $31.97. - Dividend: hold through the Dec 1 ex-date.

If the 10-Q fails: no position. Wait for Q2 and buy on a five-for-five pass, alongside the bear, likely at $36–39.

Q2 (late December): apply the five-item checklist we now share. - Pass all five: add on a close above $36.38. - Fail any one: exit.

Q3 (late March): exit if EPS comes in below about $0.32.

June: apply the §5 rule.

At any time: exit on a dividend cut.

Closing¶

At its honest size, the bull case for NKE is this:

On this year's earnings, it isn't cheap. I conceded that rounds ago.
It's priced at a trough multiple for a trough year, not for a recovery. The bear's own pass and fail values only fit today's price if the market expects near-certain success, and it plainly doesn't.
The dividend bridge is credible, because the same management whose guide he trusts chose to fund the bridge rather than cut.
The test, the pass marks and the dates are agreed. The bear has said that if the first filter comes back clean, the trade is fair.

The most likely next step is that the 10-Q says wait, and I will. If it says go, the bear and I will both be calling the starter a fair bet, at a price set before the market sees what we've seen.

Bear Researcher¶

Bear Analyst: # Bear Rebuttal: NKE

The bull's case rests on one claim: the stock has fallen much further than the business. That is only true if you measure the business by revenue. Shareholders own earnings and cash flow, not sales. By those measures, NKE's business has fallen as far as its stock. Management has also just guided to a further decline.

The bull has some fair points, and I'll address them. But the headline numbers in the opening don't hold up once you look at what's behind them.

1. The business has fallen as much as the stock¶

What shareholders own	Peak	Now	Change
Revenue	$51.4B (FY24)	$45.9B (LTM)	−10.7%
Net income	$6.05B (FY22)	$3.09B (LTM)	−49%
Free cash flow	$6.6B (FY24)	$2.1B (LTM)	−68%
EPS	$3.75 (FY22)	below $1.64 (FY27 guide)	worse than −56%
Return on equity	~43% (FY22)	~22% now, under 16% on guidance	roughly halved or worse

Revenue is the one line that has held up. It is also now weakening: five straight quarters of slowing growth, at +1.1%, +0.6%, +0.1%, −1.1% and −4.3%.

The bull also cites the 80% drop from the all-time high. That high was near $179 against FY22 EPS of $3.75, close to 48x earnings. Most of the 80% decline is a bubble multiple deflating, not a market overreacting.

2. The "16.6x trough" is neither 16.6x nor the trough¶

The bull concedes the key point and then moves past it. Management guided FY27 earnings below $1.64. That means EPS falls at least 21% from the $2.09 the bull uses to calculate 16.6x. Calling the guide "the trough" admits that today is not the trough. On guided earnings, NKE trades above 21x. That gives an earnings yield under 4.7%, below the 10-year Treasury at 5.28%.

The guide also undercuts the "stabilization" story. Q1 earned $0.48. To finish below $1.64, Q2 through Q4 must total less than $1.16. The same three quarters earned $1.61 last year, so they must fall at least 28%.

Last year's Q4 may include one-off items, which would make that comparison harsher than the underlying trend. Even allowing for that, the guide says Q1's −2% is the easiest comparison of the year, not a new run rate.

The trailing figure depends on one unusual quarter. The bull says "every quarter of FY26 fell 30–35%." Q4 FY26 was actually up 421%. That quarter contributed $0.73 of the $2.09 trailing EPS, about 35%. It came on falling sales, with an implied gross margin of 49.2% that the fundamentals analyst said Nike "has never come close to," and the analyst flagged it for possible one-offs. The bull's 16.6x and the $1.5B "seasonal" Q4 free cash flow both lean on it.

The normalization math assumes the answer. Getting back to a 9.9% net margin means adding 3.6 points. The trend has gone the other way at every step: 12.9%, 11.1%, 7.0%, 6.7%, 6.3%, and about 5–5.5% implied by the guide. FY23's 9.9% also came with 9.6% revenue growth and active buybacks, and neither exists today.

The "$50 floor" was misread. The fundamentals analyst had no live price. The $50 row was simply where the grid started, not a valuation floor. That same analyst concluded "neutral to cautious" and "priced for recovery."

3. What's behind the Q1 "stabilization"¶

Gross margin. The bull already concedes the +0.6 points may be a reclassification.
The $130M cost reduction. That line includes interest and tax, so we can't tell how much is real cost discipline and how much is a lower tax rate. If it includes marketing cuts while the brand is losing share, that is harvesting the brand, not discipline.
Net margin. It rose 0.15 points, which is small enough to come from the tax line alone.
"Choosing quality of sales over volume." If that were happening, inventory should be shrinking. Instead, non-cash current assets were flat while revenue fell 4.3%. That still needs checking against the 10-Q, but it points toward future markdowns.
Cash flow. Operating cash flow fell 39%. Free cash flow was negative.

4. The dividend gap is larger than the bull states¶

"The negative Q1 is seasonal." Compare like with like. Q1 free cash flow went from $274M (FY25) to $15M (FY26) to −$64M (FY27). Seasonality doesn't explain three years of decline in the same quarter.

"The shortfall is only $200–300M." That is on trailing figures, which include the unusual Q4. The dividend is about $2.3–2.4B a year (fundamentals estimated ~$2.3B; $0.41 × 4 × ~1.48B shares gives ~$2.4B). If FY27 net income comes in below $2.43B, as guided, and free cash flow converts at FY26's 70% rate, free cash flow is about $1.7B. That leaves a gap of roughly $700M a year.

"$6.9B in cash." That cash has other claims on it: - Current liabilities are $11.4B, and cash covers only 0.61x of them. - Current liabilities may include a bond that now matures within a year. - Cash has fallen about $3.0B since May 2024, including $660M in the last quarter alone.

"Equity rose 13%" and "buybacks are a lever." Equity rose because Nike stopped returning capital through buybacks. That doesn't show operating strength. With free cash flow below the dividend, there is no money left over for buybacks, so the lever isn't really available.

"The CFO called it the top priority." I expect the November declaration to pass, because the cash is there. That doesn't fix anything. Shareholders face two outcomes: - If the dividend is cut, the income buyers who support the stock leave. - If it is kept, it is funded from a shrinking cash balance, and reinvestment in product and marketing ranks behind it while Nike is losing share.

"A Treasury only returns par." True, and NKE returned −51.6% over the last year. The 10-year pays 5.28% and the 2-year pays 4.77%, both with no risk of a cut. NKE's 4.7% yield pays nothing extra for taking equity risk, so it can't be relied on as a floor.

5. The chart: one good day inside a downtrend¶

The bull says the Dec 19 and Apr 1 gaps "closed weak and kept falling." That isn't what happened on Dec 19. The stock fully recovered that gap, reaching $64.59 by Jan 13. That was a stronger reversal than Oct 2, which recovered only half its gap. The stock then fell about 48%.

In this downtrend, reversal days have been selling opportunities.

The current bounce also looks weak: - Volume has faded each session: 142.7M, 69.6M, 50.1M, 37.6M, 43.7M. - OBV has recovered only 28% of its drop. - RSI did not confirm the MACD divergence. - The MACD histogram is +0.01, about as small as a crossover can be. - Price is still below the 10 EMA and hasn't filled the gap. - Z-scores are around −1.6, not the −2 that marks a statistical extreme. There is room to fall further.

The rally highs keep getting lower: $64.59, $63.92, $46.46, $44.10, $39.18, $36.39. The technical report's stated base case is Scenario B: the downtrend resumes. TD-9 exhaustion signals usually produce a bounce of a few bars, not a bottom.

6. The 4–5:1 reward-to-risk doesn't hold up¶

The 8% downside isn't fixed. Stop orders don't protect against gaps, and NKE has gapped down three times in ten months: −10.5%, −15.5%, and a −7.4% open. Two catalysts fall inside the bull's holding period: the dividend declaration in mid-November and Q2 results in late December. Another −15.5% gap from $34.74 would open near $29.40, a loss of about 15%, not 8%.

The upside targets aren't probability-weighted: - The 200-day SMA at $47.31 is falling, so it will be lower by the time price could reach it. - The $46–51 "normalized value" requires a margin recovery that management's own guidance contradicts. - The realistic first target is $36.38, which is +4.7%. The technical report rated entry at current levels as 0.6:1.

7. The macro case needs three things to reverse together¶

The bull's upside scenario requires oil, the dollar and yields to all ease at the same time. Today's data points the other way:

Rates. The Fed hiked on Sep 16. The 2-year sits about 90bp above Fed funds, so the market expects more hikes. The 10-year made a new high of 5.31% on Oct 5. That doesn't look like a peak yet.
Inflation. September CPI will be the first reading to include the oil shock.
Currency. The dollar rose 3% in three weeks and EUR/USD fell 3.2%. More than half of Nike's revenue comes from outside the US, and this hasn't reached reported numbers yet. Hedges only delay it.
Input costs. WTI at $96 raises the cost of foam, rubber, polyester and freight. That pressures gross margin, the one metric the bull is relying on.
The consumer. Conditions are weakening heading into Q2, Nike's largest quarter:
The saving rate fell from 5.6% to 4.1%.
UMich sentiment is 51.7.
Gas is $4.35.
Retail sales rose 1.1% nominal, but CPI is running 3.4%.
Oil risk. The Iran comment only pushes oil risk past Nov 3. It doesn't remove it.

8. China, competition and sentiment¶

China. The market can't price numbers Nike no longer discloses. Companies usually cut disclosure when a segment is getting worse. China has historically been one of Nike's most profitable regions, so weakness there hurts margins more than revenue.

Scale. Nike's ~$19.8B in gross profit didn't stop five quarters of slowing growth. On, Hoka and challenger brands on TikTok Shop are taking share regardless. Lululemon is also reshuffling and cutting disclosure, so peers offer no help.

Sentiment. The bull calls it "extremely negative." The report says 3.8/10, "mildly bearish," with low confidence. It is based on headlines only, with no retail data, so capitulation can't be confirmed. Only two headlines were constructive, and both relied on the dividend. None cited revenue, product or innovation. That reads less like a contrarian extreme and more like an accurate description of a company without a growth story.

9. Answering the bull's questions¶

1. "At what price would it be a buy?" - On price: with guided EPS below $1.64, the earnings yield only matches the 10-year at about $31. That is below the bull's own stop, and it only gets you the risk-free rate for taking equity risk. - On evidence, which I prefer: I'd rather buy at $38 with confirmation than at $34.74 on hope. Confirmation means: - flat or positive revenue in Q2; - like-for-like gross margin confirmed in the 10-Q; - inventory falling along with sales; - free cash flow covering the dividend; - closes above $36.4 and then the 50-day SMA.

Giving up a few dollars of upside is cheap insurance against a cut or another earnings gap.

2. "What risk isn't already priced in?" - The guided earnings decline: Q2–Q4 down 28% or more on reported figures. - The September dollar move, which hasn't reached reported numbers yet. - A dividend cut, which is the main support for the stock in the headlines. - Inventory and markdown risk. - The possibility that the margin gain is an accounting change. - A trailing EPS figure that leans on one unusual quarter.

"Down 50%" doesn't mean the risks are priced in. The same was said at $71, $51 and $43.

Questions for the bull¶

Your multiple uses $2.09. Management guides below $1.64. Which number do you believe, and why buy on the one management doesn't?
How does Q1's −2% mark a turn when the guide requires the next three quarters to fall much harder?
If the 10-Q shows inventory rising against −4.3% sales, does your "quality over volume" reading survive?
If the dividend or the Q2 report causes a gap open below $31.97, what is your actual loss?

Positioning¶

Investors: avoid new longs, and don't treat the yield as a floor.
Traders: sell rallies into the $35.6–36.4 resistance zone, with a stop around $37.5. Targets are $33.81, then $31.97.
What would change my mind:
revenue turning positive in Q2;
a margin gain confirmed on a like-for-like basis;
free cash flow covering the dividend;
closes above $36.4, then the 50-day SMA, with volume increasing.

The squeeze risk the bull describes is real if oil, the dollar and yields all reverse together, and I size short positions with that in mind. Until the evidence changes, though, NKE looks like a business whose earnings are still falling, priced as if the decline has ended. Bear Analyst: # Bear Rebuttal (Round 2): NKE

The bull's corrections are real, and I'll credit them. But look at what's left once they're made. The 16.6x multiple, the $50 floor, the 4–5:1 reward-to-risk, the buyback lever and the "extreme" sentiment are all gone. Three claims remain:

The guided decline is mostly one Q4 comparison.
NKE is at its lowest multiple of the year.
FY26 proved the dividend can be funded without drawing down cash.

All three rest on the same anomalous quarter he just agreed to stop using. And his own scenario table produces an expected return that barely beats a two-year Treasury.

Where the bull is right¶

Retail sales. I compared a monthly figure with an annual one. Real spending rose about 0.8% in August. I withdraw that point.
Cash coverage. The 0.61x figure left out short-term investments. Liquidity isn't the near-term risk.
The −28%. That was on reported figures, which include Q4 FY26. I flagged the issue but still leaned on the number. The underlying decline is smaller.
Dividend on the short. Yes, a short held through Dec 1 pays $0.41. I answer this in §8.

1. Strip out Q4 and the guide shows no recovery¶

I'll accept the bull's decomposition: Q2 and Q3 roughly flat, and a "normal" Q4 of about $0.28. Now apply the same normalization to FY26:

EPS	Q1	Q2	Q3	Q4	Full year
FY26 reported	$0.49	$0.53	$0.35	$0.73	$2.10
FY26 with a "normal" Q4	$0.49	$0.53	$0.35	~$0.28	~$1.65
FY27 guide	$0.48	—	—	—	below $1.64

What follows from his own reading:

Underlying earnings power is about $1.65, not $2.09. The trailing figure overstated it by roughly a quarter.
The FY27 guide is flat to down on that base. Management is guiding to no recovery this year.
Underlying net margin is about 5.3% (roughly $2.45B on $46.4B of revenue), not the 6.3% Q1 print.
His scenarios start above that level.
His FY28 base case needs a 6.1% margin and 16% EPS growth.
His bull case needs 8.1% and 52% growth.
Both have to come from a revenue line that has slowed for five straight quarters.
The Q1 "stabilization" (6.2% to 6.3%) is one quarter. It came before the September dollar jump and the oil peak, and the full-year guide caps the year at $1.64.

He can read the guide as "mostly the Q4 lap" or he can argue for a recovery, but not both. If it's the lap, earnings are flat at about $1.64.

He asked for my Q2 estimate: mid-$0.40s.

Promotions. Q2 is the most promotional quarter. Last year gross margin fell from 42.2% in Q1 to 40.6% in Q2.
Currency. Q2 (Sep–Nov) is the first quarter to carry September's 3% dollar jump. Q1 didn't.
Oil. WTI peaked at $107 on Sep 15. Those input and freight costs land in Q2 and Q3.
Savings. Households go into the holiday quarter with a 4.1% saving rate.

That puts my estimate right at his $0.45 exit line. His thresholds have also moved: - His opening called −2% "a clear change in trend." - Under his new rules, a Q2 of $0.47, down 11%, still counts as "stabilization holds." - A quarter down by double digits isn't stabilization.

2. "Lowest multiple of the year" is what a derating looks like¶

His P/E table has the same both-ways problem he accused me of: - Today's trailing P/E uses EPS inflated by the high Q4 FY26. - The earlier P/Es use EPS depressed by the low Q4 FY25.

Here is the table with both Q4s normalized to his ~$0.28:

Date	Price	Normalized trailing EPS	P/E
Oct 1, 2025	$71.83	$2.09–2.30	~31–34x
Dec 19, 2025	$57.20	$1.84	~31x
Apr 1, 2026	$43.77	$1.65	~27x
Oct 8, 2026	$34.74	$1.64	~21x

Every row was "the lowest multiple of the year" when it printed. Each one was followed by a lower one.
Earnings and the multiple fell together. Normalized EPS fell 22–29%, and the multiple fell 10–13 turns. Nothing in the data says 21x is where that stops.
His Dec 19 comparison overstates the gap. Normalized, the starting multiple was 31x then versus 21x now. That's about two-thirds of the earlier level, not half.

3. The real-yield argument works against NKE¶

The bull says earnings rise with inflation, so the right comparison is the 2.92% real yield. That only holds for a company whose earnings keep pace with inflation. Nike's haven't:

Real revenue fell about 7.5% in Q1. Revenue was −4.3% nominal, while CPI ran +3.4%.
Net income is down 49% from FY22, a period of above-target inflation.
Inflation reaches Nike through costs first. Oil feeds into foam, rubber, polyester and freight. Falling revenue shows Nike can't pass those costs on.
Nothing is retained for growth. On guidance, the payout ratio is about 100%.

Even if you accept his framework, 1.8 points over real yields is the whole equity premium. That premium has to compensate for a cyclical with falling sales, an undisclosed China segment and a dividend above guided earnings.

Suppose you ask for a 3–4 point premium, which is still modest, and assume zero real growth. That gives a fair P/E of 14–17x. On $1.64, that's $24–28, below his stop.

On "$1.50 per 25bp": I agree this is partly a call on rates. But rates are moving against him: - The 2-year sits about 90bp above Fed funds. - The 10-year made a new high of 5.31% on Oct 5. - The first CPI to include the oil shock comes out this month.

4. FY26's dividend funding came from one quarter¶

The bull says cash rose $100M in FY26 while Nike paid the full dividend. Here is what was underneath:

Free cash flow ($M)	Q1	Q2	Q3	9 months	Q4	Full year
FY25	274	920	1,711	2,905	363	3,268
FY26	15	386	284	685	1,499	2,184
FY27	−64	—	—	—	—	—

Nine-month free cash flow fell 76% in FY26. Q4 supplied 69% of the year's free cash flow. That is the same quarter flagged for one-offs.
There is no reliable "big Q4" pattern. FY25's strongest quarter was Q3, and its Q4 brought in only $363M.
FY26 still fell short. Even with that Q4, free cash flow of $2.18B was below the roughly $2.3B financing outflow. Cash held flat because about $200M came from somewhere outside free cash flow, and the tools don't say where.
Q1 cash conversion has fallen three years running. Operating cash flow as a share of net income went 37% (FY25), 31% (FY26), 19% (FY27).

His question 2: why 70% and not the 93% average? - The two most recent readings are 70% (FY26) and 68% (last twelve months). - The 93% average is lifted by FY24's 116%, a year when Nike was liquidating inventory. - Conversion near or above 100% requires working capital to release cash. Q1's 39% drop in operating cash flow points the other way. - So his dividend math depends on the same inventory outcome as his thesis. That makes it one bet, not two independent supports. - Cutting capex to fund a dividend while losing share is harvesting the brand.

His question 3: what's different about FY27? Management's guide. - Net income falls from $3.11B to below $2.43B, about $680M less. - FY26 needed an outlier Q4 to fund the dividend from $3.1B of earnings. FY27 has to do it from less than $2.43B.

I still expect the November declaration to pass. The risk sits inside his own 12–18 month horizon: the FY27 results and FY28 guide, when the board has to look at a payout above 100% of earnings.

5. His expected return barely beats Treasuries¶

The benchmark. His +9% covers 12–18 months. The 2-year pays 4.77%, so roughly 5–7% over the same period with no risk of a cut. That leaves 2–4 points of excess return for outcomes ranging from −33% to +50%.

The real breakeven. NKE stops beating Treasuries if the bear case is about 35% likely, not 45%. His estimate is 30%, so the margin is five points.

His "base" case isn't the guide. $1.90 at a 6.1% margin requires 16% EPS growth and a margin above today's underlying ~5.3%. Make the base case literally "the guide is the trough, slow repair": - EPS of $1.75 (+7%) at 20x gives $35. - Adding $2.05 of dividends, the return is about +6.6%. - With his own 30/45/25 weights, the expected return falls to about +5.5%, below the 2-year.

Or keep his scenarios and shift ten points to the bear case (40/40/20). The expected return drops to about +2.8%.

On "buying at $38 costs 9.4%": - Cash in T-bills earns about 4.77% while you wait, close to the 4.7% dividend. The "two years of dividends" aren't really given up. - On his own weights, waiting avoids about 10 points of expected loss (30% × −33%). It gives up about 7 points of upside (70% × 9.4%). - Even if a strong Q2 gaps the stock to $40, the trade-off is roughly even, and you'd be buying with evidence instead of hope.

6. The Oct 2 reaction wasn't smaller, it came early¶

Most of the selling came before the report. The stock fell from $39.18 on Aug 28 to $35.15 on Oct 1, −10.3%. September volume ran 30–52M shares a day, versus 12–28M in July and August.
The full move matches the earlier gaps. From Aug 28 to the Oct 2 close, the stock fell 13.6%. That sits between Dec's −10.5% and Apr's −15.5%.
The bull already agrees that Scenario B is the technical base case and that volume is fading on the bounce.

7. Macro: his correction makes Nike's problem look worse¶

Consumers were spending. Real retail spending rose about 0.8% in August, unemployment was 4.2%, and claims were 197k. Nike's June–August revenue still fell 4.3%.
He said he needs employed consumers to keep spending. They did, and Nike shrank anyway. That points to share loss to On, Hoka, TikTok Shop brands and in China, not to the economy.
The spending is running down savings. The saving rate fell from 5.6% to 4.1%, heading into Nike's biggest quarter.
Both paths hurt Nike. If consumers hold up, Nike keeps losing share. If they weaken, it loses more.

8. Answers to the bull's questions¶

Q4 and the −28%. Conceded: the underlying decline is smaller. The flip side is that underlying EPS is flat at about $1.64, and the stock trades at 21x for no growth. My Q2 estimate is mid-$0.40s, at his tripwire.
70% versus 93% conversion. See §4. The latest readings are 68–70%, and Q1 conversion has fallen three years running.
Why FY27 is different. About $680M less guided net income, and FY26 was rescued by one $1.5B quarter.
The dividend on my short. Yes, $0.41 if held. The setup is built to play out over a few weeks, before Dec 1. If it hasn't, I cover or resize before the ex-date. Even counting the full $0.41 (entry ~$35.9, stop $37.5, risk $1.60):
The first target at $33.81 nets about 1:1.
The second target at $31.97 nets about 2.2:1.

Where we stand¶

We now agree on these points: - NKE trades at about 21x guided earnings and is not cheap. - The technical base case is the downtrend resuming. - Positions should be sized for gaps. - Q2 results and the 10-Q are the real tests.

The 10-Q for the August quarter is probably already filed. Both of us should read the inventory line before anyone buys.

We disagree on one thing: whether to pay for the outcome before seeing it.

Positioning: - Investors: no new longs. T-bills pay what the dividend pays, with no cut risk. Revisit after the 10-Q and Q2. - Traders: sell into $35.6–36.4, stop $37.5, targets $33.81 then $31.97. Be flat or resized before the Dec 1 ex-date. - What would change my mind: - Q2 EPS at or above last year's $0.53, with revenue flat or up. - The 10-Q showing inventory falling along with sales. - A like-for-like gross margin gain. - Nine-month free cash flow running ahead of FY26. - Closes above $36.4, then the 50-day SMA, on rising volume.

The bull's best defense of the guide is that earnings aren't falling, only flat at about $1.64. At 21x, with a payout ratio of about 100%, revenue still shrinking, and an expected return that roughly matches Treasuries, flat earnings don't justify buying now. Bear Analyst: # Bear Rebuttal (Round 3): NKE

The bull's case has narrowed a long way. It opened as "the stock has fallen much further than the business." It is now a 1.7% starter position, taken only after the 10-Q is read, betting that management's guide is too cautious. He also concedes the expected return sits near short-term Treasury yields.

He caught me on two points, and I'll concede them below. But four of his new claims conflict with his own numbers:

His Q4 anchor turns my "flat" into "falling." Management set that guide with Q1 already in hand.
His add trigger is an 11% EPS decline. He conceded in this same round that a quarter down 11% isn't stabilization.
His FY25-margin valuation shows today's price already assumes a ~32% earnings recovery.
The Q4 anomaly looks like a reclassification. If it is, his own exit condition may already be met in the 10-Q he hasn't read.

Where the bull is right¶

My $1.65 was circular. I reused the Q4 figure he backed out of the guide. My own independent estimate is in §7. It lands at about $1.80, close to his $1.84, so underlying FY26 EPS was roughly $1.80–1.84.
The half-year split is the fairer cut for FY26 cash. Second-half cash was real. The flag on Q4 was about earnings, not cash.
"Both paths hurt Nike" was unfalsifiable as I framed it. Here's a falsifiable version: if Q2 currency-neutral revenue is flat or up, my share-loss reading is wrong.
My Q2 bar (EPS ≥ $0.53 with reported revenue flat or up) was too strict for a quarter carrying a 3% dollar move. I restate it in §7 and §8.

1. His anchor makes the guide a decline, and the guide was set knowing Q1¶

	EPS	Change
FY26 underlying (his anchor / mine)	$1.84 / $1.80	—
FY27 guide	below $1.64	−9% to −11%

He escapes "21x for zero growth" by moving to "21x for a guided decline." NKE trades at about 19x trailing underlying earnings and 21x management's forecast. Neither is cheap, and the second is worse.
He calls it "a forecast decline that the one quarter we've seen hasn't shown yet." But management issued the guide around Oct 1, after Q1 closed and with a month of Q2 already known. That month included the dollar's 3% jump and the oil peak. They saw −2% and still guided Q2–Q4 down about 14% on his base. Q1 isn't evidence against the guide; it was an input to it.
His thesis is now "the guide is conservative." That is a bet against the people who can see orders and September's data.
His base case still needs growth. FY28 at $1.90 is +16% from the guided FY27 level. Calling it a "return" doesn't change that. The path has been FY24 $3.73, FY25 $2.16, FY26 ~$1.84, FY27 below $1.64. His base case requires the first up year in four.

2. His add trigger is the decline he just said isn't stabilization¶

Add / exit line: Q2 EPS of $0.47.
Last year's Q2: $0.53.
$0.47 is −11.3%.

In his concessions he wrote: "A quarter down 11% isn't stabilization." Then he set his add trigger at exactly −11%.

The thesis has moved from "earnings have stabilized" to "Nike beats a guide that calls for decline." Those are different claims. Under the second, even his success case is a double-digit EPS drop in Nike's biggest quarter. He'd be adding to the position on that.

3. FY25's margin isn't "depressed"; today's price already pays for recovery¶

Period	Net margin
FY25	7.0%
FY26 underlying (his anchor: ~$2.73B on $46.4B)	~5.9%
Q1 FY27	6.3%
FY27 guide	~5.3–5.5%

FY25's 7.0% is a blend. It averages the pre-decline first half (9.1%, 9.4%) with a 7.0% Q3 and a 1.9% Q4. Outside the flagged Q4 FY26, Nike hasn't printed a quarter above 7.0% since Q2 FY25, two years ago.
At $34.74, the price equals 16x his $2.17. That is the midpoint of my zero-growth range applied to FY25-margin earnings. $2.17 is 32% above the guide and 18% above his own underlying $1.84.
So "pays nothing for recovery" is backwards. The current price already pays for a recovery to a margin Nike hasn't earned in two years and won't earn this year on management's guide.
On 9.9–12.9% as a "free option": his own bull case tops out at 8.1%. FY21–24 margins aren't in his scenario table, so they can't be the free upside.

His Q2 answered: no. My $24–28 is the value of the earnings management has guided to. His $30–37 is the value of a 32% recovery. Today's price sits in the middle of the recovery range, not the trough range.

4. The Q4 anomaly looks like a reclassification, and that triggers his own exit¶

FY26 Q4	Gross profit	Net income
Implied	~$5.38B (49.1%)	$1,069M
"Normal"	~$4.50B (at the 41.0% nine-month margin)	~$695M (his anchor)
Excess	~$880M	~$374M

The excess gross profit mostly didn't reach net income. If ~$880M of extra gross profit were a real gain, roughly $700M would reach net income after tax. Only ~$374M did. Most of the gross margin jump stopped short of the bottom line. That is what costs moved from one line to another look like.
The size of the move. ~$880M is about 1.9 points of FY26 revenue. Suppose the annual report restated all of FY26 on the new basis, spread evenly. Then Q1 FY26 restated is about 44.1%, and Q1 FY27's 42.8% is down about 1.3 points like-for-like, not up 0.6.
Where the earnings came from. On the same arithmetic, the line below gross profit fell about 8% like-for-like, not 3%, while sales fell 4.3%. Unless that's mostly tax, Q1 EPS held up through spending cuts, not margin.
His Q2 projection has the same problem. He compares a new-basis 41.0–41.2% to an old-basis 40.6%.

This is an estimate, and the 10-Q's restated comparison will settle it. But his exit list includes "like-for-like gross margin down YoY." The document both of us agreed to read first may trigger his exit before he buys.

5. FY26 cash: he wins the split, but his $200M explanation undercuts Round 2¶

What he said in Round 2: Nike "funded its dividend from cash flow and held cash flat."
What he says now: the untraced ~$200M most likely came from short-term investments maturing. If so, cash plus investments fell. In the year he cited as proof, the dividend was partly funded from the balance sheet.
His FY27 free cash flow estimate needs better conversion. $1.85B implies about 76% conversion on ~$2.43B of guided net income. FY26 was 70% and the last twelve months were 68%. He also assumes Q2 free cash flow stays flat at $386M after Q1 operating cash flow fell 39%. At 70% conversion, FCF is about $1.7B, leaving a gap of $0.6–0.7B.
Liquidity was never my claim. The issue is the board's decision. FY27 results arrive around late June 2027, inside his horizon. The board will see a second straight year of FCF below the dividend, a wider gap, and a payout above 100% of earnings. His own table puts the dividend cut in the scenario that drives his −33%.

6. Rates and Q2 headwinds¶

Rates. I've agreed the stock is partly a rates call. But the dollar (+3%) and oil ($107 peak) aren't just discount-rate effects. They are Nike's reported earnings and costs for the next two quarters. The next two macro events, September CPI (the first to include the oil shock) and the Oct 27–28 FOMC (with the 2-year pricing in hikes), lean toward higher rates. If he's right that rates drove the selloff, his starter is a rates bet too.
"FX is just translation." His trigger is reported EPS, and translation hits reported earnings, not only revenue. More than half of revenue is international, so the $0.47 bar has to absorb the September dollar move.
"Oil hits later." Then it lands in the second half, exactly where his FCF model assumes only a 14% decline.
Share loss. He's right that US retail sales can't settle a global question. The international half is where China and the dollar hit. Q2 currency-neutral revenue is the test, and I've stated what would prove me wrong.

7. Answers to his questions¶

My independent Q4 estimate. In FY25 and FY26, Q4 was Nike's smallest revenue quarter. In FY24 it ran above Q3. With that operating deleverage, I wouldn't apply FY24's 1.1x uplift. At the plain nine-month margin, Q4 is about $632M, or $0.43, which puts FY26 at about $1.80. Our gap is small. The point that matters: on either anchor, the guide is a 9–11% decline.
Is $24–28 a "never regains FY25" forecast? No. See §3. It's the value of guided earnings. FY25's margin is a recovery case, and the current price already embeds it.
Which half was the outlier? Q4 earnings, not Q4 cash. I concede that. But the first half is where cash deteriorated (−66% FCF), FY27's first half started worse, and the $200M came from the balance sheet.
Q2 at $0.48–0.50, like-for-like margin up, inventory falling, reported revenue −5% on currency.
The short: it's built to be flat before the Dec 1 ex-date, so it wouldn't be open at Q2. If it were, I'd cover.
My investor stance: moves from avoid to neutral.
What would make me buy: that print plus currency-neutral revenue flat or better, and a close above the 50-day SMA.

That's a bar Nike can clear in FY27, not FY28.

On "waiting isn't free insurance": the Dec 19 confirmation was price-only. My list was fundamental. The report that caused the Dec 19 gap showed EPS −32% and Q2 FCF −58%. My checklist would have said no at $64, and the stock then fell 48%. His example shows that chart confirmation fails. It doesn't show that fundamental confirmation fails.

8. Where we stand¶

We now agree on these points: - Nobody buys before reading the 10-Q. - NKE isn't cheap on guided earnings. - The technical base case is the downtrend resuming. - Positions should be sized for gaps. - Q2 is the test.

We disagree on one thing: whether to hold a position before the test. His position is a bet that Nike beats a guide calling for a ~10% decline, at a price already assuming a 32% recovery, with zero excess expected return by his own math. Sizing it at 1.7% limits the damage if he's wrong. It doesn't give the position an edge.

Positioning: - Investors: no new longs. - Read the 10-Q's restated gross margin and inventory lines first. - If like-for-like margin fell, the bull's own exit rule applies. - Short-term Treasuries pay roughly what the dividend pays, with no risk of a cut. - Traders: - Sell rallies into $35.6–36.4, with a stop at $37.5. - Targets are $33.81, then $31.97. - Be flat before the Dec 1 ex-date. - Size for a squeeze if CPI or the FOMC pulls yields down.

What would move me to neutral: - Q2 EPS of $0.48 or better. - Currency-neutral revenue better than Q1's −4.3%. - Like-for-like gross margin up in the restated figures. - Inventory falling. - Q2 FCF at or above $386M.

What would move me to constructive: all of the above, plus currency-neutral revenue flat or up, and closes above $36.4 and then the 50-day SMA on rising volume.

The bull has stopped arguing that NKE is cheap. He now argues that management may be too pessimistic. That could turn out to be right in late December. Until then, the guide calls for decline, the price assumes recovery, and the evidence that would settle it arrives in ten weeks. Bear Analyst: # Bear Rebuttal (Round 4): NKE

The bull has adopted my Q2 checklist number for number and made every one of his own rules stricter. That's a fair way to settle a debate. It also narrows what's left to one question: should anyone own NKE before the test?

He gives three reasons to say yes. My fair value contradicts my checklist. My reclassification estimate was the extreme case. His exits keep the bear case away from his starter. Worked through with his own numbers, each one leads back to no:

His own reclassification table rejects the starter. Every row shows like-for-like gross margin down. His rule says a decline of even 10bp means no buy.
My checklist isn't a contradiction in the bear case; it is the bear case. On a pass, fair value is roughly today's price. On a fail, it's 20–35% lower.
Passing his tests still puts him at the June board meeting with a ~96–99% payout ratio, and at full size after his Q2 add.

Where the bull is right¶

My restatement was the extreme case. I assumed all ~$880M of excess Q4 gross profit was reclassification. His range is the fairer one.
The −33% case can't reach the 1.7% starter. With his Q2 and Q3 exits, the starter's realistic loss is a Q2 gap, about 0.3% of capital.
Carry favors him slightly, and by more than either of us said.
We both used 4.77% as the T-bill rate. That's the 2-year yield.
Bills trade near Fed funds, about 3.9%.
Over the 11 weeks to the print, the dividend beats bills by about 0.4 points. That's real, and it's small.
His demand-creation check is the right test for my brand-harvesting concern. I'll adopt it.
The rate of decline is slowing. FY27's guided −9% to −11% is smaller than the FY25 and FY26 drops. A slower decline is still a decline. §2 covers what today's price assumes.

1. His own table says no starter¶

Here is his restatement range with his own rule beside it:

Source of Q4 FY26 excess net income	Q1 FY27 like-for-like gross margin	His rule
All below gross profit (my end)	−1.3 pts	No buy
All from a real gross-profit gain (his end)	−0.1 to −0.3 pts	No buy

Every row is negative. For restated margin to come out positive, Q4 FY26 needs two unusual items of matching size in the same quarter: - a genuine gross-profit windfall near $880M, which means a ~49% gross margin quarter the fundamentals report says Nike "has never come close to"; - roughly $400M of one-off charges below gross profit to offset it.

That's possible, but it isn't the base case.

The cost picture at his end of the range: - Restated Q1 FY26 costs below gross profit come to about $4.30–4.32B, or 36.7–36.9% of sales. - Q1 FY27 was $4.09B, or 36.4%. - So even at his end, restated gross margin fell slightly and the cost ratio improved 0.2–0.4 points.

In every row of his table, Q1's net margin held up because of costs below the gross-profit line. The extreme case only changes the size of that effect. Whether the savings came from overhead or from demand creation is his new check, and it's the right one.

The upshot: the first leg of his edge is "the 10-Q filter." On his own arithmetic, that filter most likely rejects the trade. If it does, his recommendation today is the same as mine: no position.

2. My checklist is the bear case¶

His question: if Q2 prints $0.48, FY27 tracks about $1.66–1.70, which is about $27 at 16x. Why would I go neutral at $35?

Because he changed only one of five inputs. A five-for-five pass means all of these: - currency-neutral revenue improving; - like-for-like gross margin up; - inventory falling; - Q2 free cash flow up year over year.

That isn't "Q3 and Q4 stay on the guide's path." It's evidence that the path is better than guided. After that print I wouldn't value FY27 on the guide. I'd value the recovery.

My multiples, stated plainly: - About 16x (range 14–17x) on declining earnings. - About 18–19x on recovering earnings, once the recovery shows up in the numbers. That's a premium to a decliner for a recovery one quarter old, well short of the 27–31x the stock carried last year.

Q2 outcome	Earnings I'd value	Multiple	Value	vs $34.74
Five-for-five pass	FY28 back to FY26 underlying, ~$1.84–1.90	18–19x	$33–36	about flat
Fail, or guide merely met	FY27 ~$1.55–1.64	14–17x	$22–28	−19% to −37%

That's why I'd go neutral near $35 after a pass: the stock would be fairly priced. It's also why I'm bearish before the pass. At $34.74, the stock already trades at about 19x a recovery to $1.84. Today's price is the pass-case value. Owning it before the print means roughly flat if the answer is good and 20–35% down if it isn't.

This also answers his charge that I'm assuming trough margins "forever." My $22–28 isn't a permanent trough. It's the value if the trajectory doesn't change, and the evidence on that arrives in ten weeks. I'm not refusing to pay for a recovery. I'm refusing to pay for it before it shows up.

Two smaller corrections: - "The last full fiscal year before this one" is FY26, not FY25. We agreed FY26 underlying EPS was $1.80–1.84. His $2.17 is 18–21% above that. - His add rule buys above $36.38 after a pass. On my pass-case range, that's at or above fair value. Anything that pushes the stock beyond fair value would be a short squeeze, which is about positioning, not value.

3. Below-COVID margins at full employment are a warning, not a floor¶

The bull's best new fact is that the guide implies Nike's lowest net margin in at least seven years, below the FY20 COVID year. He reads that as a coiled spring.

Compare the conditions in each year: - FY20: stores closed worldwide, global recession. - FY27: unemployment at 4.2%, jobless claims at 197k, real retail sales up about 0.8% in August alone.

Nike is guiding below its pandemic-year margin in a full-employment economy. That's hard to call cyclical. A cyclical trough needs a cyclical cause. The employed consumer the bull said he needed showed up, and Nike's revenue fell anyway.

"That's how cyclicals are priced near a bottom" assumes the economic cycle has already bottomed. The macro data suggest the downturn may still be ahead: - The Fed hiked in September, and the 2-year sits about 90bp above Fed funds, so markets expect more hikes. - The 10-year is at its highest since 2002, and mortgage rates are at a three-year high. - The saving rate has fallen from 5.6% to 4.1%. - The VIX is about 15 even as yields move this fast.

If the cycle turns, Nike's margins start from below-COVID levels and go lower. 21x guided earnings is not a trough multiple on trough earnings. It's a full multiple on earnings that haven't yet been through a downturn.

4. I believe management on both counts; he believes only one¶

His question: why trust the guide but not the dividend pledge? I trust both.

On the same day, management guided earnings below the dividend and called the dividend its top priority. Read together, those say: we'll pay the dividend in FY27 and fund part of it from the balance sheet. That's what I've said since Round 1. - The November declaration will pass. - The yield is a return of capital at a payout of about 100% of earnings, not a return earned from the business.

The bull is the one splitting the two statements. He accepts the pledge and bets that the guide is too low.

On "under-promising costs little": not this time. - Guiding below the dividend produced the "yield trap" headlines. - It came with the report that sent the stock to its 12-month low on Oct 2. - A management team managing optics would have guided at or above $1.64. They chose the number that made their own dividend look uncovered.

That's the best evidence we have that the guide is a genuine forecast rather than a deliberately low bar.

The conditions behind the guide haven't changed either: - EUR/USD hasn't recovered from 1.126. - Oil rose again on Oct 8. - The 10-year is a few basis points from its high.

5. His exits protect the starter, not the larger position¶

His question 4: what path takes the starter to −33% before June 2027? None, and I concede that. The path that matters runs through his own add rule.

Step one: his pass case is close to the guide. His thresholds are Q2 EPS of $0.48 (−9.4%) and Q3 EPS of $0.32 (−8.6%).

	FY26 underlying	FY27 if he passes Q2 and Q3	FY27 guide
EPS	$1.80–1.84	~$1.66–1.70	below $1.64
Payout ratio ($1.64 dividend)	~89–91%	~96–99%	above 100%
Free cash flow vs ~$2.4B dividend	~95% coverage	gap ~$0.55–0.7B (on his $1.7–1.85B)	gap ~$0.6–0.7B

He says the payout ratio falls if Q2 and Q3 pass. That's true only against the guide. Against last year, it rises. In his success case, the board meets in June with: - a higher payout ratio than a year earlier; - a second straight year of free cash flow below the dividend.

Step two: he'll hold more by June. 1. Pass Q2, then add toward the full 5% position above $36.38. 2. Pass Q3. 3. Hold through the FY27 results, the FY28 guide and the dividend decision.

His "0.3% of capital" applies to the starter. The position he plans to carry into June is about three times as large. His exits don't screen for the June risk, because passing them barely changes the dividend math.

6. The starter's payoff is negative on his own weights¶

With carry about even, the starter is a bet on how NKE reacts to Q2.

Two facts about that reaction: - All three earnings-related moves in our data were down: −10.5% (Dec), −15.5% (Apr), and −13.6% including September's pre-report selling. There's no upside earnings gap to calibrate a beat. - His own scenario weights rate a bad outcome as more likely than a good one: bear 30%, bull 25%. His pass now requires all five tests, which is a narrower outcome than his 12–18 month bull case.

Applying his weights to the Q2 print (my extension, and illustrative):

Q2 outcome	Weight	Move	Contribution
Five-for-five pass	25%	+12% (toward the 50-day)	+3.0
In line with guide (he exits)	45%	~0%	0
Miss	30%	−15% (April's size)	−4.5
Dividend vs bills	—	—	+0.4
Total, on the position			≈ −1.1%

With symmetric ±15% moves, it's still about −0.35%. It comes out negative either way because his own weights rate a miss as more likely than a pass.

His other two edges: - "Heavily shorted." None of our reports gives a short-interest figure. It's one line in the news report's list of contrarian points. I size my own trade for a squeeze, but I wouldn't build an edge on a number nobody measured. - "Waiting is expensive only in the beat case." In that case I buy around $38–39, with evidence, at full size. On his weights, waiting avoids more expected loss in the miss case than it gives up in the pass case.

A small negative bet is still a negative bet. Sizing controls how much it costs, not whether it's right.

7. Answers to the bull's questions¶

What multiple am I using? About 16x on declining earnings, and 18–19x on recovering earnings once the recovery is evident. After a five-for-five pass, that gives $33–36, so I'd go neutral near $35. Today's price already equals that pass-case value.
Why the extreme end of the restatement? It was the extreme end, and I concede that. But his range is negative throughout, and his rule rejects every row. A positive reading needs two offsetting unusual items in one quarter.
Why trust management on the guide but not the pledge? I believe both. Together they say the dividend will be funded partly from the balance sheet. A guide that made the dividend look uncovered was costly for management, which makes it more credible, not less.
What path reaches −33%? None for the starter. The real path runs through his Q2 add into a June board meeting at full size, with a ~96–99% payout ratio in his own success case.

8. Where we stand¶

We agree on: - No position before the Q1 10-Q. - NKE isn't cheap on guided earnings. - Q2 is the test, with identical pass marks. - Long positions should be sized for gaps, and short positions for a squeeze.

A commitment on the 10-Q, so neither of us can move the goalposts: - If restated like-for-like gross margin is up, inventory is down, and demand creation fell no faster than revenue: - I drop my reclassification and inventory arguments. - I stop selling rallies. - I'll call his starter a fair bet. - My investor stance stays "no new longs" until Q2. - If restated like-for-like gross margin is down at all, as both our ranges suggest, his own rule says no starter, and we'll be giving the same recommendation.

Positioning: - Investors: no new longs. - Read the 10-Q's restated gross margin, inventory and demand-creation lines first. - The 2-year Treasury pays 4.77% for two years with no risk of a cut. Bills pay about 3.9% while you wait for the print. - Traders: - Sell rallies into $35.6–36.4, with a stop at $37.5. Targets are $33.81, then $31.97. - Be flat before the Dec 1 ex-dividend date. - Cut size into September CPI and the Oct 27–28 FOMC if yields start falling. - Stand aside if the 10-Q is clean. - What would move me to neutral: - Q2 EPS of $0.48 or better. - Currency-neutral revenue better than −4.3%. - Restated gross margin up. - Inventory falling. - Q2 free cash flow of at least $386M. - What would move me to constructive: all of the above, plus currency-neutral revenue flat or up, and closes above $36.4 and then the 50-day SMA on rising volume.

Closing¶

The debate has converged. We agree on the valuation, the test, the pass marks and the date. The last disagreement is whether to own NKE before the answer, and his own numbers argue against it:

His reclassification table shows like-for-like margin down at every point, and his own rule says that means no starter.
Today's price already equals the value of a five-for-five pass.
Passing his tests still leaves the June board with a ~96–99% payout ratio and a second year of free cash flow below the dividend.

The stock is already priced for a good Q2. I'd rather see that result before paying for it. Bear Analyst: # Bear Rebuttal (Round 5): NKE

The bull has conceded the point that matters most in practice. On his own arithmetic, the 10-Q most likely tells him not to buy. If it does, his recommendation today is the same as mine: no position.

He also caught me on framing. "Today's price is the pass-case value" was shorthand, and his implied-probability math shows what it stood for: the market is paying about 21x for a guided decline. He's right that our dispute is about the multiple. So this round defends the multiple directly. Three points decide it:

His own Round 2 table assigns 16x to a declining Nike and 20x to a recovering one. The market is paying 21x for decline.
The 10-Q is public, so a clean one is already in $34.74. The filter keeps him out of the bad outcome. It doesn't create the +1.6%.
A confident board and a worried board would both make the dividend pledge. So it tells us nothing about which kind of board Nike has.

Where the bull is right¶

"Already priced for a good Q2" and "21x is too high" are the same claim. His implied-probability math is correct on my numbers. §1 defends the multiple head-on.
"Two unusual items of matching size" overstated it. At the edge of his pass region, the offset needed below gross profit is $45–110M, which is a modest charge. I withdraw the phrase. §3 covers the item that remains.
My −1.1% was unconditional, and his trade is conditional. My commitment from last round stands. §2 explains what "fair" means.
His June rule is a real fix. It requires nine-month free cash flow above $685M, so Q2 plus Q3 must beat last year's $670M by about 12%. That screens for the risk I raised.
His macro gate is sensible. If CPI pushes the 10-year above 5.31%, waiting for the FOMC is what I'd do on the long side too.
The three down gaps don't tell us how the stock reacts to a beat. Fair. §4 uses the one print in our data that does.

1. What justifies 16x: his own table¶

His first question asks what justifies 16x for a trough year. He answered it himself in Round 2:

Bull's Round 2 scenario	EPS	Multiple he assigned
Bear: decline continues	$1.40	16x
Base: guide is the trough, slow repair	$1.90 (FY28)	20x
Bull: margins back to ~8%	$2.50	20x
Market today	≤$1.64 (FY27 guide, down 9–11%)	~21x

He gave 16x to a Nike whose earnings keep falling. He gave 20x to a Nike whose earnings have recovered by FY28. Today the market pays 21x on lower earnings that management says are still falling. That is a richer multiple than he gave his own recovery case.

The rate math says the same thing. - He withdrew the real-yield argument in Round 3, so the comparison with nominal yields stands. At 21x, the earnings yield is about 4.7%. The 10-year pays 5.28%. - With the payout near 100%, required return is roughly earnings yield plus growth. - Ask for a 3–4 point premium over the 10-year, and 21x needs 3.6–4.6% nominal growth forever. That's 1.2–2.2% real growth, with no retained earnings to fund it. - The same math at 16x implies 2–3% nominal growth, which is roughly zero real growth. - Nike's revenue grew under 1% a year from FY21 to FY26, a period of above-target inflation. 16x isn't punitive. It's the multiple Nike's last five years have earned.

On "trough years carry high multiples by construction": that holds only at a cyclical trough. He agreed last round that the consumer cycle doesn't explain this margin. Without a cyclical cause, a trough multiple is a recovery forecast in disguise. You can put the recovery in the earnings ($2.17) or in the multiple (21x on $1.64). Either way, you pay for it before you see it. That's what I meant by "priced for a good Q2."

On "the market would have to be off by 60 points": - Dec 19 was also the market's verdict after full disclosure. It traded 108.7M shares at about 31x normalized earnings, and the stock is down 39% since. - Apr 1 was the same: 114.2M shares at about 27x. It's down 21% since. - Record volume means record disagreement. Every share bought on Oct 2 was sold by someone. Since then, the bounce has come on falling volume, and OBV has recovered only 28% of its drop. - His own position is a bet that the market is wrong about the guide.

On the 5.9–7.5% yield in my fail case: before the June board decision, Nike pays three more dividends. That's $1.23, about 3.5% of today's price. The fail case has $7–13 of downside. A yield only puts a floor under a stock if the market trusts the dividends after those three, and those are the ones in question.

2. The 10-Q is public, so the filter is risk control, not edge¶

I said in Round 2 that the Q1 10-Q was probably already filed, and he repeated it. Nike usually files within days of the earnings release. If so, the restated margins, inventory and demand-creation lines have been public since early October. That makes $34.74 a post-10-Q price.

That changes his §3 arithmetic. He shifts ten points from miss to pass but holds the price at $34.74. That counts a clean 10-Q twice: once in his weights, and once in a price that already reflects it.

So the two sections of my last round don't contradict each other: - Unconditional: negative, because a miss is likelier than a pass. - Conditional on a clean 10-Q: about zero, because the market already knows it's clean. That is what I meant by "fair bet," and I'll keep my word on it. Fair means no edge.

His closing line, "a price set before the market sees what we've seen," has it backward. On the 10-Q, we're the last to see it.

The filter does have value: it keeps him out of the bad outcome. That is risk control. And even his +1.6% on a 1.7% position comes to about 0.03% of capital, earned over eleven weeks of gap risk he sized at 0.3%.

3. A pass still needs a one-off in Q4¶

I accept his threshold. Restated margin stays positive if the reclassification is under about $280M of the ~$880M Q4 excess. Here is what the pass region requires:

A real Q4 FY26 gross margin of at least 46.5%. Q3 was 40.2%, and Q4 FY25 was 40.3%.
Then a fall back to about 42.2% on the old basis in Q1 FY27.

A six-point spike that reverses within one quarter is a one-off, whatever caused it. FY22's 46.0% doesn't make it normal. FY22 was a full year at peak pricing power, not a single quarter between two quarters near 40%.

So under either reading, Q4 FY26 contained $600–880M of gross profit that won't recur, whether from an accounting change or a one-time gain.

The pass region covers about a third of the range ($280M of $880M). Inventory and demand creation then have to pass as well. We both call a pass a minority outcome, which is why both of us recommend no position today.

4. The one good print in our data, and what a pass is worth¶

The Q4 FY26 reaction. Nike usually reports Q4 in late June. That report showed EPS of $0.73, up 421%. - The stock bottomed at $40.32 on Jun 26 and rallied to $44.10 by Jul 16, about +9%. That's close to the +12% he assumes for a pass. - By Aug 27 it was at $38.04, below where the rally started. - Today it is 14% below that June low.

The report date isn't in our data, and that quarter is flagged for one-off items. It's still the only strong headline print we have.

Rally highs in this downtrend have been sold: $64.59 in January, $44.10 in July, $36.39 in September. His add rule buys on a close above $36.38, which repeats that pattern.

What a pass is worth. His $39–41 is 18–19x FY29 EPS of $2.17. That is a mid-2028 price, from when FY29 becomes the forward year. - Discount it about 1.5 years at ~9.3% (the 10-year plus four points). - Add roughly $2.3 of dividends in present value. - The result is about $36–38 in December terms.

His add trigger at $36.38 buys at the discounted value of a path that needs a five-for-five pass and then two straight years of growth. That's the point I made last round: after a pass, his add is at fair value, not below it.

5. The pledge doesn't tell us what management expects¶

His fourth question: if management saw permanent decline, why not cut on Oct 2?

Because either kind of board keeps it. - Keeping it costs little. For FY27 the gap is $0.5–0.7B, about 7–10% of cash. - Cutting on guide day costs a lot. It would have stacked a second shock on the first and driven out the income holders. The sentiment report shows the bull case in the headlines rests almost entirely on the dividend.

A confident board and a worried board would both pay that small price to keep their options open. When both types send the same signal, it tells you nothing about which type you're dealing with.

The guide is different. Only a board willing to show an uncovered dividend would issue it. That's why I give it more weight.

"Top priority" ranks the dividend above other uses of cash. That's a capital-allocation statement, not an earnings forecast. Nothing in our data shows management forecasting a recovery in FY28. Calling FY27 a "bridge year" is his reading, not theirs.

6. Two of the four margin causes don't correct themselves¶

His four causes are discounting, inventory clearance, tariffs and channel shift.

Channel shift is a mix change. It doesn't reverse when inventory is clean. If the shift is back toward wholesale partners, it lowers gross margin by design.
Tariffs "may shift" after the midterms. The macro report doesn't say in which direction.
Inventory clearance has been running since FY25, when the Q4 margin was 40.3%. Two years in, non-cash current assets are still flat while sales are down 4.3%.
Scale hasn't protected Nike. Gross profit fell from about $22.9B in FY24 to about $19.9B in FY26, down 13%, and more on a like-for-like basis if FY26 includes the reclassification. That scale didn't stop five quarters of slowing revenue while challengers took share.

His prediction table is the right test, and I accept it. Demand creation and inventory are in the 10-Q now. Currency-neutral revenue arrives with Q2.

7. Answers to the bull's questions¶

Is "priced for a good Q2" just "21x is too high"? Yes, it's the same claim. Three things justify 16x:
his own Round 2 table;
an earnings yield below the 10-year;
the 1–2% real growth forever that 21x requires, which Nike hasn't delivered in five years.
Which describes his trade, −1.1% or "fair"? Both, for different trades. Unconditional is negative. Conditional is fair, meaning about zero edge, because the 10-Q is public.
Why "two unusual items"? I concede the offset; it's small. The first item stands: a pass needs a Q4 margin of at least 46.5% that vanished by Q1.
Why pledge instead of cut? Because either kind of board would. The pledge was cheap. The guide was costly.

8. Where we stand¶

Outcome	Bull	Bear
Today	No position until the 10-Q is read	No new longs
10-Q fails (likely, by both our math)	No position	Sell rallies into resistance
10-Q clean	1.7% starter	Stand aside; call it a fair bet
Q2 five-for-five pass	Add above $36.38	Neutral, about fair value
Q2 pass, plus currency-neutral revenue flat or up and closes above the 50-day	Hold / add	Constructive
Q2 fails any item	Exit	Short-side targets

One disagreement is left: the multiple. It doesn't change what anyone does today. It decides what a pass is worth. He would pay up into a recovery. I would pay fair value once the recovery shows up in the numbers.

Positioning: - Investors: no new longs. - Read the 10-Q's restated gross margin, inventory and demand-creation lines. - Bills pay about 3.9% while you wait. The 2-year pays 4.77% with no risk of a cut. - Traders: - Sell rallies into $35.6–36.4, with a stop at $37.5. Targets are $33.81, then $31.97. - Be flat before the Dec 1 ex-dividend date. - Cut size into September CPI and the Oct 27–28 FOMC if yields start falling. - Stand aside if the 10-Q is clean. - Neutral on a five-for-five Q2 pass. - Constructive on that pass, plus currency-neutral revenue flat or up, plus closes above $36.4 and the 50-day SMA on rising volume.

Closing¶

The bull opened by saying the stock had fallen much further than the business. Five rounds later, here is where things stand: - Both of us recommend no position today. - His case is a 1.7% starter, conditional on a filing the market already has. On his own arithmetic, that filing most likely fails his test. - One question remains: does a company with falling earnings, a payout near 100% and revenue growing slower than inflation deserve 21x when the 10-year pays 5.28%?

His own table answers that: he gave 16x to a declining Nike. Until Nike shows the decline has ended, that's the multiple to use. On guided earnings it gives about $26, and at $34.74 the stock sits roughly a third above it. I'll pay for the recovery once it's in the numbers, not before.

Research Manager¶

Recommendation: Underweight

Rationale: This debate converged more than most. By the last round neither side was recommending new money into NKE today. The open question was whether a small, conditional long is justified before the Q2 print. The bear won that, and won most of the substance along the way.

The bull's opening case was that the stock had fallen much further than the business: 16.6x trailing EPS, 1.1x sales, a 4.7% yield, Q1 EPS down only 2%, a 0.6pt gross-margin gain, and a high-volume Oct 2 reversal backed by weekly and monthly TD-9 setups and a MACD divergence. Almost all of it came apart under scrutiny: - The $2.09 trailing EPS leaned on an anomalous Q4 FY26 ($0.73, up 421%, an implied ~49% gross margin). On management's guide below $1.64, NKE trades near 21x. - Both sides ended up agreeing underlying FY26 EPS was about $1.80-1.84, so the guide is a 9-11% decline, not a trough. - The Q1 gross-margin gain likely reflects reclassification. Even the bull's own restatement range puts like-for-like margin at -0.1 to -1.3pts, which fails his own entry rule. - Free cash flow is about $1.7-1.85B against a roughly $2.3-2.4B dividend. The payout is near 100% of guided earnings, and Q1 cash conversion has fallen three years running. - The technical base case, which the bull accepted, is that the downtrend resumes. Rally highs keep getting lower, volume is fading on the bounce, and OBV has recovered only 28% of its drop. - Macro leans against it: a hiking Fed, a 10-year at 5.28-5.31%, a 3% dollar jump that hits Q2, and oil-driven input costs arriving in the second half. - The bear's strongest closing point used the bull's own Round 2 table, which gave 16x to a declining Nike and 20x to a recovering one. The market is paying about 21x for guided decline. That is an earnings yield below the 10-year with no retained earnings to fund growth.

The bull did land real points, and they are why this is Underweight rather than Sell: - Liquidity is solid: $6.9B in cash plus short-term investments and a 2.07x current ratio. - Both sides expect the November dividend to be declared and FY27 to be bridged from the balance sheet. - The bull's implied-probability math showed the market is pricing a bad-but-guided year, not an assured recovery. The bear's roughly $26 fair value rests on a contested 16x multiple. - Sentiment is already weak, and a squeeze is possible if CPI or the FOMC pulls yields down. - A fully specified test, the five-item Q2 checklist, arrives in about 10 weeks and could flip the view.

So the bear's case wins on earnings trajectory, dividend coverage, valuation versus rates, and the chart. But it doesn't win decisively enough to justify exiting outright ahead of a defined catalyst while the dividend is still being paid. Even on the bull's own math, the expected return is near or below T-bill yields. The 10-Q filter he relies on is risk control rather than edge, since that filing is likely already public and priced. That points to trimming exposure, not holding at full weight.

Missing data: neither side had actually read the Q1 10-Q, so restated margin, inventory and demand-creation figures are unconfirmed. Also unavailable were the exact guide figure and its GAAP basis, China segment data, short interest, and what drove the Q4 FY26 one-offs.

Strategic Actions: 1) Today: open no new longs in NKE. Existing holders should trim to about 50% of a standard allocation. - Do the trimming into strength in the $35.15-36.4 gap-fill and resistance zone. Don't dump below about $33.8, which is the Oct 7-8 lows and lower Bollinger band. - Aim to complete the trim before the Oct 27-28 FOMC. - Size the remaining position so a 15-20% earnings gap fits your risk budget. NKE has gapped -10.5% and -15.5% on prior reports, and a stop does not protect against a gap.

2) Hard risk line: on a daily close below $31.97 (the 12-month low), cut to 25% of standard weight or less.

3) Read the Q1 FY27 10-Q immediately. It is likely already filed, but we have not seen it. Check three lines: - restated like-for-like gross margin; - inventory versus the -4.3% sales decline; - demand creation versus revenue. If any one fails (margin down at all, inventory up, or demand creation cut faster than revenue), reduce to about 25% of standard weight. If all three pass, stop trimming and hold at about 50%. Don't add before Q2.

4) Macro gate around September CPI and the FOMC: - If the 10-year closes sustainably above 5.31%, keep trimming toward 25%. - If yields fall sharply, pause trimming below $34 because of squeeze risk.

5) Mid-November dividend declaration: if the dividend is cut, exit the remainder. Holders collect the $0.41 around the Dec 1 ex-date.

6) Q2 FY27 (late December), five-item test: - EPS of $0.48 or better; - currency-neutral revenue better than -4.3%; - restated gross margin up year over year; - inventory falling; - Q2 free cash flow of at least $386M. If all five pass, upgrade to Hold. Rebuild toward full standard weight on closes above $36.38 and then the 50-day SMA (about $38.10) on rising volume. Consider Overweight only if currency-neutral revenue is flat or up. If any item fails, cut to 0-25%.

7) Late March and June: - Q3 EPS should be at least about $0.32. - Before the FY27 results and the June board dividend decision, require nine-month FCF above $685M and Q3 currency-neutral revenue flat or better. Otherwise reduce to minimal ahead of that meeting.

8) Optional tactical short, only where the mandate allows, capped at 0.25x standard size: - sell $35.6-36.4; - stop $37.5; - targets $33.81, then $31.97; - be flat before the Dec 1 ex-date; - stand aside if the 10-Q is clean; - size for a squeeze if CPI or the FOMC lowers yields.

9) Park the freed capital in T-bills (about 3.9%) or 2-year Treasuries (4.77%) while waiting for the Q2 verdict.

III. Trading Team Plan¶

Trader¶

Action: Sell

Reasoning: The plan's Underweight call becomes a measured Sell: trim existing NKE exposure to about 50% of a standard allocation and open no new longs. The trend is down on every timeframe (price below the 10 EMA, 20, 50 and 200 SMAs, all three SuperTrends down, OBV back only 28% of its drop, volume fading on the bounce), and the bear case won on falling earnings, dividend coverage near 100% and roughly 21x guided EPS against a 5.3% 10-year. The weekly and monthly TD-9 setups, the strong Oct 2 gap-day close and the MACD divergence make a relief bounce into the 35.15-36.4 gap-fill and resistance zone likely, so sell into that strength rather than at 34.74 or below the 33.8 support. Missing data that could change the size: the Q1 10-Q has not been read, and your current holdings are unknown, so apply the percentages to your own position.

Entry Price: 35.6

Stop Loss: 37.5

Position Sizing: Holders: cut to about 50% of standard weight, selling into 35.15-36.4 before the Oct 27-28 FOMC, and size what remains to survive a 15-20% earnings gap. Cut to 25% or less on a daily close below 31.97, if the 10-Q shows margin, inventory or demand-creation weakness, or if the 10-year holds above 5.31%. Exit fully if the dividend is cut. A close above 37.5 invalidates the sell thesis, so pause trimming. Optional tactical short only where the mandate allows: max 0.25x standard size, entry 35.6-36.4, stop 37.5, targets 33.81 then 31.97, flat before the Dec 1 ex-date.

FINAL TRANSACTION PROPOSAL: SELL

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: Since neither of you has spoken yet, I'll make the case first and answer the objections I expect from you both.

This Sell is the high-reward move on NKE right now. That may sound odd, since trimming a position looks cautious. But look at what the plan actually does. It goes against the popular story that a Dow component 80% off its high, yielding a record 4.7%, has to be a deep-value bargain. It times the exit to take advantage of the bounce instead of panicking. And it adds an optional short with a payoff that is strongly lopsided in our favor. That is aggressive positioning with discipline, and I'll defend all of it.

The trend is not ambiguous. NKE closed at 34.74, down 51.6% in twelve months. Every rally peak has been lower than the one before: 64.59, 63.92, 46.46, 44.10, 39.18, 36.39. Each bounce got sold.

The moving averages are stacked bearishly: 10 EMA, then 20 SMA, then 50 SMA, then 200 SMA. The 50 SMA is falling about 13 cents a session and will keep falling even if price goes sideways, because the old 41 to 42 closes are dropping out of its window. All three SuperTrends point down.

The last relief rally died at 36.39 on September 28. That is the top of our 35.15 to 36.4 sell zone and the daily SuperTrend stop. We are not guessing where sellers sit. They already showed us.

The fundamentals are getting worse, not better. Revenue growth has slowed five quarters in a row: +1.1%, +0.6%, +0.1%, −1.1%, and now −4.3%.

Q1 free cash flow was negative $64 million. Over the last twelve months, free cash flow of about $2.1 billion does not cover roughly $2.3 billion in dividends. Guided earnings are below the $1.64 dividend. Buybacks have effectively stopped, so EPS no longer gets that lift. Management has also cut back on reporting China sales, which companies rarely do when a region is doing well.

At about 21 times guided EPS, the earnings yield is under 4.7%. The 10-year Treasury pays 5.28% and real yields are 2.92%. You are being paid less to own a business with shrinking sales than to own a Treasury. That is not cheap.

To my conservative colleague, I expect two arguments, and they pull in opposite directions.

The first is "just sell everything now at 34.74." That gives away money. We have: - weekly and monthly TD-9 buy setups both complete; - an Oct 2 gap day that closed at about 95% of its range on record volume of 142.7 million shares; - a higher MACD low (−1.125) than in September (−1.205), even though price made a lower low.

All of this points to a few days of bounce. Price is only 41 cents from the 35.15 gap-fill level. Selling at 35.6 to 36.4 instead of 34.74 improves the exit by roughly 2.5% to 4.8% on half the position. Panic-selling at the bottom of the range, just above 33.81 support, is the worst execution available. Patience here earns return.

The second argument is "don't short a stock with a near-5% yield and squeeze risk." The plan already contains that risk: - Size: at most 0.25x standard. - Hard stop: 37.5, above the upper Bollinger band at 37.40 and about one ATR above the daily SuperTrend. - Dividend: we are flat before the Dec 1 ex-date, so we never pay it.

Entering near 36.4 risks about 1.1 to make 2.6 at 33.81 or 4.4 at 31.97. That is roughly 2:1 to 4:1. Even entering at 35.6 offers nearly 2:1 to the second target.

As for the yield being a floor: a 4.7% yield sits below the 10-year and roughly level with the 4.77% two-year, which carries no risk of a cut. Income buyers have no reason to step in and defend this stock.

To my neutral colleague, I expect you to say the signals are mixed, sentiment is bombed out, EPS fell only 2%, and we should wait for the 10-Q. Here is why waiting is a decision with its own cost.

The bounce signals don't hold up. RSI did not confirm the MACD divergence: it made a lower low at 28.49. OBV has recovered only 28% of its September drop. Volume has fallen steadily on the rebound, from 69.6 million to 43.7 million shares. A rally on fading volume looks like a bear flag, not a bottom.
The stock is stretched but not extreme. The weekly and monthly z-scores are about −1.6, short of the −2 level that usually marks an extreme. There is room left to fall.
The flat EPS is not what it seems. It came from cost cuts while sales fell 4.3%, and cost cuts do not keep compounding. The one bullish number, a 0.6-point gross margin gain, may not hold up either. The annual figures imply a 49.2% Q4 FY26 margin, which looks like a cost reclassification, so the improvement may not be like-for-like.
The 10-Q is mostly downside risk. Non-cash current assets are flat at $16.8 billion while revenue fell 4.3%. That hints at an inventory build, which usually means more discounting later. The plan already says to cut to 25% if the 10-Q shows that.

The macro picture adds to the pressure: - The Fed hiked in September, and the two-year yield implies more hikes. - The dollar is up about 3% in three weeks, which hurts a company with over half its revenue overseas, just before its biggest quarter. - Oil around $96 raises foam, rubber and freight costs. - The household saving rate is down to 4.1%.

September CPI and the Oct 27–28 FOMC both land before Nike's next company catalyst. I want to be done trimming by then, not reacting after a hot inflation print.

The plan already cuts what we can't cut ourselves. Its 37.5 stop protects us if the bounce turns into a real reversal. Keeping 50% of the position preserves upside if yields, oil and the dollar all reverse together. It escalates to 25% or a full exit on objective triggers: a daily close below 31.97, a 10-year holding above 5.31%, or a dividend cut.

If anything, I'd push it harder. Where the mandate allows, run the full 0.25x short rather than a token amount. If price closes below 31.97, the higher-timeframe exhaustion signals are cancelled and the data shows no support below. That is where I'd let part of the short run on a trailing stop instead of covering everything at the target.

NKE is a broken chart attached to a weakening income statement, in the worst macro setup for consumer cyclicals in years. Selling into strength is how you profit from that instead of riding it down. Aggressive Analyst: Aggressive Analyst: Start with what we already agree on. All three of us say Sell. All three of us take holders to about half weight. Nobody here is defending the yield as a floor. So the argument is about how much return we give up while executing a call we share, and I think both of you give up too much.

First, the contradiction charge. My conservative colleague says I use the bounce signals to delay the trim and then dismiss them to justify the short. That isn't a contradiction; it is the trade. The TD-9s and the strong gap-day close say a bounce of a few bars is likely. The RSI lower low, the 28% OBV recovery and volume falling from 69.6 to 43.7 million say that bounce has no buyers behind it and should fail. Exhaustion without accumulation is how lower highs form, and this chart has printed six in a row. My neutral colleague saw that and said so.

The claim that my plan depends on the "less likely scenario" misreads our own technical report. Scenario B, the base case, lists "rejection in the 35.0 to 36.4 zone" as its first signal. The base case runs through the zone. Getting there doesn't need a big rally either. The gap fill at 35.15 is 41 cents away, about a third of one day's ATR. The 20-day at 35.60 is less than one ATR away. Touching those levels within five sessions is ordinary noise for a stock moving 3.2% a day.

He also says a 37.5 stop sits inside normal daily noise. Look at what 37.5 is. It sits above the upper Bollinger band at 37.40 and above the 36.38 daily SuperTrend, where the last rally died. A move that takes out 37.5 has flipped the daily trend and broken the band. That isn't noise. That is the invalidation, and the stop is supposed to sit there.

Now the concessions. At 35.6, the short risks 1.9 to make 1.79 to the first target. That is below one-to-one, and I shouldn't have let 35.6 stand as the short's headline entry. The short belongs only in the upper half of the zone, 36.0 to 36.4. There it risks 1.1 to 1.5 to make 2.2 to 2.6 at the first target and 4.0 to 4.4 at the second.

I'll also take the conservative's fix on the 37.5 rule. A close above 37.5 kills the short, but the trim to 50% still finishes. A pop toward a 50-day at 38.10 that is falling 13 cents a session is still a place to sell. Both of those amendments make the plan sell more, not less.

On the cost of waiting, my neutral colleague already caught the conservative comparing upside on the whole position with downside on half of it. On the same shares, it is 2.5 to 4.8% of upside against 2.7 to 8% of downside. Now weight those by distance. The upside sits a third of an ATR to one and a half ATRs away, and it lies on the base-case path. The 8% downside requires breaking 31.97 within the same five sessions, and that is the exact low that just completed weekly and monthly TD-9 buy setups. Weighted by probability, waiting on part of the trim has positive expected value.

So I accept the ladder, the deadline before CPI, and a market sale on a close below 33.81. But the slice sold now should be a third of the reduction, not half. Selling half the trim at 34.74, within a week of RSI printing 28 and just 93 cents above lower-band support, is paying for insurance against the least likely path.

On gap risk, the conservative points to gaps of 7, 10 and 15% on news in ten months and says a stop can't protect a short. Look at which way those gaps went. Every one of them was down, so every one paid the short side. The tape's history of news gaps runs entirely in the short's favor, and he is using it against the short.

The upside gap he worries about is a theoretical squeeze. The macro report calls NKE "heavily shorted," but nobody in this room has a short-interest figure, so we are debating a squeeze with no data on how much fuel there is. That uncertainty is why the short is capped at 0.25x. A gap from 36.4 to 40 is about 10% on a quarter-size position, roughly 2.5% of a full position's value. It is sized to survive, which is the point of sizing.

The dividend argument is where the conservative case undercuts itself. He calls the mid-November affirmation "a known upside catalyst" that I would be short through. Then his own plan cuts holders to 25% before that same declaration. You can't call an event a known upside catalyst and also pre-sell your longs into it. My neutral colleague found the other hole: the "unless FCF coverage improves" exception can never trigger, because no cash flow data arrives before late December.

My read is that the affirmation is already priced. The CFO publicly called the dividend the top priority, and it is in the headlines. Repeating a pledge the market already has won't surprise anyone. The unpriced outcome is a cut, and that gaps down. For a short, the declaration leans our way. Still, I'll meet the neutral partway. If the first target is hit, take it off before the declaration, and anything still open goes into the event with its stop at entry or better.

On the 35 to 40% "until the 10-Q is read," the neutral is right that the filing is already public. Reading it takes a couple of days; it isn't a future event. I said the 10-Q leans toward downside risk and I stand by that, which is why the plan already ties the 25% trigger to it. Selling to 35% and then buying back to 50% after a clean read is a round trip that likely buys back higher, after the bounce we all expect.

On netting, fine. For holders, a 0.25x short against a 0.5x long nets to 0.25x, and selling stock gets there without borrow. That changes the vehicle, not the trade. Holders run it as a tactical trim: sell an extra quarter-weight into 36.0 to 36.4, buy it back at 33.81 or 31.97, and cancel the buyback above 37.5. The payoff is the same, with no borrow and no margin. The actual short is for flat accounts, and there I want the full 0.25x the mandate allows, not a token position.

Now my neutral colleague's valuation correction. Trailing EPS of 2.09 includes a fiscal Q4 of 73 cents, on revenue down 1.1%, against 14 cents a year earlier. Our fundamentals report flags that quarter as a likely one-off, and the same quarter implies a 49.2% gross margin. Replace it with a normal quarter of 35 to 53 cents and trailing EPS becomes 1.71 to 1.89. That is 18 to 20 times earnings, an earnings yield of 4.9 to 5.4%, which is about the same as the 10-year at 5.28%. The free cash flow yield of 4.1% is below it.

The real-yield comparison only works for a company that passes inflation through to prices. Nike's nominal revenue fell 4.3% while CPI ran at 3.4%, so real sales fell about 7.5%. That is the opposite of pass-through. A business losing real revenue doesn't earn a comparison against a 2.92% real yield.

On Oct 2, I'll take the neutral's read that it was the earnings reaction. A 3.6% close-to-close drop from 35.15 fits Zacks' "more than 2%" headline, and that helps my case. It answers the conservative's objection that we don't know what drove the record volume. We do: the Q1 print, with revenue down 4.3% and guidance below the dividend, and the market has absorbed it.

The strong close tells you about the next few bars, not about the trend. The December gap recovered all the way to 64.59 and then the stock nearly halved. Whether a gap day closes strong or weak, the recovery has been a place to sell.

On macro being two-sided: oil is off its peak but still up a third since July. Gasoline is $4.35 against $3.78 in July. September CPI is the first print that includes any of that. Jobless claims at 197 thousand are why the Fed hiked and why the two-year is pricing more hikes. The saving rate fell from 5.6% to 4.1% this year, so consumers are funding spending from savings going into Nike's biggest quarter, with the dollar up 3%. The Iran headline didn't remove the oil risk; it deferred it until after November 3, which puts it in the middle of our short window. That tail risk sits on my side of the trade.

On shorting only below 31.97 and not trailing: I'll add the breakdown entry the neutral proposed, because I like it. But the reason to trail below 31.97 is the same reason he gives for entering there: the data shows no support below it. A fixed target in an air pocket means covering at the first round number while the trend keeps going. A trailing stop isn't open-ended. Its risk is defined and only moves in our favor. Open-ended would be holding a long with no exit below 31.97, and nobody here is proposing that.

I accept the neutral's upside rule as the trigger to stop trimming: a close above 36.4, RSI over 45, and the 10-year under 5%. Look at what it requires. RSI hasn't topped 41.64 in a month. The 10-year would have to fall 28 basis points during a hiking cycle with the oil-shock CPI about to land. It's a good rule because noise won't set it off.

So here is where I land.

Holders: - Sell a third of the planned reduction now. - Ladder the rest at 35.15, 35.60, 36.00 and 36.40. - Sell whatever is left at market before CPI, or on any close below 33.81. - Finish at 50% even if price goes above 37.5. - Read the 10-Q this week, and go to 25% if it shows an inventory build plus a reclassified margin. - Run the extra quarter-weight tactical trim into 36.0 to 36.4 and buy it back at the targets.

Flat accounts: - Run the full 0.25x short, entered in the upper half of the zone or on a close below 31.97. - Stop at 37.5 for zone entries, or about one ATR above entry for breakdowns. - Take the first target off before the declaration and trail the rest. - Be flat before December 1.

Everyone parks proceeds in two-year Treasuries at 4.77%.

The conservative plan sells right at support, pre-sells ahead of a catalyst he himself calls bullish, and refuses the one trade with a defined payoff of roughly one and a half to four times its risk. The neutral plan is close, but it caps the winner with a fixed target in a zone with no support. This trend has rewarded sellers at every lower high for twelve months, and I want us selling into the next one. Aggressive Analyst: Aggressive Analyst: My neutral colleague is right that we've been arguing hardest over the smallest amounts of money. So I'll concede what the data has settled and spend my time where the plans still differ in ways that pay.

Here is what I concede. Sell half the reduction now, not a third. The bounce-decay sequence decides it: 11%, 9.4%, 3%, 2.5%, and we're already 2.6% off the Oct 2 close. The edge I wanted to protect has been shrinking for six months. I also drop the holders' buyback round trip, because the conservative is right that it buys at the same levels where the plan sells on a close. I'll take 36.20 as the top rung. Resting an order a penny above the 36.39 close where the last rally died was poor placement. And I agree to read the 10-Q inside the ladder window, so the trim and the size decision happen once.

That decay data also supports the bear case. Every rally in this stock is weaker than the one before it, and each lower high comes with less buying power. That is exactly why the short belongs in this plan. I won't let anyone use the decay to justify selling half now and then ignore it when we discuss the short.

On the stop, the conservative says I've put my stop below the level where I'd want to sell. The trim and the short answer different questions over different horizons. Holders are reducing exposure to a business with five straight quarters of slowing revenue that they'd otherwise carry into a December print. For that decision, any price above fair value is a sale, so 38 is fine. A short is a bet on the next three to four weeks. A close above 37.5 is above the upper band and the daily SuperTrend, and within a week, as the neutral showed, it is above a 50-day falling to about 37.45. When that happens, the multi-week path is no longer reliably down, even if the long-term thesis still holds. Covering a short there and selling stock you own there are not contradictory. They are two time horizons behaving correctly.

His post-gap analogs also hold up worse than he suggests. The April rally to 46.46 took about seven weeks. Seven weeks from Oct 2 is around Nov 20, after the date all three of us now agree to be flat. Only the December analog fits inside the window. And look at what the entry filter does to his scenario. If the stock rips 11 to 13% in a straight line, there is no rejection candle at 36.0 to 36.4 and we never enter. We only lose if we get a rejection that then reverses through 37.5. That costs about 0.9% of a standard position at quarter size from 36.2. The reward from that entry is about 1.65% at 33.81 and about 2.9% at 31.97, which is 1.8 to 1 and 3.3 to 1. A trade can lose and still be right to take, and that is the definition of one.

On size, the conservative says unknown short interest means go smaller than 0.25x. But we've all agreed to size by a gap budget, and the gap budget is the uncertainty adjustment. Shading below what it allows double-counts the same unknown. On what gap to budget for: the 7, 10 and 15% gaps in our history were all earnings gaps. Earnings fall after everyone is flat, and the dividend declaration is now excluded too. What's left in the window is macro. A 10% adverse gap is a generous allowance for that, and it is the conservative's own first-round anchor. "Size it for a gap to 40" from 36.4 is almost exactly 10%. At 0.25x, that is 2.5% of a standard position, which most risk budgets can carry.

The neutral says the short rests on the chart alone. It doesn't. Look at the macro events that fall inside the window. September CPI is the first print with the oil shock in it, and it captures peak gasoline of $4.48 on Sep 21 against $3.78 in July. Then comes an FOMC where the two-year at 4.77% is already pricing more hikes. The dollar is up 3% heading into Nike's biggest quarter. The conservative's squeeze case needs oil, yields and the dollar to reverse together within three weeks, during a hiking cycle, right before a hot inflation print. That can happen, but the skew in this window points our way.

The 10-Q should also set how much short conviction we carry. So here is a tweak to the neutral's split. If the zone half never triggers by the CPI deadline, its allocation shouldn't just disappear. If the 10-Q shows the inventory build or a reclassified margin, the unused zone allocation rolls to the breakdown entry, still under the 0.25x cap. If the filing is clean, the breakdown half stays half. That ties the short's size to the fundamentals, so it isn't a chart bet.

Now the trailing stop and the conservative's yield arithmetic. He's right that 1.64 divided by 5.28% is 31.06. But parity with the 10-year is the price at which a buyer gets nothing for dividend-cut risk. It is the break-even for someone who thinks the dividend is perfectly safe. The yield-trap headlines tell you the market doesn't think that, so parity is not support.

The neutral's fix also has a flaw. Take partial profits near 31 on a short entered on a close below 31.97, and the first tranche makes about 80 cents against a stop roughly 1.1 away. That is under one to one, because 31 sits inside one ATR of the trigger. The better structure is this: take a third off at 31, move the stop on the rest to entry, and trail it. If income buyers really do show up below parity, the bounce costs us nothing, and if they don't, we keep the move through the air pocket. That answers the conservative's concern at zero cost and keeps the upside in the trade.

On the declaration, I'll accept being flat beforehand. The neutral's description of the event is the best argument made in this debate: a probable small pop on affirmation against a possible large drop on a cut. That isn't a stock short's payoff, but it is exactly the payoff an out-of-the-money put spread is built for. So where the mandate allows, flat accounts should close the stock short before the declaration and carry the cut tail through a small put spread. We'd lose a little premium on the likely outcome and earn a lot on the unlikely one, with the risk capped.

One more thing to check, because it comes from Nike's history rather than our tools. November is traditionally when Nike announces its annual dividend increase. With guided EPS below the payout, a raise is hard to justify. If that history holds, a flat dividend may read as a broken streak more than as relief. That weakens the conservative's claim of a known upside catalyst. And if the stock closes below 31.97 again after the event, the breakdown half should be allowed to re-enter under the same rules, flat before the Dec 1 ex-date. The trend doesn't end because the binary event did.

On put spreads as the default, the conservative wants them preferred for flat accounts. We have no implied volatility data. Volatility after a record 142.7-million-share gap day is likely elevated, and skew in a name the macro report calls heavily shorted is probably steep. Making a vehicle we can't price the default over one we can price is backwards. Here is the clean rule: use options for dated binary events such as the declaration and December earnings, and use stock or shorts for the trend. Use the put spread when it prices well, not by preference.

On the Oct 2 close, both of you lean on the 95% close as the thing that breaks the pattern. That close told us about the next few bars, and those bars have now traded. Four sessions after the strongest close of the year, the stock still can't close above its 10 EMA: 34.74 against 34.94. The gap at 35.02 to 35.15 is unfilled. Volume has gone 69.6, 50.1, 37.6, 43.7 million. OBV has recovered 28% of the drop. Whatever information that close carried has mostly played out, and what followed is a weak bounce.

I agree with the neutral that December is where the real money is. Ten points of a standard position on a 20% gap dwarfs everything else here. That is why I want the 10-Q tiers applied without hesitation. Two red flags means 25% and stay there. And holders whose mandate allows it should put the put spread through Q2 earnings, which is the dated, binary event options are meant for. Run the cross-exposure check on dollar, China and oil names first, as the neutral said.

So my final position is this, still a Sell. Holders sell half the reduction now near 34.74. Ladder the rest at 35.15, 35.60 and 36.20. Sell what's left at market before CPI or on a close below 33.81, and finish to tier size even above 37.5. Set the tier once after reading the 10-Q: 25%, 35% or 50%. Keep the downside triggers and the upside rule, and park proceeds in two-year Treasuries at 4.77%.

Flat accounts run a short sized at the smaller of 0.25x or a 10% gap budget, split between two entries. The first half goes on a confirmed rejection at 36.0 to 36.4, stop 37.5, cancelled by the CPI deadline. The second half goes on a close below 31.97, with the unused zone allocation rolling into it if the 10-Q shows red flags. Take a third off at 31, move the stop to entry and trail the rest. Close the stock short before the declaration, carry the cut tail with a small put spread where it prices well, and re-enter the breakdown afterward if it re-triggers, flat before Dec 1.

This trend has paid sellers at every lower high for twelve months, and every bounce has been weaker than the last. The plan adds the controls you both asked for and still keeps us positioned for the next leg down. Aggressive Analyst: Aggressive Analyst: I'll start with where we've ended up, because it shapes how we finish. Two rounds ago my conservative colleague wanted no zone short at all. His final position is that the only zone short he'd sign is one entered after the 50-day has fallen below 37.5 and outside the CPI window. My neutral colleague wrote the same rule on his own: no zone short before CPI, then enter on a confirmed rejection at 36.0 to 36.4 once the 50-day is at or below the stop. That is still the trade, just with a later entry date, and I accept the window.

One detail on how the rule is written. If price bounces toward 36, the 50-day falls closer to 11 cents a session than 13, because the 41-to-42 closes leaving the window are replaced by 36s instead of 34s. So the crossover could slip a day or two past October 15. The trigger should be the 50-day itself, not a calendar date, and the neutral's wording already does that.

Now the conservative's bounce-decay test, which he says kills the zone half. Follow it through. If the decay holds, the bounce is already over at 34.74 and the zone order never fires. An order that never fires costs nothing, and in that world the breakdown half and the half of the trim we sold today do the work.

If the decay breaks and we get a big bounce, the neutral did the arithmetic: one of the three rallies big enough to reach the zone survives the stop. On its own, that only breaks even to the first target. But look at what happened after every rally in this chart. All five, from the December gap rally to the September bounce, ended with a new closing low below the low they started from.

The one rally that survives our stop is the 9.4% move from 40.32 to 44.10. It then fell to 38.04, about 5.7% below where it started. Apply that to the 33.87 close and you land at about 31.96, which is our second target almost to the penny.

So the expected value isn't zero. From a 36.2 entry risking 1.3, it's roughly break-even to 33.81 and about plus 0.4 of the risk unit to 31.97. The fix is to weight the zone half's exit toward 31.97, not to delete the trade. And that one-in-three comes from rallies early in the decline, before the 50-day had come down to meet our stop. Under the post-CPI rule, getting stopped requires clearing the 50-day and the stop in the same move, so I'd treat one in three as the cautious estimate.

On macro, the conservative says the hot inflation headline is already priced because gasoline prices are published weekly, while a soft core print isn't priced. That doesn't hold together. Core PCE running near 2% annualized for three months is just as public as weekly gasoline. If one is in the forecasts, so is the other.

Look at what's actually driving the 10-year. It's up about 72 basis points since July 10, and the real yield is up about 60 over the same stretch, with breakevens at only 2.36%. The curve steepened from 0.20 to 0.47 with the long end leading. That is a real-yield and term-premium sell-off, which is how our own macro report describes it, not an inflation scare. A soft core print moves breakevens and front-end hike pricing. It has much less effect on the 60 basis points that came from real yields, so one print won't unwind it.

VIX at 15 doesn't help his squeeze case either. The macro report reads it as underpriced tail risk, right beside the line that rapid yield moves have preceded nearly every major blowup. A blowup is a downside tail for a consumer cyclical, and that's the short's side.

I'll take the neutral's split for where proceeds go, because it helps the short more than he said. If a soft core print is the squeeze scenario, it's also the day the two-year rallies. Holding short collateral in two-years partly offsets the exact tail the conservative worries about. Holders, who already carry the rates bet through NKE, go to bills.

On the gap budget, the neutral's data request is the right answer and I accept it. Short interest is published twice a month and the prime broker quotes borrow on request, so the desk should rarely be unable to get it. But I disagree with the reasons he gave for leaning toward 15%.

A surprise activist or strategic-review headline is a real upside-gap risk for many fallen Dow names, but a weak one here. At 34.74 on 1.483 billion shares, the market value is about 51.5 billion. And though this isn't in our tools, so please verify it, Nike's Class A shares, held largely by the founder's family vehicle, elect about three-quarters of the board. A hostile activist runs straight into that. The missing news week isn't an open question either: it was the earnings window, and we've all agreed Oct 2 was the earnings reaction.

So if short interest is moderate and borrow is cheap, use the 10% budget and the full 0.25x. Use 15% only if the data comes back elevated or truly can't be obtained.

Now the concessions. Rolling the unused zone allocation into the breakdown entry goes. The neutral beat me with my own horizon argument: inventory red flags show up in the December print, and the short is flat by mid-November. That information belongs in the holders' tier and the December hedge, and I'll put it there.

The conservative is right that "costs nothing" overstated moving the stop to entry. It costs nothing if price moves continuously. On a gap it costs the gap, and that remainder already sits inside the gap budget. Two consecutive closes above 5.31% as the 10-year trigger is fine with me.

On the breakdown stop, he says one ATR is 3.5% in a stock that moves 3.2% a day. Look at where it lands. Enter on a close just under 31.97, say 31.8, add the 1.12 ATR, and the stop sits around 32.9. That is just above the 32.76 higher low from October 5. Getting stopped there means price closed back above the post-gap higher low. That's a failed breakdown, not noise.

On re-entering after the dividend declaration, the neutral's version answers the conservative directly. The path where the dividend is cut, and we'd be shorting the morning after a 15 to 20% gap, is excluded. That leaves affirmation. If Nike affirms and the stock pops and holds above 31.97, the order never fires and costs nothing, just as the conservative predicts.

If Nike affirms or nudges the dividend up and the stock still closes below 31.97 two sessions later, that's the most informative signal anyone has offered in this debate. It's the market rejecting the floor management just reaffirmed, and the math explains why that could happen. At 41 cents a quarter on 1.483 billion shares, the run-rate payout is about 2.43 billion against 2.1 billion of trailing free cash flow. That's about 0.87 times coverage, and every cent of increase widens the gap by roughly 60 million a year. Run it at half size and be flat before Thanksgiving on November 26. With an ATR of 1.12, five sessions is enough to reach the 31 partial-profit level.

That brings me to December, where all three of us say the money is. The conservative's step-down before the Q2 print is right, and it means the plan sells more, which is what I've argued from the start. But I'd push further, because December is where the high-reward trade sits.

The conservative listed the record himself. Every earnings reaction in our data went down: a 10.5% gap in December, 15.5% in April, and a 7.4% gap at the open on October 2. The next print covers Nike's biggest quarter. Inside that quarter the euro is down 3.2% and the broad dollar is up 3%. Revenue growth has slowed five quarters in a row, and non-cash current assets are flat while sales fall. Three for three is a small sample, and I'll say so. But a dated, two-outcome event with that record is exactly what a put spread is built for. It's also the split we've all accepted: options for dated events, stock for the trend.

So for holders, if a put spread passes the neutral's test of costing no more than a third of its width, prefer it to the step-down. An at-the-money spread would have paid on all three reactions in our sample, so this isn't insurance you expect to waste, and it keeps the recovery path the neutral wants protected. If it fails the test, step down a tier.

Flat accounts shouldn't sit in bills through the highest-payoff event in the window. Where the mandate allows, they should own the same December spread. Risk no more premium than one short leg risks, under a point of a standard position, for a payoff of two to one or better if the print gaps like the last three.

Here's my final plan, still a Sell.

Holders follow the consensus trim: 1. Sell half the reduction now near 34.74. 2. Ladder the rest at 35.15, 35.60 and 36.20. 3. Sell anything left at market before CPI, or on a close below 33.81. 4. Finish to the tier size even above 37.5. 5. Read the 10-Q within two or three sessions and set the tier at 25, 35 or 50. 6. Keep the triggers: a close below 31.97, two closes above 5.31% on the 10-year, and a full exit on a dividend cut. 7. Let the upside rule only stop further cuts. 8. Run the cross-exposure check first, and hold proceeds in bills. 9. Before Q2, use the put spread if it passes the pricing test, otherwise step down a tier. Restore the tier only on positive revenue growth and like-for-like gross margin above 43%.

Flat accounts pull short interest and borrow first. Size the short at the smaller of 0.25x or a 10% gap budget if the data is benign, and 15% if it isn't. Then: 1. Zone half: after CPI, with the 50-day at or below 37.5, enter on a rejection at 36.0 to 36.4. Stop at 37.5, targets 33.81 then 31.97, with the exit weighted toward 31.97. 2. Breakdown half: enter on a close below 31.97, stop one ATR above, which sits just over the 32.76 higher low. Take a third off at 31, move the stop to entry and trail the rest. 3. No rolling allocation between the halves. 4. Be flat before the declaration, or by the end of the first week of November if no date is announced. 5. Affirmation-path re-entry only, at half size, flat before November 26. 6. Hold collateral in two-years. 7. Own a December put spread through Q2 earnings where the mandate allows.

This chart has made six lower highs in twelve months. All five rallies ended in new lows, and all three earnings reactions gapped down. The conservative plan only manages that risk; this plan also positions us to profit from it. Aggressive Analyst: Aggressive Analyst: The holder plan is finished and I'm signing it as written. I'll use this last turn on the two questions still open. First, do flat accounts get to express this call at all? Second, can our 10-Q scorecard actually catch the problem that made us suspicious?

I'll start with what I'm accepting from my neutral colleague's last round, which is most of it.

The single window, from the CPI release to the November 3 close, is right, and it's simpler than anything I proposed. The half-ATR buffer, with the 50-day at or below about 36.95, is right. So is gating the zone half on short-interest and borrow data.

I accept days to cover above three, or borrow above general collateral, as "elevated." I'll also take the three-month volume denominator, even though it leans against me. That window includes the July and August lull of 12 to 28 million shares a day, so it will make days to cover look bigger, not smaller. If the zone half passes a test tilted against it, it has earned its place.

The re-entry goes. And my conservative colleague's timing on my analog is correct: the move to 31.97 lands around the first days of December, outside every window we've agreed. So the zone half takes two-thirds off at 33.81, moves the stop on the rest to entry, and closes at the November 3 close. The analog's job was to show which way rallies in this stock end, and on that question all five rallies agree.

Now to my conservative colleague, starting with the Fed meeting. The neutral already answered it: the statement comes at 2 p.m. with the market open, so a stop works, and the gap budget covers slippage.

There's a second point. Your best squeeze argument is that a two-year already pricing hikes moves more on a dovish surprise than a hawkish one. The biggest dovish surprise available in this window is September CPI. Under the window we just agreed, no stock short is open through it. The zone half can't even fire until the buffer is met, around October 21 to 23.

So consider what our entry actually requires. If CPI comes in soft and yields and the dollar fall, NKE does one of two things. It rips straight through the zone, in which case there's no rejection candle and no trade. Or it rallies into 36.0 to 36.4 and gets rejected anyway. That second case means the stock got exactly the macro relief you're worried about and still couldn't get past a falling 50-day. I can't think of a stronger reason to be short. The entry rule turns your squeeze scenario into a filter.

On the statistics, I'll hold you to your own standard. You said one win in three is consistent with a true hit rate anywhere from 1 to 90 percent, so the zone short is uncompensated variance. You said three for three is consistent with a rate near 30 percent, so a December spread is speculation. Both intervals are computed correctly.

But in the same round, you used that same three-for-three record to require every unhedged holder to step down a tier before December. If three observations are too few to justify a quarter-size short with a hard stop, they're too few to change every holder's December size. If they're enough for the step-down, then one in three is evidence too.

You also cited the euro and the revenue slowdown for the step-down, and fairly so. The zone short rests on more than the analog as well: six lower highs, a falling 50-day, and fading volume on the bounce. I'm not asking anyone to throw out small samples. I'm asking that we apply the standard all three of us actually use: when the sample is small, make the trade survivable if it's wrong. The buffer, the gap budget and the data gate do exactly that for the zone half.

Then look at which leg you kept. You argued the breakdown entry sits at a new 12-month low, with weekly and monthly z-scores heading toward minus 2. You also noted it sits about a dollar above 31.06, where the dividend yield matches the 10-year. Those were your objections to the breakdown leg. Now it's the only leg you'll allow.

Meanwhile you deleted the leg entered under a falling 50-day, a daily SuperTrend that can only ratchet down from 36.38, and six consecutive lower highs. I think the stop above the 32.76 higher low and the third taken off at 31 answer your breakdown objections. But if you believe those objections, you can't keep the breakdown leg and kill the zone leg. Run both, inside one budget, as the neutral wrote it.

On "one good macro day does it": 1.16 ATRs is today's figure, and today's ATR is inflated by the October 2 session. That day's true range, from the 35.15 prior close to the 31.97 low, was 3.18. Before the gap, ATR was 0.96.

If daily ranges stay anywhere near September's pace, ATR drifts back toward a dollar by the time the buffer lets us in. A 36.2 entry with a 37.5 stop is then closer to 1.3 ATRs, with the 50-day sitting between them. A good macro day would have to clear both the 50-day and the stop in one move, in a stock that was just rejected below them.

You're right that the two-year collateral is a rounding error, but it's still the right place to hold it. On stress events, the Fed responds after the blowup, and the blowup hits a consumer cyclical whose real sales are falling about 7.5 percent first. The weekly borrow recheck is our early warning for a recall, and I'm glad it's in the plan.

Now December. You caught me, and I concede it. An at-the-money spread that would have paid on all three reactions won't pass a one-third-of-width test. The out-of-the-money spreads that do pass wouldn't have paid on October 2.

Here's what I'd add, and it comes straight from our price history. In all three reactions, the reaction week was the time to own the put: - The December 2025 gap recovered fully to 64.59 within four weeks. - April made its low four sessions after the gap, then rallied to 46.46. - October 2 hasn't closed below its gap-day close since.

A flat account holding a December spread to expiry would have handed back all three payoffs. So for flat accounts, the spread is a trade on the print itself. Buy it after the November 3 close, inside the shared budget, at no more than a third of width. Sell it into the reaction rather than holding to expiry.

On whether it belongs in this call at all: the trader's plan sizes holders for a 15 to 20 percent earnings gap because the December print is the biggest identified risk in the call. The plan already permits flat accounts an optional short. A spread with a capped loss, inside the same budget, carries less risk than that stock short.

Two rounds ago, a live-priced put spread was your own default for flat accounts. If the options market has already priced the three gaps, the spread fails the pricing test and the account sits in bills. That's what the test is for.

For holders, I'll move closer to your position than you might expect, and it's because of my bearish view, not despite it. I've said all along that the December print most likely gaps down. The neutral's grid shows the step-down wins on a routine miss, and two of our three reactions were routine. So consistency says the step-down is the default.

For anyone who fails the 20 percent gap test, the spread shouldn't replace the step-down; it should go on top of it. Run the neutral's numbers: - Step down to 35 and add a quarter-of-width spread, from 10 to 20 percent down, on that 35. The loss is about 4.4 points whether the print is a routine 10 percent miss or a 20 percent tail. - Hedge the full 50 instead, and the loss is about 6.25 in both cases.

The combination costs under a point on a rally compared with stepping down alone. For a book whose budget breaks at a 20 percent gap, it's the best choice on the grid.

Last, the 10-Q scorecard. I think we're about to build a test that can't fail on the very thing that made us suspicious.

The neutral's inventory test counts as adverse only if inventory is up year over year. But the warning sign was non-cash current assets staying flat while sales fell 4.3 percent, and flat inventory passes his test. Cost of revenue fell 5.3 percent, so flat inventory means days of inventory rose about 5.6 percent. Make the test adverse if inventory fell less than about 2 percent. Anything shallower means days of inventory rose more than three and a half percent, which sets up discounting.

The scorecard is also missing a test the trader's plan names explicitly: demand creation. The plan says to cut to 25 percent on margin, inventory or demand-creation weakness, and Nike reports demand creation as its own line. Part of why Q1 EPS fell only 2 percent on sales down 4.3 percent is that costs below gross profit fell about 130 million.

If marketing was cut faster than revenue to hold earnings, that borrows from the November and February quarters. It's especially costly while challenger brands are among the fastest-growing TikTok Shop shoe sellers. So mark it adverse if demand creation fell faster than revenue.

Note that the trader's plan sends any single one of those findings to 25 percent, so our tiers are already softer than the plan. I'll accept the tiers: two or more adverse findings go to 25, one goes to 35, none stays at 50. But they should be scored on five tests, not four.

So here's where I land, still a Sell.

For holders: run the consensus plan exactly as written. Score the 10-Q against five pre-committed tests, with the inventory test tightened and demand creation added. Before December, step down a tier by default. Anyone who fails the 20 percent gap test adds a quarter-of-width spread on top, covering both the dividend declaration and the print. Restore the tier only on the agreed Q2 evidence.

For flat accounts: pull short interest and borrow data first, against the committed thresholds and the three-month denominator. Use one budget, the smaller of 0.25x or the gap budget that data implies. Hold stock shorts only between the CPI release and the November 3 close. - The breakdown half runs as agreed. - The zone half needs benign data, the 50-day at or below about 36.95, and a rejection at 36.0 to 36.4. Its stop is 37.5. Take two-thirds off at 33.81, move the stop on the rest to entry, and close it at the November 3 close. - No re-entry. - After November 3, buy a December spread at a third of width or less, within the same budget, and sell it into the reaction. - Hold collateral in two-years and recheck borrow weekly.

My conservative colleague says optional risk has to earn its place, and I agree. The zone half earns it by entering only after the macro print that could squeeze it, under a falling 50-day, inside a budget sized for a gap. The December spread earns it by capping the loss on the one dated event where this stock has gapped down three times running.

Declining those trades isn't protecting the firm. It leaves the best-defined parts of a call we all agree on unexpressed. Selling half today was the start, not the profit. The trend that has paid sellers at every lower high for twelve months is still in place, and this plan keeps us positioned to collect on the next one.

Conservative Analyst¶

Conservative Analyst: Conservative Analyst: I agree with the direction. NKE should be sold down, and my aggressive colleague has the fundamentals mostly right. Revenue growth has slowed for five straight quarters and is now at minus 4.3%. Trailing free cash flow of about $2.1 billion doesn't cover roughly $2.3 billion in dividends. Guided earnings sit below the $1.64 payout, buybacks have stopped, and the stock yields less than a 10-year Treasury. I won't argue any of that.

Where I part ways is the amount of risk he wants us to take while acting on it. Inside his plan are two bets presented as discipline. The first is that a bounce arrives before we finish selling. The second is that we can short a record-yield Dow component and get out cleanly through a stop barely one ATR away. We don't need either bet to act on the thesis, and both can cost the firm money the thesis doesn't require us to risk.

Start with the contradiction in his argument. To justify waiting for 35.6 to 36.4 before trimming, he leans on the bounce signals: the weekly and monthly TD-9s, the 95% close on the Oct 2 gap day, and the MACD divergence. Then, to justify the short and dismiss my colleague in the middle, he tells us those same signals don't hold up. RSI made a lower low, OBV has recovered only 28%, and volume is fading in what looks like a bear flag. He can't have it both ways.

If the bounce is weak, we may never see 35.6, and we end up selling lower than today. If the bounce is strong, it runs straight at a short with a 37.5 stop. Our own technical report doesn't call the bounce the base case. It calls continuation of the downtrend the base case. So the execution plan depends on the less likely scenario.

Now the arithmetic of waiting. Selling at 35.6 instead of 34.74 gains 86 cents. Selling at 36.4 gains 1.66. On half the position, that improves the total by roughly 1.2% to 2.4%.

The downside is closer and larger: - Support at 33.81 is 93 cents away, less than one day's ATR of 1.12. - If 33.81 breaks before any bounce, the half we were holding back is down about 2.7%. - If price retests the 31.97 low, it is down 8%. - The September CPI print, the first one to include the oil shock, lands in the middle of this waiting window.

We would be risking more than we stand to gain, so I don't count waiting as patience.

There's a second flaw in the plan as written. It says that a close above 37.5 invalidates the sell and we pause trimming. If price runs through the zone before our orders fill, we end up holding the full position. Nothing fundamental would have changed. The 50-day is at 38.10 and falling, and the weekly SuperTrend stop is at 42.72. A short-term chart signal shouldn't be what leaves us fully exposed to a weakening income statement.

The short is where I object most. The 2.35-to-1 and 4-to-1 ratios assume entry at 36.4, the very top of the zone. The plan's headline entry is 35.6, and from there the trade looks much worse: - It risks 1.9 to make 1.79 at the first target, which is worse than one-to-one. - The better second target requires breaking a low that the higher-timeframe exhaustion signals say should hold. - Even entered at 36.4, a 1.1-point stop sits inside one normal day's range, so ordinary noise can stop us out.

The bigger problem is that a stop doesn't protect against a gap. This stock has gapped 7%, 10% and 15% on news three times in ten months. Our macro report explicitly flags short-squeeze risk in a heavily shorted Dow name if oil, yields or the dollar reverse. Oil already swung from $107 to $96 on a single Iran headline.

Timing makes it worse. Management calls the dividend its top priority, and the declaration is due around mid-November. That is inside the short's holding window, which runs until we go flat before the Dec 1 ex-date. An affirmation is a known upside catalyst, and he wants to sit short through it.

We also don't know what caused the record 142.7 million-share day, because news from Sep 24 to Oct 1 is missing from our data. Opening a short while that question is unanswered is a risk we don't need to take.

There's also a simpler point. For anyone who already holds NKE, a 0.25x short against a 0.5x long nets out to 0.25x exposure. If that's the exposure he wants, sell more of the long. That gets the same result without borrow costs, margin, squeeze risk, or the operational complexity of running both sides. Letting the short ride below 31.97 on a trailing stop turns a tactical trade into an open-ended trend bet, and that goes beyond any mandate I'd sign off on.

I'd also push back on keeping 50% as the core. Our colleague's own argument says the 10-Q is mostly downside risk: - Non-cash current assets are flat while sales fell 4.3%, which points to a possible inventory build. - The implied 49.2% Q4 margin suggests the 0.6-point gross margin gain may come from a reclassification rather than real improvement.

If the unknowns lean negative, the default size should be the lower one until the filing clears it, not the higher one until it condemns it. The "exit fully on a dividend cut" trigger is also reactive. A cut would gap the stock, and we would be selling after the damage. The April episode went from 51.80 to 41.87, about 19%, in a week. A combined cut and miss could exceed the 15% to 20% gap the plan sizes for.

Cash is not a penalty here. Two-year Treasuries pay 4.77%, roughly the same as NKE's yield, with no cut risk and no 3% daily swings. Every share we sell early earns nearly the dividend while carrying none of the downside.

To my neutral colleague, I expect the arguments that the signals are mixed and that sentiment looks washed out. Mixed signals are a reason to take less risk, which means no short and an earlier trim. They are not a reason to delay selling. And the "bombed-out sentiment" read rests on 14 headlines with no StockTwits or Reddit data. The sentiment report itself says confidence is low, so I wouldn't anchor a contrarian hold on it. Waiting for the 10-Q makes sense before adding exposure, not before reducing it.

So here is my adjustment, still a Sell: - Trim now: sell half of the planned reduction today near 34.74, taking holders to about 75% of standard weight. - Ladder the rest: place resting limits for the remainder at 35.15, 35.60 and 36.20. - Deadline: if those orders haven't filled by the session before September CPI, or on any daily close below 33.81, sell the remainder at market. - Above 37.5: finish the trim to 50% anyway, and only pause cuts below that level. - Hold to about 35% to 40% until the 10-Q is read: go back to 50% only if it shows no inventory build and a like-for-like margin gain. - Get to 25% before the mid-November dividend declaration: do this unless free cash flow coverage has visibly improved, rather than waiting to react to a cut. - No short. If the mandate insists, take it only after a rejection candle at 36.2 to 36.4, and size it for a gap to 40, not for the 37.5 stop. - Park proceeds in short-dated Treasuries.

This plan captures the same bearish thesis without depending on the bounce or on a stop to protect a position that can gap. Conservative Analyst: Conservative Analyst: I'll start with what I got wrong, because it matters for the rest of this.

My neutral colleague caught me comparing gains on the whole position with losses on half of it. On the same shares, waiting is 2.5 to 4.8 percent of upside against 2.7 to 8 percent of downside. That's a close call, not a lopsided one. He's also right that the 10-Q is already filed, and that my "unless free cash flow coverage improves" exception could never trigger, because no new cash flow data arrives before late December. I withdraw all three. None of them changes my conclusion, though. Several of the aggressive plan's new additions take on more risk than the thesis needs, and the strongest evidence against them is in our own price history.

Start with the short's stop. My aggressive colleague now says that if price runs above 37.5, the trim should still be finished, because a pop toward a falling 50-day at 38.10 "is still a place to sell." I agree. But his short is stopped out at 37.5. He has put his stop below the level where he says he'd want to sell. If 37.6 to 38.1 is a selling opportunity, a stop at 37.5 means buying back the short right before the price he likes most.

Our data says that path is likely. NKE has had two big gap-downs before this one. After the December gap, the stock rallied from a 57.20 close to 64.59, about 13 percent, in under four weeks. After the April gap, it rallied from 41.87 to 46.46, about 11 percent, over roughly seven weeks. Both came within a window as long as his short's, and both happened in the middle of a bear market that kept going.

Apply the same 11 to 13 percent to this gap's 33.87 low close and you get roughly 37.6 to 38.3. That is through his stop and into the 50-day. Two instances is a small sample, but it's the same tape he cites to argue that history favors the short. In this stock, a break above the daily SuperTrend hasn't meant the bear thesis was wrong. It has meant shorts got stopped before the next leg down. The thesis can be right and the trade can still lose.

Second, the claim that every gap was down and therefore paid the short. Those were earnings gaps. The next earnings report is in late December, after he has promised to be flat. The only company event inside his window is the mid-November dividend declaration, and management has already called the dividend its top priority.

He says an affirmation is already priced. If the market fully believed the dividend was safe, the stock wouldn't carry a record yield, and mainstream outlets wouldn't be running "yield trap" headlines. Cut risk is partly priced, so an affirmation removes some of it, and in a name the macro report calls heavily shorted, that moves against him.

He also says I contradicted myself by pre-selling longs into an event I called bullish. I didn't. Each position should be judged by the outcome that hurts it. A long fears the unlikely cut. A short fears the likely affirmation. That said, I've dropped the broken rule and replaced it with something better, which I'll come to.

His plan to carry the remainder through the declaration with "stop at entry or better" doesn't protect him either. If the stock gaps 7 percent on declaration morning, the stop fills at the open, not at entry.

Third, the size of the slice to sell now. He wants a third rather than half because half "sells right at support." Look at his own list of lows: 41.87, 40.32, 38.04, 35.51. Every support level in the last twelve months has broken. Selling at support in this chart has been the right decision every time.

The base case doesn't require the zone either. Scenario B's signals are rejection in 35.0 to 36.4, or a daily close below 33.81. The second route skips the bounce entirely. His ladder also leaves two-thirds of the reduction on resting orders. The top two rungs are 1.1 to 1.5 ATRs away, and the 36.40 rung sits a penny above the 36.39 closing high where the last rally died.

The difference between a third and a half is about eight points of standard weight. At his best fill, waiting earns about four-tenths of a percent of one standard position. When the edge is that small and unproven, take the fill you can see. Two of us have now landed on half.

Fourth, the holders' tactical round trip has triggers that conflict. He wants to sell an extra quarter-weight into the zone and buy it back at 33.81 or 31.97. His plan also says to sell at market on a close below 33.81, and to cut to 25 percent on a close below 31.97. So the plan buys at a level and then sells on a close beneath it. That will whipsaw holders back and forth around those levels. If holders should be at 25 percent, take them there and leave them there.

Fifth, the trailing short below 31.97. "No support in the data" really means our twelve months of data don't go that low. It doesn't mean there are no buyers down there. The weekly and monthly z-scores are already near minus 1.6, so a break would push toward the minus-2 extreme.

His own income argument also changes near that level. A 1.64 dividend yields the same as the 5.28 percent 10-year at about 31.06. Below roughly 31, NKE out-yields the Treasury he keeps comparing it to. The trailing stop would carry the short into the zone where his own argument that income buyers won't step in stops applying.

On short interest, he says nobody has a figure. Not knowing how much fuel a squeeze has is a reason to size smaller. It isn't a reason to run the full 0.25x. The trader's plan says max 0.25x; that is a ceiling, not a target.

To my neutral colleague: I'll adopt most of your plan, and I agree with the aggressive's correction to your valuation. Trailing EPS of 2.09 includes the odd 73-cent fourth quarter. Normalize it and the stock is near 18 to 20 times earnings, roughly level with the 10-year. That doesn't make NKE a short. It makes it a stock we don't need to own much of, which is my case. I'd tighten your plan in two places.

First, sequence the 10-Q read inside the ladder window. The trim and the size decision then happen together, with no round trip. That resolves my objection and yours. Read it for inventory, the restated prior-year margin, the rise in current liabilities, and China, as you said.

Second, apply your 20 percent gap test now, not just before December. A cut is unlikely at the declaration, but if it comes, it comes as a gap. At 50 percent weight, a 20 percent gap costs ten points of a standard position, and that has to fit the budget from today.

So here is where I land, still a Sell.

For holders: 1. Sell half the reduction now. 2. Ladder the rest at 35.15, 35.60 and 36.20. 3. Sell whatever remains at market before CPI, or on a close below 33.81. 4. Finish the trim to 50 percent even above 37.5. 5. Read the 10-Q before the last rungs fill and use your tiers: both red flags means 25 percent, one means 35, a clean filing means 50. 6. Whatever the tier, size the remainder to survive a 20 percent gap. Where options are allowed, a put spread through the declaration and December earnings can do that. 7. Use your upside rule to stop trimming, keep the 31.97, 5.31 percent and dividend-cut triggers, and skip the buyback round trips. 8. Check exposure across other names hurt by the dollar, China or oil. 9. Park the proceeds in bills or two-year Treasuries.

For flat accounts, my preference is a defined-risk put spread priced live, and no short. If the mandate insists on a short: 1. Treat 0.25x as the cap. 2. Enter only on a confirmed rejection at 36.2 to 36.4 on fading volume, or on a close below 31.97. 3. Size it for a 10 to 15 percent adverse gap. 4. Use fixed targets and no trailing stop. 5. Be flat before the mid-November declaration.

That captures the same bearish view without betting that the bounce stops exactly where the stop happens to be. Conservative Analyst: Conservative Analyst: We've narrowed this a long way, so let me start by locking in what's agreed. Holders sell half the reduction now near 34.74. The ladder tops out at 36.20. The 10-Q gets read inside the ladder window, the tiers are 25, 35 and 50, the buyback round trips are gone, and any stock short is flat before the dividend declaration. My aggressive colleague has also accepted that a put spread is the right tool for the declaration, which is the structure I've argued for from the start.

I'll concede two points as well. His horizon argument holds: covering a three-week short above 37.5 while holders keep selling into 38 isn't a contradiction, because they answer different questions. And "a gap to 40" from 36.4 was my anchor. That's about 10%, so I won't pretend otherwise.

Three places still take more risk than the thesis needs, and on a fourth, December, I think all three of us are still too comfortable.

First, the zone short, tested against the bounce-decay numbers we're all now relying on. From the 33.87 gap-day close, a bounce the size of the last two, 2.5 to 3%, tops out around 34.7 to 34.9. That's where the stock closed yesterday. A rejection at 36.0 to 36.4 needs this bounce to run 6.3 to 7.5%, bigger than any bounce since July. So the zone entry only fires if the decay pattern breaks.

Now look at the bounces in our own history big enough to reach that zone: 9.4%, 11% and 12.9%. Applied to 33.87, they top out near 37.05, 37.60 and 38.24, so two of the three run through the 37.5 stop. My aggressive colleague says the decay supports the short. For a breakdown entry, maybe. For the zone entry, the decay says one of two things happens. Either the trade never triggers, or it triggers in exactly the regime where the stop gets hit. The entry condition selects for the outcome that hurts it.

Timing makes this worse. My neutral colleague showed the 50-day falls about 13 cents a session, so the stop becomes a real invalidation in about a week. But his own rule restricts the zone entry to the bounce window and cancels it at the CPI deadline, three or four sessions out. Through that window the 50-day sits around 37.6 to 38. So every zone short opened under his rule is opened while the stop sits below the 50-day. That's the same level my aggressive colleague calls a place to sell. The stop is weakest on the days it's most likely to be tested, and requiring a stricter candle doesn't change that.

The straight-line argument doesn't save it either. If the stock rallies in a straight line, there's no rejection candle and the short never enters, true. But rallies like December's 57.20 to 64.59 usually pause at resistance. A stall at the 36.38 SuperTrend, a rejection candle, then a push through is the most ordinary path there is, and it's precisely the losing case. The filter doesn't screen that path out.

Second, the claim that macro skew favors the short. My aggressive colleague says a squeeze needs oil, yields and the dollar to reverse together within three weeks. They don't need three separate moves; one print can do it. Gasoline prices are published weekly, so the September peak of 4.48 is already in every CPI forecast. A hot headline is the consensus view: the 10-year is at a 2002 high and the two-year already prices more hikes. What isn't priced is core inflation. Core PCE has run at about 2% annualized for three months. A soft core reading moves yields and the dollar in the same hour, and oil has already shown it can drop 10% on a single headline. With the VIX around 15, almost nobody is paying for protection against that.

That's why I side with my neutral colleague on budgeting for a 15% gap rather than 10%. The gap budget isn't automatically the uncertainty adjustment, as my aggressive colleague claims. Picking the gap size is where the adjustment happens, and we have no short interest, no borrow cost and no implied volatility to inform it. At 0.25x, a 15% budget means 3.75% of a standard position at risk instead of 2.5%. Every one of those unknowns argues for the larger assumption.

Third, the extensions bolted onto the breakdown short.

Rolling the unused zone allocation into the breakdown half on 10-Q red flags sounds like tying size to fundamentals, but the 10-Q is public. My aggressive colleague accepted that point last round. For holders, reading it is risk management, because we're learning what we own. For a short, it's no edge, since the market has had it since it was filed. Upsizing on it just doubles the entry that sits at a new 12-month low. That entry has the weekly and monthly z-scores heading toward −2 and sits about a dollar above the 31.06 level where the dividend yield matches the 10-year. Its one-ATR stop is about 3.5% of price, in a stock whose average daily range is 3.2%.

I do like moving the stop to entry after taking a third off at 31. It's tighter than my neutral colleague's version. But "costs nothing" isn't true. Two rounds ago we agreed a stop at entry fills at the open on a gap, and that applies here exactly as it did for the declaration.

The post-declaration re-entry should go entirely. It reopens a window we just agreed to close and adds the Black Friday headlines. Worse, think about which outcome triggers it. If the dividend is affirmed, the stock probably pops and doesn't close below 31.97 in the two weeks before the ex-date. If it's cut, the gap itself takes price below 31.97, and the rule shorts the morning after a 15 to 20% drop. At that point the z-scores are past −2 and the yield-trap story has resolved. The rule mostly fires after the move has already happened.

The November dividend-increase streak doesn't come from our tools. Our data only shows 41 cents paid each quarter. If the market expects a raise, a token raise from a CFO who calls the dividend his top priority would read as relief. That's plausible given $6.9 billion of cash and the lowest leverage in our data. Either way we're flat, so it shouldn't drive any rule.

On the put spread, the argument that "we can't price the option" doesn't hold. The desk sees a live quote when it trades. What we genuinely can't price is the stock short's tail, because we have no short-interest or borrow data. If skew is steep, a vertical spread is the structure that suffers least from it, because you sell the lower strike at the richer volatility. And elevated implied volatility hits both legs. If the quote is bad, the right answer is no trade and bills, not a fallback to a vehicle whose worst case is invisible to us.

Fourth, December, where my neutral colleague is right that the real money sits. A 20% gap on a 50% position costs ten points of a standard weight. A clean 10-Q tells us about August inventory. It tells us nothing about the risks in the November quarter: - It's Nike's biggest quarter. - The euro has fallen 3.2% against the dollar, and more than half of revenue comes from outside the U.S. - Revenue growth has slowed for five straight quarters. - All three earnings reactions in our data went down: a 10.5% gap in December, 15.5% in April, and a 7.4% gap at the open on October 2.

So the 10-Q tier should set size through the declaration. Before the Q2 print, books without a hedge should step down one tier, from 50 to 35 or from 35 to 25, unless a put spread covers the event. At 35%, the same 20% gap costs seven points instead of ten. Those three points matter more than everything else we've argued about this round combined. And since we don't know anyone's book, "most books pass at 50%" is an assumption we can't verify. That's why the cross-exposure check has to come first.

Two small fixes. First, define "the 10-year holding above 5.31%" as two consecutive daily closes above that level, so nobody debates the trigger in the moment. Second, park proceeds in bills or a short ladder rather than all in the two-year. Its roughly 90 basis points over fed funds is payment for hike risk, and we're selling to remove risk, not to move it somewhere else.

So here's where I land, still a Sell.

For holders: 1. Sell half the reduction now near 34.74. 2. Ladder the rest at 35.15, 35.60 and 36.20. 3. Sell anything unfilled at market before CPI, or on a close below 33.81. 4. Finish to the tier size even if price runs above 37.5. 5. Read the 10-Q within two or three sessions and set the tier once: 25, 35 or 50. 6. Keep the 31.97 trigger, the tightened 10-year trigger and the dividend-cut exit. 7. Use the upside rule only to stop cutting, never to add. 8. Run the cross-exposure check first. 9. Before December earnings, step down one tier unless a put spread covers the print. 10. Hold proceeds in bills.

For flat accounts: 1. The default is a put spread priced live. If it doesn't price, stay in bills. 2. If the mandate requires a stock short, skip the zone half. If someone insists on one, the only version I'd sign is entered after the 50-day has fallen below 37.5, not inside the CPI window. 3. Enter the breakdown half only on a close below 31.97. 4. Size it at the smaller of 0.25x or a 15% gap budget, with a stop one ATR above entry. 5. Take a third off at 31, move the stop to entry and trail the rest. 6. No rolling allocation into it, and no re-entry after the declaration. 7. Be flat before the declaration, or by the end of the first week of November if no date is announced.

That keeps the bearish view the trend supports, and it stops us from paying for the scenarios our own data says are most likely to hurt us. Conservative Analyst: Conservative Analyst: We've converged far enough that I'll start with concessions, because they set up the rest.

My aggressive colleague is right that the zone short should trigger off the 50-day itself, not a calendar date. He's also right that my priced-versus-unpriced framing of CPI was loose. Weekly gasoline and three months of core PCE are equally public. The real asymmetry is positioning: a two-year already pricing more hikes moves less on a hawkish surprise than on a dovish one. I hold that loosely.

His breakdown stop at about 32.9 is well placed. A close back above the 32.76 higher low is a failed breakdown, so I withdraw my 3.5-versus-3.2 percent objection. Excluding the cut path from the re-entry answers my main concern there. And I accept my neutral colleague's split on proceeds: bills for holders, two-years as collateral for short accounts.

The holder plan is now done, and it's good. What's left is how much optional risk we bolt onto a Sell for accounts that don't own the stock, and how we define December. On both, the latest round added risk the evidence doesn't pay for.

Start with the zone short, and finish my aggressive colleague's analog for him. He says the one rally that survives our stop, 40.32 to 44.10, then fell to a new low that maps almost exactly onto 31.97. Look at the clock on that analog. It took about 13 sessions to go from low to peak, then about 30 sessions to reach the new low. Mapped onto October 2, the peak lands around October 21 and the new low around the first days of December. That is after the declaration, after Thanksgiving, and after the latest flat date anyone in this room has proposed.

His plus 0.4 of a risk unit depends entirely on reaching 31.97. On the only winning case in our data, that happens about three weeks after we've agreed to be out. Inside the window, the trade is his break-even case to 33.81, before borrow costs and before a stop that fills worse than 37.5 in a fast tape. That's negative.

That one win also survives the stop by just 45 cents, under half a day's range. And the sample is three. One win in three is consistent with a true hit rate anywhere from about 1 percent to 90 percent. Our evidence can't tell a good trade from a bad one. My neutral colleague's own verdict was that the expected value is close to zero. A trade with near-zero expected value and a real gap tail is uncompensated variance, and protecting the firm means declining that.

Moving the window after CPI didn't remove the binary problem; it swapped one binary for others. The post-CPI window now contains the October 27–28 FOMC and the November 3 midterms. My neutral colleague himself said tariff policy can shift either way after the midterms. If we don't open a short into CPI, the same logic says we don't hold one through a Fed meeting that a two-year 90 basis points over fed funds says is live.

On the stop geometry, I wrote the rule about the 50-day falling below 37.5, and it was too loose. My aggressive colleague just showed the 50-day's slope isn't constant. "Below 37.5" lets it sit a nickel under the stop. At that point they're one level, and a stop placed exactly where every trend follower is watching gets run.

So my preference is to drop the zone half. If the desk keeps it, there are three conditions. First, the 50-day must be at least half an ATR below the stop, around 36.95 or lower, at entry. Second, be flat before the October 28 FOMC statement. Third, take profits at 33.81 rather than weighting toward 31.97, because the second target sits outside the window on the only evidence we have. Those conditions leave maybe a handful of sessions in the week of October 21 when it can fire at all. If that means it rarely fires, that's the honest answer.

On the squeeze, I don't need yields to unwind 60 basis points. The stop sits 1.16 ATRs from a 36.2 entry, in a stock whose ordinary day moves 1.12. One good macro day does it.

The two-year collateral helps, but by a rounding error. A 25 basis point rally on a duration near 1.9 is about half a percent, against a 10 percent gap on the short.

As for a VIX blowup being the short's friend: in stress, borrow gets recalled, crowded shorts get forced out at the worst prices, and the Fed's response to a blowup is easing, which is the yield drop that lifts this stock.

On the gap budget, I accept my neutral colleague's data rule with one addition. Write down what "elevated" means before the data is pulled, not after. Days to cover above about three, or any borrow fee above general collateral, counts as elevated and means 15 percent.

On the dual-class argument, take it as true for the moment. Founder control blocks a hostile activist, but it does nothing to stop a friendly upside gap. A controlling holder can bless a management change or a capital-allocation shift without any fight at all. More importantly, he flagged it himself as outside our tools. A firm should let unverified information reduce risk, never increase it.

The re-entry after the declaration should go. The signal it trades on, an affirmed dividend followed by a close below 31.97, is already captured by the holder trigger that takes positions to 25 percent. As a trade, it gets a handful of sessions at half size, and its best case to 31 is worth a few tenths of a point of a standard position. My neutral colleague already said he wouldn't object to dropping it, so that's two of three.

On December, we all agree on the step-down, so the question is what counts as covered. A put spread only covers the print if its lower strike reaches roughly a 20 percent gap from the pre-print price. Below the lower strike you're unhedged. If the strikes stop short, the uncovered part still gets the step-down.

There's also a conflict between my aggressive colleague's two claims. He says an at-the-money spread would have paid on all three reactions, and that the spread should pass the one-third-of-width test. Those don't fit together. At-the-money spreads in an elevated-volatility name typically cost 40 to 50 percent of their width. The spreads that pass a one-third test are out of the money, and one struck around 10 percent down wouldn't have paid on October 2. That session fell 7.4 percent at the open but closed only 3.6 percent below the prior close.

One more practical point he handed me. His 0.87 times run-rate coverage and his broken-streak theory make the November declaration a two-sided risk for holders too. So a single spread expiring after late December should cover both the declaration and the print, and holders who fail the 20 percent gap test today should buy it now.

As for flat accounts owning a December spread as a directional bet, that sits outside the trader's plan entirely. The plan's only optional short is flat before the December 1 ex-date. Three of three is consistent with a true rate near 30 percent, and the options market has seen the same three gaps, so the puts will be priced for them. If a separate options mandate wants that trade, judge it on its own merits, not as part of a Sell call on reducing exposure.

My neutral colleague made a basis error, the same kind he caught me making. He measured each short leg at the stop, under a point, and the December decision at a 20 percent gap, three points. On the gap basis we agreed to size by, each half-leg is about one and a quarter to two points. Add up the zone half, the breakdown half, the re-entry and a December spread, and the flat-account program carries tail risk of the same order as the decision he called the real money. Not all of it is open at once, but none of it hedges anything. By his own test of where the money is, the program deserves the same scrutiny as December.

Two governance points before the plan. Score the 10-Q before opening it. My neutral colleague listed four items: inventory, the restated prior-year margin, current liabilities and China. Define what "adverse" means for each in advance. Then two or more adverse findings means 25 percent, one means 35, and none means 50. If the rise in current liabilities is a bond maturing within a year, check cash after repayment, not before.

Second, count the rules. The latest plan has around thirty conditional triggers spread across CPI, FOMC, the midterms, the declaration and Thanksgiving. The holder core needs about ten. Execution error is a risk too.

So here's where I land, still a Sell. Holders run the consensus plan exactly as all three of us listed it. Add the pre-scored 10-Q tiers, and a put spread through late December if a holder fails the 20 percent gap test today. Otherwise step down a tier before the print, and restore only on positive revenue growth and like-for-like margin above 43 percent.

Flat accounts default to bills. Where a short is mandated, run only the breakdown half: half the 0.25x cap, with no rolling, as we all agreed. Enter on a close below 31.97, stop just above the 32.76 higher low, take a third off at 31, move the stop to entry and trail the rest. Size it to the pre-committed gap threshold, hold two-years as collateral, and be flat before the declaration or the end of the first week of November.

There's no zone short unless all three conditions hold. There's no re-entry, and no December directional bet under this call.

My aggressive colleague says my plan only manages the risk while his profits from it. For holders, selling half today into a broken trend is the profit, and it's already been taken. Everything after that is optional, and optional risk has to earn its place. On our own data, the extra short legs haven't. Conservative Analyst: Conservative Analyst: I'll start with what I'm conceding, because three of these concessions change my plan.

My neutral colleague is right about the Fed meeting. The statement comes out at 2 p.m. while the market is open, so a stop can act, and the gap budget covers the slippage. I withdraw my rule to be flat before the FOMC and accept the single window from the CPI release to the November 3 close. I'll add one caveat so nobody treats the window as more protection than it is. September retail sales come out before the open in mid-October. The September PCE report and the first Q3 GDP estimate normally land in the last days of October, at 8:30 in the morning. That PCE report carries the core inflation reading I've been worried about. The desk should confirm those dates. The broader point is that no window avoids every overnight print. The window simplifies the calendar, but the gap budget is still what protects us.

My aggressive colleague is right about the 10-Q. If inventory is flat while cost of revenue fell 5.3 percent, days of inventory rose about 5.6 percent, and the test as written would have passed that. His tighter threshold and the demand-creation test both go in.

He also caught something I should have caught, since I proposed the tiers myself: they're softer than the trader's plan. The plan says weakness in margin, inventory or demand creation takes holders to 25 percent. It doesn't say two of them. We're executing that plan, so we shouldn't quietly soften it. Any one adverse finding on those three goes to 25. Current liabilities and China were our additions, so they can stay tiered: one adverse finding means 35, both mean 25.

I also welcome his move on December. All three of us now agree that stepping holders down a tier before the print is the default.

Now his consistency charge. He says I call one win in three too thin to short on, yet treat three for three as enough to step holders down. I'm applying the same test to both: does the action improve risk-adjusted return under the thesis all three of us signed?

That thesis is that NKE is not cheap and the trend is down. By our own call, the exposure a holder drops before December has zero or negative expected return. Dropping it costs nothing in expectation and removes ten points of tail. That decision doesn't need the three gaps to be predictive. It only needs the risk to be real, and the euro, the revenue slowdown and Nike's biggest quarter make it real. He conceded those were fair.

The zone short is the opposite case. My neutral colleague's own estimate puts its expected value near zero, and it adds variance. The same test gives opposite answers. Reducing risk needs evidence that the risk exists, while adding risk needs evidence of an edge. That's the principle I stated and the neutral endorsed: unverified information can tighten risk but shouldn't loosen it. It also answers the neutral's point that thin evidence cuts both ways. For a new trade it doesn't. When we can't tell whether there's an edge, the default is to not take the risk.

My aggressive colleague says I kept the leg I objected to and killed the one with the better setup. I kept the leg whose objections got structural answers, and he agrees they were answered: the stop above the 32.76 higher low, and the third taken off at 31. A close below 31.97 also cancels the weekly and monthly exhaustion signals. So that leg trades with the trend and without the main counter-signal against it.

The zone leg's problem can't be engineered away, and our own changes have made its numbers worse. The neutral's break-even of about 35 percent assumed the whole position exits at 33.81. That's no longer the trade. Two-thirds come off at 33.81, and the last third moves its stop to entry. If that last third is stopped at entry, a win pays about 1.6 against 1.3 of risk, and the break-even rises to about 45 percent. Depending on where the last third ends, the hurdle sits between 35 and 45 percent. Our only evidence is one in three, and that's before borrow costs and before slippage on a 37.5 stop in a fast market. The aggressive's own analog puts the move to 31.97 in December, after the window closes, so on that evidence the remainder doesn't get there either.

On the ATR, I'll grant that the October 2 range of 3.18 is inside today's average. But the sessions since haven't been quiet. October 5 alone traded from 32.76 to at least 33.96. Even if he's right, a 36.2 entry with a 37.5 stop is 3.6 percent of price, about one ordinary day for a stock whose daily range averages 3.2 percent. A falling average range also tells us nothing about Fed day, which is when the stop gets tested. October 2 is what an event day looks like in this stock.

Price also doesn't need to clear the 50-day and the stop "in one move," as both of you put it. It can close over the 50-day on Monday and hit the stop on Wednesday. The window is about ten sessions long.

His filter argument has a dating problem. CPI comes out mid-October, and the buffer doesn't let the zone half fire until about October 21 to 23. So the entry isn't conditioned on the stock absorbing a soft CPI; it's conditioned on the calendar. If CPI does come in soft, the market's next question is whether the Fed stops hiking on October 28, with the two-year still about 90 basis points over fed funds. A short opened the week before puts us in front of the second half of the same dovish story, with the PCE report right behind it.

As for all five rallies ending in new lows: in a stock down 52 percent in a year, that just describes the sample. It says nothing about the rally that eventually doesn't fail. Shrinking bounces and z-scores near minus 1.6 fit selling running dry as well as they fit weakness.

We can test the December spread for flat accounts on our own data before anyone asks for a quote. We've agreed that strikes close enough to have paid on all three reactions won't pass the one-third test. So take a spread that might pass: 10 to 20 percent below the pre-print price, bought at a third of its width.

On intrinsic value at the gap-day close, here's what it would have paid: - December paid about half a point of width. - April paid five and a half. - October paid nothing. It closed down 3.6 percent, and its worst print was about 9 percent down.

That's roughly 6 points back for 10 points of premium. Give April its closing low on April 7 and it's 9.7 against 10. Whatever time value remains after the print helps a little, but implied volatility usually collapses the morning after earnings. So on the very history he cites, the spread that passes our own pricing test roughly broke even only with perfect hindsight.

It also isn't in the trader's plan. The plan's optional short is flat before December 1, and this spread would extend a flat account's risk into late December. "Less risk than the stock short" is the wrong comparison. The right comparison is bills.

For holders, I'll grant his arithmetic. Holding 35 percent plus a quarter-of-width spread from 10 to 20 percent down loses about 4.4 points in both a 10 percent miss and a 20 percent tail. Now compare it with simply stepping down to 25 percent: - On a 10 percent rally, they make almost the same: about 2.6 against 2.5. - On a 5 percent miss, 25 percent loses 1.25 and the combination loses about 2.6. - On a 10 percent miss, 25 percent loses 2.5 and the combination loses 4.4.

The combination only wins for gaps between about 17.5 and 26 percent, and by at most six-tenths of a point. Past 26 percent it falls behind again, because a spread's protection stops at its lower strike. For a book whose budget breaks at a 20 percent gap, a hedge that stops at 20 percent is the wrong tool. April reached minus 19 percent in a week, and a dividend cut on top of a miss could go further. Selling protects at every gap size, costs nothing to price, and doesn't depend on choosing an expiry after an earnings date nobody has confirmed, in thin holiday trading.

Last round I said holders who fail the gap test should buy a spread now. This grid changes my mind. They should cut to the size that passes. The spread is for holders who can't sell, because of tax lots or a mandate minimum, and then only at a quarter of width or less, with expiry after a confirmed print date.

One governance point. We pre-scored the 10-Q so nobody could grade it after seeing it. The zone half's trigger, a "confirmed rejection," is still a judgment call made in the middle of a rally. If the desk runs it, define it now: a session that trades into 36.0 to 36.4 and closes in the bottom third of its range, on volume below its 20-day average. Measure the buffer on the actual 50-day at entry, not on a projected slope, since the aggressive himself showed the slope changes if price bounces.

So here's where I land, and it's still a Sell.

For holders, the consensus trim stands exactly as all three of us wrote it: 1. Sell half the reduction now near 34.74. 2. Ladder the rest at 35.15, 35.60 and 36.20. 3. Sell anything unfilled at market before CPI, or on a close below 33.81. 4. Finish to tier size even above 37.5.

Beyond the trim: - Score the 10-Q on five pre-committed tests, with the tighter inventory threshold and demand creation added. One adverse finding on margin, inventory or demand creation goes to 25 percent, as the trader's plan says. Current liabilities and China stay tiered. - Run the cross-exposure check and the 20 percent gap test today. Books that fail cut to the size that passes. The spread is only for those who can't sell. - Step down a tier before the Q2 print by default, and restore only on the agreed Q2 evidence. - Keep the three downside triggers, let the upside rule only stop further cuts, and hold proceeds in bills.

For flat accounts, bills are the default. Where a short is mandated, run the breakdown half inside the CPI-to-November-3 window. Size it from the pre-committed short-interest and borrow thresholds, hold two-years as collateral, and check borrow weekly.

My preference is still no zone half. If the desk insists, run the neutral's version with the pre-defined rejection candle and the buffer measured at entry, and accept a break-even of 35 to 45 percent against evidence of one in three. There's no December directional spread under this call, because our own three reactions say it doesn't pay at a price that passes our test.

My aggressive colleague says declining these trades leaves the call unexpressed. For a flat account, owning no NKE is the Sell, fully expressed. Anything beyond that is a new bet that needs its own edge. Holders have already done the selling that pays. The tail they still carry sits in December, so that's where the firm's capital is at risk, and that's where our remaining caution belongs.

Neutral Analyst¶

Neutral Analyst: Neutral Analyst: Most of the decision is already settled among the three of us. NKE should be underweight. Sales growth has slipped for five straight quarters to minus 4.3%. Trailing free cash flow of about $2.1 billion doesn't quite cover roughly $2.3 billion in dividends. Buybacks are gone, and every timeframe trends down. Cutting holders to about half a standard weight is right. The real argument is about execution and tail risk, and there each of you is overconfident in a different direction.

Start with my aggressive colleague. The conservative called his argument a contradiction. I don't think it is. "Bounce first, then fail" is a coherent thesis. But it's a narrow one. You need a bounce strong enough to reach 35.6 to 36.4, weak enough to stay under 37.5, and then you need it to roll over. You've attached two positions to that one sequence: the delayed trim and the short. If the bounce never comes, the trim gets worse. If it comes too hard, the short gets stopped. Both legs depend on the same forecast being right.

The short is where you overreach most. At the plan's headline entry of 35.6, you risk 1.9 to make 1.79 at the first target, which is worse than one to one. The 37.5 stop sits inside a single day's ATR of 1.12 even from the top of the zone. And you'd be entering against weekly and monthly TD-9 buy setups that both just completed.

Your own logic actually points somewhere else. You said a close below 31.97 cancels those exhaustion signals and leaves no visible support. That is where a short has the cleanest case, not into a bounce off fresh exhaustion. And for anyone who already holds the stock, the conservative is simply right: a 0.25x short against a 0.5x long nets to 0.25x. Sell more stock instead and skip the borrow cost and squeeze risk. Running the full 0.25x and trailing it below 31.97 turns a tactical trade into an open-ended trend bet.

Your valuation point also needs qualifying. "You're paid less than a Treasury" uses guided EPS, and we only know that guidance from a headline. Nobody here has verified the actual figure. On trailing EPS of 2.09, the stock is at about 16.6 times earnings, a 6% earnings yield, a free cash flow yield near 4.1%, and roughly 1.1 times sales. Earnings are also a claim on a business that can pass inflation through to prices, so the fairer comparison is the 2.92% real yield, not the 5.28% nominal one. The equity premium is thin, but it isn't negative. That supports an underweight. It doesn't support shorting hard.

The macro picture isn't one-way either. Oil has already fallen from 107 to 96. Gasoline is off its peak. The Iran strike risk has been pushed past the midterms. Jobless claims are at 197 thousand and unemployment is 4.2%. Michigan sentiment, at 51.7, is weak but better than the 44.8 in May. The consumer is stretched, not broken, and the macro report flags squeeze risk in a heavily shorted Dow name if yields, oil or the dollar turn.

Then there's the mid-November dividend declaration, which falls inside your short window. The CFO has called the dividend the top priority. There's $6.9 billion of cash, the payout is about 75% of net income, and liabilities to equity is at the lowest level in our data. A cut in November is the unlikely outcome. An affirmation is the likely one, and that is exactly the kind of event that forces shorts to cover.

You also wave away the Oct 2 session, and I think it's the most informative day on the chart. It was very likely the earnings reaction. The Oct 1 close at 35.15 was followed by a gap, there's a Zacks headline about shares falling after Q1, and our fundamentals pull already contains filed Q1 numbers. So the market took in revenue down 4.3% and guidance below the dividend, gapped 7%, and then closed at 95% of the day's range on record volume. The two previous gaps, in December and April, both closed weak. That doesn't make this a bottom, but you shouldn't short into it with a stop inside one ATR.

Now to my conservative colleague. Your execution structure is better than the original plan's, and I'll adopt most of it. But some of your reasoning overstates the case.

Your waiting arithmetic mixes two different bases. You expressed the gain from waiting as 1.2% to 2.4% of the total position, but the loss as 2.7% to 8% on the half being held back. On the same shares, it's 2.5% to 4.8% of upside against 2.7% to 8% of downside. The 8% case requires a full retest of 31.97, the level the higher-timeframe exhaustion signals point to holding. So this is a close call with a fat left tail, not a lopsided one. A close call is a good reason to split the trade, which is what you propose anyway. Your structure is right; your numbers made it sound more one-sided than it is.

You also say we don't know what caused the record-volume day, and you want to hold 35 to 40% "until the 10-Q is read." The filing is already out. Our fundamentals pull includes the August-quarter figures from EDGAR. The gap is that inventory isn't tagged in our data and nobody has opened the document. That's a couple of days of homework, not a future event to wait for. If you sell to 35% now and then buy back to 50% once the filing checks out, you pay for the round trip, and you may well buy back higher after the very bounce we're all expecting. Read it this week and set the size once.

Your plan to be at 25% before the dividend declaration "unless free cash flow coverage has visibly improved" has a hole in it. No new cash flow data arrives before mid-November, because Q2 isn't reported until late December. So the exception can never be met, and the rule is really a firm commitment to 25% going into an event where affirmation is the likely outcome. You're insuring against the unlikely branch and paying for it with the upside of a relief move in a heavily shorted name. Your point that cash earns 4.77% is fair: carrying cash costs us little in income. What it costs is the upside we give up.

The "combined cut and miss" scenario also blurs two separate events. The declaration is mid-November and earnings are late December. April's 19% gap sits inside the 15 to 20% band the plan already sizes for. The real gap risk is the December print. That's Nike's biggest quarter, and the dollar is up 3% going into it. That's where the next de-risking decision belongs, not in November.

There's also a flaw common to both of you: your plans only ratchet one way. You both list what would make you cut further, but neither of you says what would make you stop cutting. A balanced plan needs both.

Here is where I'd land. Holders sell half the planned reduction now near 34.74, taking them to about 75% of standard weight. Ladder the rest with resting limits at 35.15, 35.60 and 36.20. I'm taking the conservative's deadline: if those orders aren't filled by the session before September CPI, or on any daily close below 33.81, sell the remainder at market. That deadline also matches the technicals, since completed TD-9 setups usually bounce within a few bars. If we don't get the gap fill in about five sessions, the bounce isn't coming. If price runs above 37.5, finish the trim to 50% anyway. One short-term chart signal shouldn't leave anyone fully exposed to a weakening income statement.

This week, read the 10-Q for four things: inventory, the restated prior-year gross margin, what's behind the rise in current liabilities, and anything on China. The current liabilities matter because a bond maturing within a year, refinanced at 2002-high yields while free cash flow doesn't cover the dividend, would be a real issue. If inventory is building against falling sales and the margin gain turns out to be a reclassification, go to 25%. If only one of those shows up, go to 35%. If the filing is clean, hold 50% through the declaration.

Before the late-December earnings, size whatever remains so a 20% gap fits the risk budget. If the mandate allows options, a defined-risk put spread does that job better than a short. We have no implied volatility data, so it would need to be priced live.

The downside triggers stay as they are. A close below 31.97 or the 10-year holding above 5.31% takes the position to 25%. A dividend cut means a full exit. On the other side, a daily close above 36.4 with RSI above 45 and the 10-year back under 5% means we stop trimming at 50%, but we don't add. Adding back should wait for fundamentals: positive revenue growth in Q2, like-for-like gross margin above 43%, and buybacks resuming.

On the short: none for holders. For flat accounts whose mandate allows it, keep it to at most 0.25x. Enter only on a confirmed rejection candle at 36.2 to 36.4 on fading volume, or on a close below 31.97. Size it for a 10 to 15% adverse gap rather than to the stop. Cover before the mid-November declaration, not the December ex-date, and don't trail it. Park the proceeds in bills or two-year Treasuries.

Since we don't know the rest of anyone's book, check combined exposure across other names that are hurt by the dollar, China or oil before deciding the remaining 50% is comfortable.

That plan is still a Sell. It doesn't depend on the bounce arriving on schedule, and it doesn't sell at the worst possible moment because of a filing that's already public. Neutral Analyst: Neutral Analyst: We agree on more than either closing statement admits. All three of us are selling, and all three take holders to about half weight. We all read the 10-Q before the size is final, and we all finish the trim even above 37.5. We all sell the remainder at market before CPI or on a close below 33.81, and we all accept the same upside rule. What's left is whether to sell a third or a half now, how to build the short for flat accounts, and how long that short stays open. Before we argue further, I want to put a price on those, because the money at stake is smaller than the argument suggests.

The gap between a third and a half is about eight points of standard weight. On those shares, the best ladder fill adds about 0.4% of one standard position, and a drop to 33.81 costs about 0.2%. On the short, getting stopped at 37.5 from a 36.2 entry at quarter size costs about 0.9% of a standard position. Now compare the half-weight position holders keep into December. A 20% earnings gap on that costs ten points of a standard position, more than ten times either item we've been fighting over. The decision that really carries risk is reading the 10-Q and sizing for December, and that's where I'd ask both of you to focus.

Still, the data settles the smaller questions better than either of you did, so let me go through them.

On the first slice, each of you is citing half the price history. The conservative says every support level broke, so selling at support was always right. Compared with holding, that's true. But after each of those lows, the stock bounced to a lower high where selling would have been even better: 41.87 to 46.46, 40.32 to 44.10, 38.04 to 39.18, 35.51 to 36.39. So the aggressive is right that waiting for the bounce beat selling at support every time.

Now look at how big those bounces were: 11%, 9.4%, 3%, then 2.5%. The rally after the December gap was 12.9%, so the payoff from waiting has shrunk at every step. Price is already 2.6% above the Oct 2 close. By the size of the last two bounces, we're near the top now. By the size of the two post-gap rallies, there's 11 to 13% left. That's exactly the situation where you split the trade. Since bounce size has been falling, I'd lean toward the larger slice now: half. Not because two of us said so, but because the edge the aggressive wants to protect has been decaying for six months.

The same evidence weakens the conservative's case against the short. He projects 11 to 13% post-gap rallies through the 37.5 stop. But those two rallies came early in the decline, and the three since were 9.4%, 3% and 2.5%. With two observations, you can't tell whether the big bounces happened because of the gaps or because it was early in the downtrend.

Also, the 50-day he says the aggressive wants to sell into isn't fixed at 38.10. It's falling about 13 cents a session, so it will be near 37.45 in a week and near 36.8 in two. Within a week, a close above 37.5 will be a close above the 50-day, the upper band and the daily SuperTrend. That's a genuine invalidation, so the aggressive is right that the stop sits at a sound level. The conservative's objection only applies to a short opened in the next few sessions, while the 50-day is still above the stop.

So the fix is to be strict about when the zone short is allowed at all, not to move the stop. Take it only on a confirmed rejection candle at 36.0 to 36.4 on fading volume, and only inside the TD-9 bounce window. If the zone hasn't been tested by the CPI deadline, cancel that entry.

Then split the short across the two setups instead of putting the full size into the one that fights fresh weekly and monthly exhaustion signals. Put half the allowed size on a confirmed zone rejection. Hold the other half for a close below 31.97, which cancels those exhaustion signals. That spreads the short across the two ways the base case can play out. The aggressive gets a real position if the bear case runs, and the conservative's post-gap rally scenario costs half as much.

On size, the aggressive's own arithmetic is the right method: a jump from 36.4 to 40 costs about 2.5% of a standard position at quarter size. It's also what the conservative asked for. So let that test set the number. Use whichever is smaller: 0.25x, or the size at which a 15% adverse gap fits your per-trade risk budget. We have no short-interest figure, so we can't estimate how strong a squeeze could be, and that unknown should push size down, not up.

On trailing below 31.97, each of you is half right. The aggressive is right that a fixed target in a stretch with no support gives away the move. The conservative is right that "no support in our data" only means our data stops there. His yield arithmetic is also sharp: at about 31.06, a 1.64 dividend matches the 10-year. Below that, the aggressive's own argument that income buyers won't defend the stock stops working. So take partial profits around 31 and trail the rest. The trail was never what made the trade open-ended; the missing end date was. Put a hard date on it and the trail is fine.

That brings me to the dividend declaration. Neither "the affirmation is priced in" nor "the affirmation will squeeze shorts" can be proven. The CFO's pledge is public, so most of that news is out. But the record yield and the "yield trap" headlines show the market hasn't dismissed cut risk either. The honest read is a lopsided outcome: probably a small pop on affirmation, possibly a large drop on a cut. A short held through it pays the frequent small loss to collect the rare big win. That isn't the bet the short thesis is about. The thesis is the trend, and the trend doesn't require holding through a yes-or-no event.

A stop "at entry or better" doesn't help here, because a gap fills at the open. Be flat before the declaration, and if Nike hasn't announced the date, be flat by the end of the first week of November. That also clears the midterms. The aggressive counts the Iran oil risk as working for him, but tariff policy can shift either way after Nov 3.

There are two points where the conservative simply wins. First, the holders' round trip contradicts itself: it buys back at 33.81 and 31.97, while the plan sells at market on closes below those same levels. Drop it. If the 10-Q says 25%, go there and stay there. Second, "every gap went down, so history favors the short" refers to earnings gaps, and the next earnings report comes after everyone is flat. The latest gap also broke the pattern by closing at 95% of its range.

Where the aggressive wins is valuation. Normalizing the unusual 73-cent quarter puts NKE at 18 to 20 times earnings, which is an earnings yield roughly equal to the 10-year's. Real revenue fell about 7.5%, which undercuts my real-yield comparison, so I withdraw it. But "not cheap" doesn't mean "short it." A stock priced about in line with bonds is one you underweight, which is our consensus. The short rests on the chart alone, which is why it should be small, confirmed and short-lived.

To the conservative: your gap test from today is a fine check, and most books pass it at 50% weight. It matters for a concentrated book, or one already heavy in names hurt by the dollar, China or oil, where several names gapping together does more damage than NKE alone. Run the cross-exposure check before the gap test, not after.

So here's the adjusted plan. It's still a Sell.

For holders: sell half the planned reduction today near 34.74. Ladder the rest at 35.15, 35.60 and 36.20, keeping the top rung under the 36.38 to 36.39 resistance, because sellers tend to get ahead of a level that well known. Read the 10-Q in the next two or three sessions, before the top rungs fill and before the CPI deadline. Then set the size once by tier: inventory building plus a reclassified margin means 25%, one red flag means 35%, and a clean filing means holding 50%.

Sell anything unfilled at market before the September CPI release, or on a close below 33.81. Finish at the tier size even if price runs above 37.5, and skip the buyback round trips. Keep the existing triggers: a close below 31.97, the 10-year holding above 5.31%, or a dividend cut. The upside rule (a close above 36.4, RSI above 45, and the 10-year under 5%) stops further cuts but doesn't add. After checking correlated exposure, size what remains to survive a 20% gap, and where options are allowed, use a put spread through December earnings.

For flat accounts: the preference is a defined-risk put spread priced live. If the mandate calls for a short, size it at 0.25x or the 15% gap budget, whichever is smaller, and split it between the two entries. 1. Zone half: enter on a confirmed rejection at 36.0 to 36.4 within the bounce window, with a stop at 37.5. Cancel it if it hasn't triggered by the CPI deadline. Targets are 33.81, then 31.97. 2. Breakdown half: enter on a close below 31.97, with a stop about one ATR above. Take partial profits near 31 and trail the remainder.

Everything is flat before the dividend declaration, and proceeds go into bills or two-year Treasuries.

This plan sells into the bounce if it comes and still gets the selling done if it doesn't. It keeps the bearish trade alive without betting that the stop survives a post-gap rally. And it puts our attention where the risk actually is: the half we're still holding into December. Neutral Analyst: Neutral Analyst: I'll start with what's settled, because the remaining arguments are smaller than they sound and most of them can be decided by a calendar fix and one data request.

All three of us now agree on the following. Holders sell half the reduction today near 34.74 and ladder the rest at 35.15, 35.60 and 36.20. Anything unfilled sells at market before September CPI or on a close below 33.81. The trim finishes to tier size even above 37.5. We read the 10-Q inside the ladder window and set the tier once at 25, 35 or 50. The buyback round trips are gone. The downside triggers stay, and the upside rule only stops further cuts. Cross-exposure gets checked first. Every stock short is flat before the dividend declaration. And the breakdown short takes a third off at 31, moves the stop to entry and trails the rest.

What's still open is the zone short, the gap budget, rolling allocation into the breakdown, the post-declaration re-entry, which vehicle to use, the December step-down, and where the proceeds go. Let me take them in that order.

On the zone short, my conservative colleague caught me in an inconsistency and I'll own it. I argued the 37.5 stop becomes a genuine invalidation once the 50-day falls through it. But I also cancelled the entry at the CPI deadline, before that happens. The arithmetic is simple. At 38.10 and falling about 13 cents a session, the 50-day sits around 37.6 to 37.7 through CPI and crosses below 37.5 around the fifth session, roughly October 15. That is almost exactly when CPI lands. So the fix is to move the window, not to cancel the trade.

His history test is useful, so let's finish it rather than just cite it. Three past bounces were big enough to reach the zone. Applied to the 33.87 close, they top out near 37.05, 37.60 and 38.24, so one of three survives the stop. The aggressive's own reward-to-risk is 1.8 to 1 at the first target and 3.3 to 1 at the second. That means the trade breaks even at about a 36% win rate to the first target and about 23% to the second. A one-in-three hit rate sits right at break-even on the first target and is modestly positive on the second.

So it isn't the trap the conservative describes. It also isn't the clean asymmetric trade the aggressive keeps describing. On the only evidence we have, its expected value is close to zero. A trade like that shouldn't be opened into a CPI binary while the stop still sits below the 50-day. It becomes worth taking after the print, once the 50-day has dropped beneath the stop and puts its sellers under our stop instead of above it.

My conservative colleague has also made the point that core PCE has run near 2% annualized for three months. A soft core reading isn't a tail event; it's the recent trend. That is one more reason not to be freshly short into the print.

There's a side benefit to my aggressive colleague here. A second test of the zone after the exhaustion bounce has faded is the textbook lower-high setup. It no longer fights fresh weekly and monthly TD-9s, which was my original objection.

So the rule is: no zone short before CPI. After CPI, enter on a confirmed rejection at 36.0 to 36.4 with the 50-day at or below the stop. The setup stays valid until the declaration, or the end of the first week of November if no date is announced. Cancel it if the upside rule fires.

On the gap budget, the aggressive is right that we shouldn't shade the size twice for the same unknown. The conservative is right that choosing the gap size is where the uncertainty adjustment happens. So the question is which number to use, and the aggressive's case for 10% rests on the claim that only macro risk remains in the window. Our data can't establish that.

A Dow brand trading near 1.1 times sales and 80% off its high is the kind of name where activist, management or strategic-review headlines arrive without warning. Those headlines gap up, not down. Our news feed is also missing September 24 through October 1 entirely.

The way to settle this is to pull short interest, days to cover and the borrow rate before anyone opens a short. If short interest is moderate and borrow is cheap, a 10% budget and a stock short are fine. If either is elevated, or the desk can't get the data, use 15%, and the put spread becomes the better vehicle for the trend leg too. That one request settles both the size argument and the vehicle argument.

On the vehicle itself, I think the aggressive's division of labor is the cleaner principle: options for dated binary events, stock for the trend. The conservative is right that "we can't price it" only means "price it at the desk." So here is the pricing test. Pay no more than about a third of the spread's width, which gives at least two to one at maximum payoff. If the quote fails that test, the answer is bills, not a stock short carried through a binary event.

On rolling the unused zone allocation into the breakdown entry, the aggressive's own horizon argument decides it against him. He argued, correctly, that the trim and the short answer different questions over different horizons. The 10-Q red flags predict inventory turning into discounting and margin pressure, and that shows up in the late-December print. The short is flat by mid-November.

That information belongs in instruments whose horizon spans the print: the holders' tier and the December hedge. It doesn't belong in a three-week trade. I'd drop the conservative's "it's public, so there's no edge" reasoning, though. By that logic the chart is public too. The horizon mismatch is the real reason. No rolling.

On re-entry after the declaration, each of you is right about a different path. The conservative is right about the cut path. Shorting the morning after a 15 to 20% gap, with z-scores past minus two, is chasing. The fact that holders exit fully on a cut doesn't make a fresh short there sensible.

The aggressive is right about the affirmation path. Suppose Nike affirms or makes a token raise and the stock still closes below 31.97 a couple of sessions later. That's the market telling you the dividend no longer supports the stock, which is a strong signal.

On which path is likely, our data shows the 41-cent rate starting with the December 1 ex-date. That is consistent with a November raise cadence, though we can't see the earlier rate. A one-cent raise costs about 60 million dollars a year against 6.9 billion of cash, so a token raise looks like the likely outcome.

So I'd allow re-entry only on the affirmation path. It needs a close below 31.97 at least two sessions after the announcement, at half the original size. It should be flat before Thanksgiving on November 26 rather than the December 1 ex-date, so nobody is short through Black Friday headlines in a thin holiday tape. That leaves maybe five sessions, so if either of you wants to drop the re-entry for simplicity, I won't object.

December is where the money is, and I think the conservative's step-down is the most valuable thing said last round. It also fixes the one-way ratchet I complained about earlier. The add-back conditions we agreed on, positive revenue growth and like-for-like gross margin above 43%, are exactly what the Q2 print reveals.

So holders step down one tier before the print unless a put spread covers it. If Q2 delivers both conditions, they restore the pre-print tier. That way any buyback happens on evidence, not on price.

Hedging is the better choice when it prices well, because it keeps the recovery path. The December 2025 gap fully recovered in four weeks, and the October 2 session closed at 95% of its range. The upside rule shouldn't cancel the step-down, because one rule is about the trend and the other is about a binary event.

On proceeds, you're each right for a different book. NKE has been trading as a rates story; the macro report says its first good sign would be the 10-year back under 5%. A holder who keeps half a position and parks the proceeds in two-years has stacked the same yield bet twice, so both rally or both fall together. Holders should use bills or a ladder out to about a year.

A flat account running a short is in the opposite position. The conservative's squeeze scenario, a soft core print that drops yields, is exactly when the two-year gains. So two-years work as collateral for a short.

I accept defining the 10-year trigger as two consecutive closes above 5.31%. And to the aggressive: yes, the October 2 close has done its work. Four sessions under the 10 EMA with the gap unfilled says the bounce is weak.

Here is the adjusted plan, and it's still a Sell.

For holders, execute the consensus trim as listed at the start. Set the 10-Q tier once. Put proceeds in bills. Before late December, either hedge with a put spread that passes the pricing test or step down one tier. Restore the tier only if Q2 shows positive revenue growth and like-for-like margin above 43%.

For flat accounts, first pull short interest and the borrow rate. Size the total short at the smaller of 0.25x or the gap budget that data implies, and use 15% if the data isn't available. Split it evenly between a post-CPI zone rejection and a close below 31.97, with no rolling between them. Everything is flat before the declaration, and any affirmation-path re-entry is flat before Thanksgiving.

For most accounts the holder plan is the whole decision. Each short leg risks less than a point of a standard position. The December decision risks three points. Neutral Analyst: We've reached the point where the holder plan is finished. What's still open is how much optional risk flat accounts carry, and how to define December. I'll start with my own mistake, then offer one principle that settles more of the open items than any of the individual arguments.

My conservative colleague caught my basis error. I measured each short leg at its stop and December at a gap. On the gap basis we agreed to size by, each half-leg risks 1.25 to just under 2 points of a standard position. So the flat-account program does deserve the same scrutiny as December. I also said most books would pass the 20 percent gap test at half weight. I can't verify that, so the test should run today.

Now the principle. The events that hurt a stock short are the ones that resolve while the market is closed, because a stop can't act until the next open.

September CPI comes out at 8:30 in the morning, before the open. Election results arrive overnight on November 3. Both of those can gap the stock. The FOMC statement comes at 2 p.m. with the market open, so a stop works there. It fills with some slippage, and the gap budget already covers slippage.

So the conservative's "same logic" doesn't carry over to the Fed meeting. The aggressive's "the stop protects us" doesn't carry over to CPI or election night.

That gives one window for both stock-short legs: from the CPI release to the close on November 3. That single window replaces four rules we've been carrying: - cancelling the zone entry at the CPI deadline - being flat before the dividend declaration - the end-of-first-week fallback - the Thanksgiving deadline

It also takes care of the midterm tariff risk I raised two rounds ago, which can move a company with Nike's supply chain either way. If the stock breaks 31.97 before CPI, the breakdown entry waits for a close below 31.97 after the release. Holders already have that same level as their trigger to 25 percent.

On the zone half, the conservative's timing beats the aggressive's analog. The 40.32-to-44.10 rally took about 13 sessions to peak and about 30 more to make its new low. Mapped onto October 2, the move to 31.97 lands around the start of December. That's after every flat date anyone here has proposed. The plus 0.4 of a risk unit isn't available inside any window we'd sign, so weighting the exit toward 31.97 should go. Inside the window, the trade is the 33.81 target.

But the conservative's statistics cut both ways. If one win in three is consistent with a true rate anywhere from 1 to 90 percent, that's no more an argument for deleting the trade than for keeping it. What actually changes the odds is how the trade is built, and the fix is his half-ATR buffer.

At 11 to 13 cents a session, the 50-day reaches about 36.95 around October 21 to 23. The aggressive's own analog puts the bounce peak around October 21. So the buffer doesn't cost him the rejection his analog predicts. It only costs him the early entries, where the 50-day would still sit above his stop. The buffer also lands after CPI on its own, so this leg doesn't need a separate CPI rule.

Where the conservative overreaches is being flat before the October 28 statement. That event happens during market hours. Without that rule, the window runs from about October 21 to November 3. That's roughly ten sessions, not "a handful."

From a 36.2 entry, the trade risks 1.3 to make 2.39 at 33.81. That's about 1.8 to 1, so it breaks even at a hit rate near 35 percent. With the buffer, getting stopped means clearing both the 50-day and the stop in the same move. Take two-thirds off at 33.81, move the stop on the rest to entry, and close anything left at the November 3 close.

One more condition lets the data settle what we can't. The zone half exists only if the short-interest and borrow data comes back benign. If it comes back elevated, drop the zone half and run only the breakdown half. The conservative gets his way when there's fuel for a squeeze, and the aggressive gets his trade when there isn't.

The aggressive's point that every rally here ended below its starting low still matters, but it supports the breakdown leg. It's the argument for letting that leg's remainder trail, which we've already agreed to.

On the gap budget, committing to thresholds in advance is right. I accept days to cover above three, or any borrow fee above general collateral, as "elevated." One fix on the measurement: days to cover divides short interest by average volume. Excluding the record day, the last week averaged about 50 million shares a day, against 12 to 28 million in July and August. Measured on the post-earnings week, days to cover could look a third to a half smaller than it would on normal volume. So commit now to a three-month average volume as the denominator.

Recheck borrow weekly while short. The conservative's point about borrow being recalled in a stress event is exactly what a rising fee would warn us about first.

That makes the dual-class argument moot. The conservative's principle is right: unverified information can tighten risk but shouldn't loosen it. The data pull decides 10 versus 15 percent anyway.

Drop the post-declaration re-entry; two of us have now said so. The aggressive's best argument for it is that the run-rate payout is about 2.43 billion against 2.1 billion of free cash flow, roughly 0.87 times coverage. That argument is more useful elsewhere. It makes the declaration a two-sided risk for holders, which is why holders who fail the gap test should hedge now and cover the declaration too, as the conservative said. And the signal the re-entry traded on, an affirmed dividend followed by a close below 31.97, already takes holders to 25 percent.

For the flat-account program as a whole, use one risk budget, measured on the gap basis, used in sequence and never stacked. The two stock legs together already fit inside the smaller of 0.25x or the gap budget.

A December put spread for flat accounts can draw on that same budget, under three conditions: - It's bought only after the stock shorts are flat on November 3. - Its premium is no larger than one half-leg's gap allowance, about 1.25 points of a standard position. - It passes the one-third-of-width test.

To the conservative: two rounds ago, a put spread priced live was your default vehicle for flat accounts. A December spread is the same instrument, with an expiry covering the one event in our data with a three-for-three record. You're right that the options market has seen those gaps too. That's an argument for the pricing test, not against the trade. If the implied move already prices the history, the spread fails the test and the account sits in bills.

To the aggressive: the conservative caught a real inconsistency. At-the-money spreads in a name like this won't pass a one-third test. The out-of-the-money spreads that do pass wouldn't have paid on October 2, which closed only 3.6 percent down. "Would have paid on all three" and "passes the test" can't describe the same spread.

Now the holders' December decision, which is still where the money is. Take a holder at 50 percent weight, and compare two choices. One is stepping down to 35 percent. The other is keeping 50 percent and buying a spread from 10 to 20 percent below the pre-print price on the whole position. That spread pays at most 5 points.

Here's how they compare: - In a 20 percent gap, the stepped-down holder loses 7. The hedged holder loses 5 plus the premium. - In a 10 percent miss like December's, the spread pays almost nothing. The hedged holder loses 5 plus premium, against 3.5 for the stepped-down holder. - On a 10 percent rally, the hedged holder makes 5 minus premium, against 3.5.

So neither of you is simply right. The spread wins in the tail and on the upside, and the step-down wins in a routine miss. Two of our three prints were routine: December closed down 10.5 percent and October down 3.6. April, which reached minus 19 percent within a week, was the tail.

The premium decides it. On that spread, each point of premium is a fifth of the width. At one point, the spread clearly earns its place in the tail. At two points, the step-down is at least as good in every outcome we've seen. So the one-third test is too loose for a hedge. Holders should require about a quarter of width or less, because a hedge competes with the step-down, not with the 2-to-1 payoff we want from a bet.

Then the choice depends on the book: - If a 20 percent gap is what breaks your budget, buy the spread now, through the declaration and the print. - If correlated dollar, China and oil names mean a routine 10 percent miss already hurts, step down. - If the spread doesn't price at a quarter of width, step down.

Either way, restore the tier only on the Q2 evidence we agreed.

The conservative's idea of scoring the 10-Q before reading it is the best governance idea in this debate. Here are definitions to commit to before anyone opens the filing: - Inventory: adverse if it's up year over year, since sales fell 4.3 percent. - Margin: adverse if gross margin didn't improve against the 10-Q's own restated prior-year figure. - Current liabilities: adverse if a debt maturity inside twelve months leaves cash and short-term investments, after repayment, below about two years of dividends, roughly 4.9 billion. - China: adverse if the reported figures show it shrinking faster than the company total, or if disclosure has been cut further than the headlines already reported.

Don't count the disclosure cut we already know about. It's in the headlines and the price, and counting it would quietly turn "two or more red flags" into "one more." Then two or more adverse findings means 25 percent, one means 35, and none means 50.

The conservative is also right that execution error is a risk. With the single window, the shared budget and the re-entry gone, here is the whole plan.

Holders: 1. Sell half the reduction now near 34.74. 2. Ladder the rest at 35.15, 35.60 and 36.20. 3. Sell anything unfilled at market before CPI, or on a close below 33.81. 4. Finish to tier size even if price runs above 37.5. 5. Score the 10-Q on the four tests and set the tier once. 6. Keep the three downside triggers: a close below 31.97, two closes above 5.31 percent on the 10-year, and a full exit on a dividend cut. The upside rule only stops further cuts. 7. Run the cross-exposure check, and hold proceeds in bills. 8. Run the 20 percent gap test today. If it fails, hedge now with a spread priced at a quarter of width or less, or step down a tier.

Flat accounts: 1. Default to bills. 2. Where the mandate allows a short, pull short interest and borrow data first, against the committed thresholds. 3. Size the whole program at the smaller of 0.25x or the implied gap budget. 4. Hold stock shorts only between the CPI release and the November 3 close. 5. Run the breakdown half as agreed. 6. Add the zone half only with benign data and the 50-day at or below about 36.95. 7. No re-entry. 8. After November 3, a December spread may replace the shorts within the same budget if it prices well. 9. Hold collateral in two-years.

It's still a Sell. It sells into the bounce if one comes and finishes the trim if it doesn't. The aggressive keeps a real short with a window that runs through the Fed meeting. The conservative gets the buffer, thresholds committed in advance, and no position held across an overnight binary event. And holders, who carry the real risk, get a December rule that weighs the hedge against the step-down on the same numbers rather than on preference. Neutral Analyst: The holder trim is settled, and I'm not reopening it. In this last round I want to fix one mistake of mine, point out one inconsistency on each side, and raise an assumption all three of us have made without saying it. That assumption matters more for December than anything else still open.

My mistake first. My conservative colleague is right about the zone half. Taking two-thirds off at 33.81 and moving the stop on the rest to entry raised the break-even hurdle. From a 36.2 entry, two-thirds of 2.39 is about 1.6 against 1.3 of risk, so the hurdle climbs toward 45 percent. That idea was mine, and it made the trade worse. My aggressive colleague's own analog puts the move to 31.97 in December, after our window closes. So the zone half should be a single-target trade at 33.81, which puts the hurdle back at about 35 percent.

Now the inconsistency on the conservative side. His principle is that cutting risk only needs evidence the risk is real, while adding risk needs evidence of an edge. In absolute-return terms that's correct, and it fairly answers the aggressive's charge about small samples in the December step-down. But he applies it to one short leg and not the other. Run his own worst-case method on the breakdown half. Enter near 31.8 with a stop near 32.9, which risks 1.1. Taking a third off at 31 makes about 27 cents. If the remainder then comes back to entry, the trade earns 27 cents against 1.1 of risk. Almost all of that leg's value comes from the trailing remainder running into a price range our data doesn't cover. That isn't a measured edge either. It's a structural argument: the leg trades with the trend, the exhaustion signals have been cancelled, and the stop sits at a failed-breakdown level. That's the same kind of argument the aggressive makes for the zone leg.

The inconsistency on the aggressive side is calling the zone leg the best-defined part of the call. The only base rate it has sits right at break-even. My conservative colleague also fairly caught a dating problem in the "soft CPI as a filter" idea. CPI lands before the buffer allows an entry, so the entry depends on the calendar, not on how the stock absorbed the print.

That dating problem can be fixed. Add one condition to the zone leg: the 10-year must still be above 5 percent at entry. The macro report calls a drop below 5 percent the first good sign for this stock. With that condition, a soft CPI that pulls yields under 5 percent blocks the trade, which addresses the conservative's concern about shorting into the second half of a dovish story. If yields hold above 5 percent and the stock is still rejected under a falling 50-day, the aggressive gets the setup he described.

Neither leg has a measured edge, so I'd size them by how much each structure improves on the raw odds. The breakdown leg stays at half the program cap, as agreed. The zone leg becomes an eligibility test at a quarter of the cap. It can fire only if all of these hold: benign short-interest and borrow data, the buffer measured on the actual 50-day, the conservative's pre-defined rejection candle, and the 10-year above 5 percent. Its single target is 33.81.

On the gap basis we agreed to use, that leg risks well under a point of a standard position. The conservative is right that price can reach the stop over two or three sessions rather than in one move, and the buffer doesn't stop that. Small size is the answer to that risk, not deleting the leg.

On the overnight-print caveat, I concede the conservative's point. Retail sales, the September PCE report and the Q3 GDP estimate all come out at 8:30 inside the window, so no window avoids every print. What the window really avoids is high-surprise events overnight. PCE is mostly predictable once CPI and PPI are out, so its surprise is usually small. Retail sales lands before the zone leg can even fire. He's right that the gap budget is what actually protects us, and the window just simplifies the calendar.

Now the assumption I mentioned. Every December number in this debate assumes NKE risk is absolute risk. The trader's plan talks about "standard weight," and we don't know whether that means a position-size unit or an index weight. NKE is a Dow and S&P component, so plenty of books hold it against a benchmark. For those books the December logic reverses.

Take a benchmark-relative holder at 50 percent weight. A 20 percent down-gap is a relative gain for them. The outcome that hurts them is an up-gap, and that isn't a remote possibility. The December 2025 gap fully recovered in four weeks. The October 2 session closed at 95 percent of its range. The macro report calls NKE a heavily shorted name. Stepping that holder down to 35 percent deepens the underweight from minus 50 to minus 65, which increases exposure to the outcome that actually hurts them.

So the conservative's two claims, that dropping exposure costs nothing in expectation and that selling protects at every gap size, hold only for absolute-return books. In a relative book, cutting below benchmark is itself adding active risk. By his own standard it then needs evidence of an edge. Our shared fundamental view gives us that edge for the 50 percent weight and the 10-Q tiers. The December event step-down rests on the three-gap record, which is the thin evidence he won't accept for a short.

The same distinction settles the argument about flat accounts. The aggressive says declining the short leaves the call unexpressed. The conservative says owning no NKE is the Sell, fully expressed. For a flat benchmark-relative account, owning nothing is already a full underweight, the strongest bearish position a long-only book can take. Adding a short on top would stack the same view. For a flat absolute-return account, owning nothing is just neutral, so the only real question is whether a short has an edge. That's the question we've been debating, and the answer is small and conditional.

So December should branch on the type of book. I checked the conservative's grid for absolute-return books and his numbers are right. Thirty-five percent plus a quarter-of-width 10-to-20-percent spread beats simply going to 25 percent only for gaps between about 17.5 and 26 percent, and by at most six-tenths of a point. For an absolute book whose budget breaks at a 20 percent gap, cutting to the size that passes is the better tool. Step down by default, and use spreads only for holders who can't sell.

Benchmark-relative books should make no event-driven step-down. The 10-Q tier is their December size. They should size the underweight so that a 15-to-20 percent up-gap fits their tracking-error budget, and they shouldn't add a stock short.

On a December spread for flat accounts, the conservative's backtest changes my mind, and I withdraw the allowance I offered. A 10-to-20 percent spread bought at a third of its width would have returned about 6 points for 10 points of premium, measured at gap-day closes. But that is a lesson about strike placement, not about the instrument. A 5-to-15 percent spread on the same three reactions would have paid 5.5, 10 and zero, which averages about half its width.

The rule I'd write down is to pay no more than two-thirds of what the exact structure would have paid on average across our three reactions. For the 10-to-20 spread, that's about 13 percent of width, which will almost never price. For the 5-to-15 spread, it's about a third. Even so, we have three observations, the options market has seen the same gaps, and the trade runs past December 1. That puts it outside the trader's plan. It belongs with an options mandate as a separate idea, not in this Sell. The same pricing rule works for holders who can't sell. The closer strikes also cover the routine misses, and two of our three reactions were routine.

On the 10-Q, you've each overcorrected in opposite directions. The conservative put the aggressive's tighter inventory threshold together with a rule where any single finding goes to 25 percent. That combination will almost certainly fire, which quietly makes 25 percent the default before anyone has read the filing. The aggressive's tiers make the trader's plan softer, since the plan sends genuine weakness straight to 25.

The fix is to grade severity, and to write the thresholds down before anyone opens the document.

On inventory, it's a fail if inventory rose year over year, and a watch if it fell less than about 2 percent. On margin, it's a fail if like-for-like gross margin fell, and a watch if the restated gain shrinks below about a quarter point. On demand creation, it's a fail if spending fell more than about three points faster than revenue, and a watch if it fell faster at all. Any single fail goes to 25, as the trader's plan says. Two watches go to 25, and one watch goes to 35. Current liabilities and China each move the tier down one step.

So here's the plan, and it's still a Sell. Holders run the trim exactly as all three of us wrote it. They score the 10-Q on the graded tests above and run the cross-exposure check first.

For December, the book type decides. Absolute-return books step down a tier or cut to whatever size passes the 20 percent gap test, and use spreads only if they can't sell, priced by the backtest rule. Benchmark-relative books hold their 10-Q tier and size the underweight against an up-gap. The three downside triggers stay as they are. The upside rule only stops further cuts. Proceeds go into bills.

Flat benchmark-relative accounts stay flat. Flat absolute-return accounts with a short mandate pull short-interest and borrow data first and size the program at the smaller of 0.25x or the gap budget that data implies. They hold stock shorts only between the CPI release and the November 3 close. The breakdown half runs as agreed. The zone leg is allowed at a quarter of the cap only if every eligibility condition holds, with a single target. There's no re-entry and no December directional spread under this call. Short collateral sits in two-year Treasuries, and borrow gets rechecked weekly.

The aggressive keeps a live short where the structure justifies one. The conservative gets the evidence standard he asked for, applied to both short legs alike. Holders get a December rule that fits the risk their book actually carries, which matters more than either of those.

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Underweight

Executive Summary: Underweight NKE. Open no new longs. Holders cut to about 50% of a standard allocation: sell half of that reduction now near 34.74 and ladder the rest at 35.15, 35.60 and 36.20. Sell anything unfilled at market before September CPI or on any daily close below 33.81, and finish the trim even if price runs above 37.5. Cut to 25% or less on a daily close below 31.97, on two straight 10-year closes above 5.31%, or on any single fail in the pre-scored 10-Q tests (inventory, like-for-like gross margin, demand creation), and exit fully on a dividend cut. Before the late-December Q2 FY27 print, absolute-return books step down one more tier or to whatever size survives a 20% gap, while benchmark-relative books hold their 10-Q tier; park proceeds in T-bills for the 2-3 month wait to the Q2 verdict.

Investment Thesis: RATING CHOICE. The Research Manager's Underweight, the trader's measured Sell and all three risk analysts agree on the action: no new money, holders trimmed to about half weight, and objective triggers to 25% or exit. On the 5-tier scale that is Underweight, not Sell. The trader's Sell label describes a trim, and for flat accounts it means avoid entry. The bear case wins on substance, but not decisively enough to exit outright before a defined catalyst while the dividend is still being paid.

WHAT DECIDED IT. (1) Revenue growth has slowed five quarters in a row: +1.1%, +0.6%, +0.1%, -1.1%, -4.3%. With CPI at 3.4%, real sales fell about 7.5%, so there is no pricing-power defense. (2) Earnings: trailing EPS of $2.09 leans on an anomalous Q4 FY26 ($0.73 with an implied ~49.2% gross margin). Both debate sides agreed underlying FY26 EPS was $1.80-1.84, so guidance below $1.64 is a 9-11% decline. (3) Valuation versus rates: about 21x guided EPS, or 18-20x normalized trailing, is an earnings yield near 5%. That is roughly level with a 5.28-5.31% 10-year and close to the 4.77% 2-year, which carries no cut risk. (4) Cash: Q1 FCF was -$64M. Trailing FCF of about $2.1B against a run-rate payout of about $2.43B is roughly 0.87x coverage. The payout is near 100% of guided EPS, buybacks have stopped, and cash fell from $9.86B to $6.90B. (5) Chart: 34.74 sits below the 10 EMA (34.94), 20 SMA (35.60), 50 SMA (38.10, falling) and 200 SMA (47.31). All three SuperTrends are down and there have been six lower highs. OBV has recovered only 28% of its drop, bounce volume faded from 69.6M to 43.7M, and bounce sizes keep shrinking (11%, 9.4%, 3%, 2.5%). (6) Macro: a hiking Fed, a 3% dollar jump into Nike's biggest quarter, oil-driven input costs and a 4.1% saving rate.

WHY NOT SELL. Liquidity is solid: $6.9B cash, a 2.07x current ratio, equity up 13%, and liabilities to equity of 1.48x, the lowest in the data. The mid-November dividend is likely affirmed. Weekly and monthly TD-9 buy setups are complete. Oct 2 closed at about 95% of its range on a record 142.7M shares, and MACD made a higher low (-1.125 vs -1.205). Z-scores near -1.6 are not extreme. The bear's ~$26 rests on a contested 16x. A squeeze is possible if yields fall, and a fully specified Q2 test arrives in about 10 weeks.

WHY NOT HOLD. Even on the bull's math the expected return is near or below T-bills. The trend is down on every timeframe.

EXECUTION DECISIONS FROM THE RISK DEBATE. - Sell half the reduction now rather than waiting. The shrinking bounces show the payoff from waiting has decayed, and the base case can skip the bounce through a close below 33.81. - Keep the top ladder rung at 36.20, below the 36.38-36.39 SuperTrend and Sep 28 resistance. - Set a hard deadline before CPI. - Finish the trim even above 37.5. A short-term chart signal should not leave holders fully exposed to a weakening income statement. - I reject the trader's 35.6 short entry. From there it risks 1.9 to make 1.79, worse than 1:1. - Holders should not short against their long. Selling stock gets the same net exposure without borrow or squeeze risk.

FLAT ACCOUNTS. Default to T-bills. Where an absolute-return mandate requires a short: - First pull short interest and borrow. Treat it as elevated if days to cover exceeds 3 (on 3-month average volume) or borrow costs more than general collateral; if elevated, budget for a 15% gap instead of 10%. - Size at the smaller of 0.25x or that gap budget. - Hold stock shorts only between the CPI release and the Nov 3 close. - Main leg: enter on a close below 31.97. Stop about 32.9, above the 32.76 higher low. Take a third off near 31 and trail the rest. - The 36.0-36.4 rejection leg is marginal: its one-in-three history sits at its ~35% break-even. Allow it only at a quarter of the cap, and only if the data is benign, the actual 50-day is at or below about 36.95, a predefined rejection candle prints, and the 10-year is above 5%. Single target 33.81. - No re-entry and no December directional spread.

10-Q SCORING, committed before reading. - Inventory: fail if up year over year; watch if down less than about 2%, since cost of revenue fell 5.3%. - Like-for-like gross margin: fail if down against the restated prior year; watch if the gain is under 0.25pt. - Demand creation: fail if it fell more than 3pts faster than revenue; watch if it fell faster at all. - Any fail, or two watches, means 25%. One watch means 35%. A clean result holds 50%. - Current-liability or debt-maturity stress (cash plus short-term investments below about $4.9B after repayment) and China weakness each move the tier down one step.

DECEMBER. This is the largest risk: a 20% gap on a 50% position costs 10 points of a standard position. Run the cross-exposure check (dollar, China and oil names) and the 20% gap test today. The debate's grid showed a plain step-down beats a 35% position plus a spread except for gaps of roughly 17.5-26%, and then by at most 0.6pt. So spreads are only for holders who cannot sell. Proceeds go to T-bills (~3.9%), not 2-years, to avoid stacking the rates bet.

WHAT CHANGES THE VIEW. - Upgrade to Hold if Q2 passes all five tests: EPS of $0.48 or better, currency-neutral revenue better than -4.3%, restated gross margin up, inventory falling, and Q2 FCF of at least $386M. Then rebuild on closes above 36.38 and the roughly 38.10 50-day on rising volume. - Overweight only with flat-or-better currency-neutral revenue, like-for-like gross margin above 43%, and buybacks resuming. - The upside rule (close above 36.4, RSI above 45, 10-year under 5%) stops further cuts but never adds. - Move toward exit on a dividend cut, any Q2 test failing (0-25%), or a close below 31.97.

PRICE TARGET: $32.40. - Valuation method: underlying EPS of about $1.80 x 18x = $32.40. 18x is the midpoint of the bull's own 16x (declining) and 20x (recovering) multiples, because Q2 has not yet decided which applies. - Cross-check: 20x x about $1.62 guided FY27 EPS = $32.40. - Technical cross-check: the base-case retest of 32.76-31.97. - Bear downside case: 16x x $1.62 = about $26. - From 34.74 the target implies -6.7%, or about -5.6% total return including the $0.41 dividend (Dec 1 ex-date).

CONFIDENCE is medium. The analysts converged strongly, but several gaps remain: the Q1 10-Q is unread; the guidance figure and its GAAP basis are unverified; China data, short interest, borrow, implied volatility, Sep 24-Oct 1 news and the Q4 FY26 one-offs are all missing; and it is unknown whether standard weight is absolute or benchmark-relative. Holdings are also unknown, so apply the percentages to your own position.

Current Price: 34.74

Price Target: 32.4

Confidence: Medium

Time Horizon: 2-3 months